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Abstract 
 
Chemical biology uses the tools of chemistry in order to study and better understand biological systems. 
Techniques such as synthetic chemistry have proved invaluable in the discovery of novel medicines to 
treat a host of conditions. Polymer chemistry has already provided large numbers of synthetic materials 
with wildly varying physical and mechanical properties which are useful in every facet of day-to-day life. 
However, the need for further innovation still remains. Fewer and fewer new medicines make it into 
clinical use every year as discovery of genuinely novel treatments becomes more difficult and regulatory 
approval becomes more and more difficult to obtain. The ubiquity of synthetic polymers inevitably 
results in large amounts waste products which were often useful in the first place because of their 
exceptional stability. This work describes the application of chemical biology techniques to the process 
of drug discovery and also to the development of biodegradable packaging materials. 
High serum cholesterol levels are a major cause of atherosclerosis which in turn is a major cause of heart 
disease. Ischemic heart disease is the number one cause of death worldwide. Cholesterol lowering 
drugs, known as statins, are strongly associated in a reduction of mortality rates from heart disease. A 
library of novel statin compounds was screened for its ability to inhibit HMG-CoA reductase. Several of 
these compounds showed in vitro activity at least as good as the existing best in class drugs and may 
also display a novel mode of HMG-CoA reductase binding. 
The rise of antibiotic resistance is a major concern and the need for novel antibacterial drugs has 
become critical. A number of novel fluoroquinolone compounds were screened for their antibacterial 
properties. None of these compounds showed activity in vitro although their structures may function as 
prodrugs in vivo. 
The sachet market provides an opportunity for low earners in developing countries to afford detergents 
and toiletries. Poor waste disposal infrastructures mean that waste sachets have become a major 
environmental concern. The possibility of producing a biodegradable shampoo sachet using existing 
commercially available materials was investigated. A novel, ‘bilayer’ approach proved unsuccessful due 
to limitations in the cellulose and polyvinyl alcohol materials used. A simpler approach using a type of 
polyhydroxyalkanoate was also unsuccessful. While several biodegradable polymers are currently 
available, all have limitations to their use as packaging materials particularly when storing liquids.  
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1. Introduction 
 
1.1 Synthetic Chemistry and Drug Development 
One of the most influential approaches to drug discovery has been the search for and discovery of 
naturally occurring compounds which bring therapeutic benefits in the treatment of particular medical 
conditions. Isolation, purification and characterisation of such compounds may then give some insight 
into the mechanisms by which these natural products act. Indeed, it was the isolation of aspirin from 
willow bark which allowed Vane (1971) to prove that the compound inhibits cyclooxygenase enzymes. 
Many common drugs are either found in nature, or are derived from natural products. In 1990, 80 % of 
available drugs were natural products or related analogues (Li and Vederas, 2009). Advances in synthetic 
chemistry over time have allowed easier synthesis of many complex molecules including many naturally 
occurring compounds, such as the complex ring structure of taxol (Masters et al., 1995). Coupled with 
advances in structural biology leading the elucidation of the structures of many drug targets this has 
allowed far more targeted development of drugs. So much so, in fact, that during the 1990s the 
proportion of new drugs derived from natural sources fell to only 50 % and between 2005 and 2007 only 
thirteen of the new drugs approved for use in the USA were natural-product derived (Harvey, 2008). 
The rise of synthetic chemistry has coincided with a decrease in the number of drugs being approved for 
clinical use. Approval for new drugs is now much more difficult to obtain (Bennani, 2012). Where, in the 
past, many compounds were novel treatments for certain conditions, now new drugs must be proven to 
be significantly more effective than the existing best in class treatment. There is also an unhelpful 
emphasis on so called blockbuster drugs within the pharmaceutical industry which has led to only a 
limited range of drug targets being investigated in the hope of finding a compound which will generate 
large revenues to sustain the scale of the pharmaceutical sector. The expiring patents on a number of 
existing blockbuster drugs combined with the failure to successfully discover new drugs to replace them 
has led to a reduction in spending on research and development, amplified by the current economic 
downturn. 
To overcome such problems, evermore innovative methods of designing, synthesising and testing new 
compounds are required. Also important is an increased understanding of pharmacokinetics and the 
effects of compounds not only on their intended target but on other systems in the body. The problem 
of drug resistance must also be addressed as many existing treatments are ineffective for some patients 
who posses variation in the gene encoding the drug target. Synthesis of increasingly varied libraries of 
drug analogues and investigation of their interactions with different targets will inevitably lead to better 
appreciation of the properties required for effective treatments. Potentially, should all of these factors 
be understood to a sufficient level, the design of compounds could take place almost entirely via 
modelling. This would allow large numbers of compounds to be “virtually” screened for their level of 
interaction with a drug target and their possible side-effects due to interactions with other proteins in 
the body. 
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Some of the greatest successes of natural product discovery have been in the field of antibiotics. 
Penicillin was famously isolated from Penicillium fungi and many other common antibacterial drugs 
were originally discovered in nature. Other common antibacterial drugs have completely synthetic 
origins although often their antibacterial properties were discovered by accident as was the case for 
nalidixic acid (Jacoby and Hooper, 2012). A major barrier to successful discovery of new antibacterial 
compounds is the development of resistant bacterial strains. Mutations in the genes encoding drug 
targets in humans develop resistance mutations very slowly. However, due to the rapid rate at which 
bacteria divide, antibiotic resistance mutations can accumulate very quickly. Bacterial strains resistant to 
multiple drugs are now a serious problem in hospitals and the discovery of novel antibacterial drugs is 
urgently needed in order to treat infections caused by these strains. New drugs must employ novel 
mechanisms of action which are able to circumvent mechanisms of antibacterial resistance (Drlica et al., 
2012). 
 
 
1.2 Polymer Chemistry and Biodegradable Packaging Materials 
The field of polymer chemistry has allowed the creation of a diverse range of materials with hugely 
varying mechanical properties. A significant focus of the field is in the development of plastics. These are 
most commonly derived from non-renewable fossil fuels such as oil and are in widespread use as 
packaging materials for a variety of products. Unfortunately, the majority of commercially used plastics 
are not biodegradable and so, when discarded, end up in landfill sites or simply as litter. Waste 
packaging is a significant problem on a global scale. In the European Union (EU) approximately 10 million 
tonnes of plastic packaging waste are produced every year (European Commission, 2012). The waste 
disposal infrastructure in developed countries such as those found in the EU is generally good and 
around 30 % of this waste is recycled. In developing countries, however, the infrastructure is poor with 
no avenues for recycling. In India, an estimated two million tonnes of plastics waste are produced every 
year, 42 % of which comes from packaging materials (Chandrappa and Das, 2012). The degradation 
times of many plastics in widespread use can be as long as centuries. This results in the constant 
accumulation of plastic waste which is unsustainable. 
Development of novel, biodegradable packaging materials is highly desirable. If the volume of packaging 
waste can be reduced it will have an immediate impact on the associated pollution and health issues. 
Additionally, many existing biodegradable polymers are not derived from fossil fuels so an increase in 
their use would have the secondary benefit of decreasing the consumption of non-renewable energy 
sources. However, a range of different packaging materials are required for the packaging of different 
items. This requires the production of a number of different biodegradable materials with varying 
physical and mechanical properties in order to fulfil these needs. An understanding of the mechanisms 
by which materials are broken down in nature by microorganisms is essential for the development of 
successful biodegradable packaging. Different packaging materials will have different fates and 
encounter different populations of microorganisms. Design of novel biodegradable plastics must take 
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into account the mechanical properties of the material as well as whether or not it will be successfully 
broken down by the environment. 
 
 
1.3 Chemical Biology Approaches 
The work described here involves the use of chemical biology techniques in order to investigate a range 
of biological targets related to both drug discovery and polymer chemistry. Chapters two and three 
relate to testing the in vitro activities of novel drug molecules. Chapter two contains details of the 
testing of hypolipidaemic drugs. These are an important tool in treatment of heart disease, the number 
one cause of death in the UK (Murray et al., 2013). Chapter three describes the testing of novel 
antibacterial compounds. Chapters four and five deal with the design of a biodegradable packaging 
solution intended for use in developing countries. In view of the diversity of biological targets addressed, 
each Chapter includes a more specific introduction to the background literature related to each topic.
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2. Small Molecule Inhibitors of HMG-CoA Reductase 
2.1 Introduction 
2.1.1 Cholesterol 
Cholesterol is a membrane lipid found in eukaryotes. Its structure comprises a steroid with a 
hydrocarbon chain attached at the C17 position. It plays an essential role in regulating membrane 
fluidity and is found in virtually all animal membranes (Berg et al., 2002). Cholesterol and its associated 
biochemistry is one of the most intensely studied areas of biology and no fewer than thirteen Nobel 
Prizes have been awarded to scientists for work in this field. 
 
 
 
Figure 2.1. The structure of cholesterol.  
The hydroxyl group forms hydrogen bonds with the hydrophilic head groups of membrane phospholipids. 
The linear tail region forms van der Waals interactions with hydrophobic fatty acid chains. The site of 
addition of the hydroxyl group of oxysterol is indicated (*). 
 
 
The hydroxyl group of cholesterol is able to form a hydrogen bond with the hydrophilic head group of a 
membrane phospholipid (Berg et al., 2002). This allows the cholesterol molecule to insert into the 
membrane, increasing the van der Waals interactions between neighbouring membrane lipids in the 
process. An increase in the amount of cholesterol in a membrane causes a reduction in membrane 
fluidity. This has an important effect in regulating the permeability of the membrane (Berg et al., 2002). 
In humans, cholesterol is obtained from the diet but is also synthesised de novo via the mevalonate 
pathway (Bloch, 1965). 
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2.1.2 Dietary Cholesterol Uptake 
In a typical Western diet, an individual will consume around 300-500 mg of cholesterol per day and a 
further 1100-1500 mg of cholesterol reaches the small intestinal lumen from bile and the turnover of 
intestinal mucosal epithelium (Wang, 2007). Due to its poor solubility in aqueous conditions, cholesterol 
must be solubilised by bile acids before it can be absorbed by the intestine. Hydrophobic bile acids form 
mixed micelles with fatty acids, monoacylglycerides, lysophospholipids and cholesterol (Wang et al., 
1999). These particles facilitate the uptake of cholesterol from the intestinal lumen into enterocytes via 
the cholesterol transporter NPC1L1 (Davis et al., 2004). 
Once cholesterol has been absorbed from the intestine it is transported in the blood and lymph, along 
with triacylglycerols, in the form of lipoprotein particles. These particles are made up of a core region 
consisting of hydrophobic lipids surrounded by a hydrophilic shell made up of polar lipids and proteins. 
Different forms of lipoprotein are classified based upon their densities and these forms have varying 
compositions of lipids and proteins (Betteridge and Morrell, 2003). 
 
 
 
Figure 2.2. Lipoprotein particle structure 
The polar lipids and apolipoproteins of the hydrophilic shell are represented. The core consists of 
cholesterol esters and hydrophobic lipids. This figure is adapted from Lund-Katz et al. (2003). 
 
 
Dietary cholesterol and lipids are transported away from enterocytes in lipoprotein particles called 
chylomicrons. These particles have the lowest density of all lipoproteins due to approximately 99 % of 
8 
 
their composition being triacylglycerols. The amphipathic protein shell of chylomicrons is made up 
primarily of a 240 kD protein called apolipoprotein B-48 (apo B-48). These particles leave enterocytes by 
exocytosis and enter the circulation via intestinal lymphatics.  
Once they reach the blood, chylomicrons bind to lipoprotein lipase enzymes on the surface of capillary 
endothelial cells. Lipoprotein lipase hydrolyses the chylomicron triacylglycerols to fatty acids and 
glycerol. This process allows fatty acids to be oxidised as fuel in muscle or be stored in adipose tissue 
after being re-esterified to triacylglycerol. The lipoprotein particles remaining after this hydrolysis are 
rich in cholesterol and are known as chylomicron remnants. These particles are less dense than 
chylomicrons and bind to the LDL-related protein (LRP) on the surface of liver cells before being 
internalised (Hey et al., 1998). Once inside the liver, cholesterol is secreted into bile, converted to bile 
acids, esterified for storage or incorporated into new lipoproteins. 
 
 
2.1.3 Cholesterol Biosynthesis 
In addition to the absorption of dietary cholesterol, the human body also synthesises cholesterol de 
novo. Cholesterol synthesis occurs primarily in the liver although significant amounts are also 
synthesised in the intestine. A typical adult, eating a low-cholesterol diet, synthesises approximately 
800 mg of cholesterol each day. Cholesterol is synthesised from acetoacetyl coenzyme A (acetoacetyl 
CoA) and acetyl CoA in a sequence of reactions involving 30 enzyme controlled steps, which is known as 
the mevalonate pathway. The pathway was first elucidated by Konrad Bloch who was awarded the 
Nobel Prize in Medicine for his work (Bloch, 1965). The first step in the mevalonate pathway is catalysed 
by an enzyme called 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) synthase and is shown in figure 
2.3. 
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Figure 2.3. Synthesis of HMG-CoA by HMG-CoA synthase. 
 
 
The second step in the pathway is catalysed by the enzyme HMG-CoA reductase and is the reduction of 
HMG-CoA to mevalonate. HMG-CoA reductase performs this four electron reduction using two 
molecules of NADPH as co-factors as shown in figure 2.4. Early studies in yeast determined this step in 
the biosynthetic pathway to be rate limiting (Bloch, 1965).  
 
 
 
Figure 2.4. The reduction of HMG-CoA to mevalonate by HMG-CoA reductase. 
 
 
Following the conversion of HMG-CoA to mevalonate, mevalonate is converted to 3-isopentenyl 
pyrophosphate. This conversion consists of three steps, each of which requires the hydrolysis of ATP, as 
shown in figure 2.5. Isopentenyl pyrophosphate is an activated molecule which acts as an essential 
building block for a number of biological molecules. The most notable of such molecules in humans is 
isopentenyl adenosine which is found in some transfer RNA (tRNA) molecules (Persson et al., 1994). 
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Isopentenyl adenosine is a cytokinin; these are a group of molecules that are found in plants, where 
they regulate growth functions. It is also a precursor to a number of other compounds found in plants, 
for example terpenes, which are volatile compounds made up of two or three isoprene units and are 
responsible for plant fragrances (Berg et al., 2002).  
 
 
 
Figure 2.5. The three step conversion of mevalonate to 3-isopentenyl pyrophosphate.  
Initially, mevalonate kinase phosphorylates mevalonate kinase to 5-phosphomevalonate. 
Phosphomevalonate kinase subsequently carries out a further phosphorylation to make 5-
pyrophosphomevalonate. Finally, mevalonate-5-pyrophosphate decarboxylase carries out a 
decarboxylation reaction to leave 3-isopenteyl pyrophosphate. 
 
 
The next stage in the biosynthesis of cholesterol is the condensation of six isopentenyl pyrophosphate 
molecules to form squalene. To allow this condensation reaction to occur, isopentenyl pyrophosphate 
must be converted to dimethylallyl pyrophosphate by the enzyme isopentenyl pyrophosphate 
isomerase, as shown in figure 2.6(A). Dimethylallyl pyrophosphate forms an allylic carbocation (figure 
2.6(B)) which then undergoes a condensation reaction with a molecule of isopentenyl pyrophosphate to 
form geranyl pyrophosphate (figure 2.6(C)) (Berg et al., 2002).  
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Figure 2.6. Synthesis of Geranyl Pyrophosphate from 3-Isopentyl Pyrophosphate 
 (A) Isomerisation reaction carried out by isopentenyl pyrophosphate isomerase, converting 3-
isopentenyl pyrophosphate to dimethylallyl pyrophosphate. (B) Formation of an allylic carbocation from 
dimethylallyl pyrophosphate through loss of pyrophosphate. (C) Condensation reaction between 3-
isopentenyl pyrophosphate and the allylic carbocation to form geranyl pyrophosphate, as catalysed by 
the enzyme farnesyl pyrophosphate synthase. 
 
 
Geranyl pyrophosphate condenses with another molecule of isopentenyl pyrophosphate to form 
farnesyl pyrophosphate (figure 2.7). This reaction is also catalysed by farnesyl pyrophosphate synthase 
and takes place via the same mechanism of reaction as the synthesis of geranyl pyrophosphate, as 
shown in figure 2.6(C). Two molecules of farnesyl pyrophosphate then undergo a further condensation 
reaction to produce one molecule of squalene. This reductive coupling reaction requires the cofactor 
NADPH and is catalysed by squalene synthase. The synthesis of squalene from isopentenyl 
pyrophosphate is shown in figure 2.7. 
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Figure 2.7. Synthesis of squalene from six molecules of isopentenyl pyrophosphate.  
These reactions are catalysed by the enzymes farnesyl pyrophosphate synthase and squalene synthase. 
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Like isopentenyl pyrophosphate, farnesyl pyrophosphate is an important precursor for a number of 
biological molecules. Dolichols consist of up to twenty isoprene units and play an important role in the 
addition of oligosaccharides to glycoproteins (Swiezewska and Danikiewicz, 2005). Ubiquinone is an 
essential electron carrier in the electron transport chain of oxidative phosphorylation and also functions 
as an antioxidant (Kawamukai, 2002). Farnesyl pyrophosphate is also required for the synthesis of haem 
A, an iron-porphyrin complex found in the enzyme cytochrome c oxidase (Hederstedt, 2012). Like 
ubiquinone, cytochrome c plays an essential role in oxidative phosphorylation. Isoprenoid compounds 
are also often attached to the C-termini of proteins as a means of membrane targeting. The most 
common attachments are farnesyl or geranylgeranyl units, and their attachment to a protein confers 
hydrophobic character (Seabra, 1998). 
Before squalene can cyclise to form the steroid nucleus of cholesterol it must be activated. Activation is 
achieved by the formation of squalene epoxide, a process which is catalysed by squalene epoxidase. This 
reaction requires a further molecule of NADPH as well as a molecule of oxygen. The activated squalene 
epoxidase is then able to cyclise to form a protosterol cation before a further rearrangement reaction 
produces lanosterol. The mechanism for the conversion of squalene to lanosterol is shown in figure 2.8. 
Biosynthesis of the complete cholesterol molecule from lanosterol is a complex process involving a 
further 19 steps (Risley, 2002). 
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Figure 2.8. Cyclisation of squalene to form lanosterol.  
First, squalene is activated by conversion to squalene epoxide as catalysed by squalene epoxidase. 
Oxidosqualene cyclase then catalyses the cyclisation and rearrangement of squalene epoxidase to 
lanosterol. 
 
 
15 
 
In addition to its role in regulating membrane fluidity, cholesterol is the starting point for the 
biosynthesis of a number of different compounds. One large group of such compounds is the steroid 
hormones. The synthesis of steroid hormones first requires the cleavage of the side chain from 
cholesterol to form pregnenolone. From pregnenolone, a wide range of hormones including 
progesterone, cortisol and testosterone are synthesised (Berg et al., 2002). Another major type of 
compound synthesised from cholesterol is bile salt. Bile salts are excreted by the gall bladder in order to 
solubilise dietary lipids (section 2.1.2)(Mikov and Fawcett, 2006). The photolysis of 7-dehydrocholesterol 
by ultraviolet light produces previtamin D3, of which a deficiency in childhood causes rickets or, in 
adulthood, causes osteomalacia (Holick et al., 1977). 
 
 
2.1.4 Cholesterol Transport 
Cholesterol that has been synthesised in the liver and intestine is transported around the body in 
lipoprotein particles. As discussed in section 2.1.2, these particles consist of a lipid core surrounded by a 
hydrophilic shell made up of polar lipids and proteins. The particles are classified by density and the 
least dense forms, chylomicrons and chylomicron remnants, are responsible for the transport of dietary 
cholesterol and lipids to the liver. 
Cholesterol is transported away from the liver as part of very low density lipoprotein (VLDL) particles. 
These particles are similar in density to chylomicron remnants but differ in the make-up of their protein 
shell. Whereas the protein shell of chylomicrons is primarily made up of apo B-48, the protein shell of 
VLDL contains apo B-100. Apo B-100 is a very large protein, 513 kD in size. Both apo B-48 and apo B-100 
are encoded by the same gene but the transcribed mRNA undergoes alternative splicing in order to 
generate the two different proteins. Chylomicrons and VLDL also contain other apoproteins which are 
involved in receptor binding (Betteridge and Morrell, 2003). 
VLDL particles are synthesised in the rough endoplasmic reticulum (ER) of hepatic cells which is the 
same location at which cholesterol synthesis occurs (Gordon et al., 1995). They are excreted from the 
cell via the Golgi apparatus and behave in a similar way to chylomicrons in the blood. VLDL 
triacylglycerols are hydrolysed by lipoprotein lipase on the surface of endothelial cells, although the rate 
of hydrolysis is lower in VLDL than in chylomicrons probably due to the smaller size of VLDL (Betteridge 
and Morrell, 2003). After the hydrolysis of the triacylglycerol content of VLDL, cholesterol rich particles 
known as intermediate density lipoproteins (IDL) remain. Some IDL particles are taken up for processing 
by the liver via the low density lipoprotein (LDL) receptor. The triacylglycerol content of the remaining 
IDL particles is further hydrolysed by hepatic lipase to form low density lipoprotein particles. 
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Figure 2.9. The lipoprotein pathway.  
Dietary cholesterol is transported to the liver in chylomicrons and chylomicron remnants. Endogenous 
cholesterol leaves the liver in very low density lipoprotein particles which are converted to intermediate 
density and low density lipoprotein particles as they lose triglycerides. 
 
 
LDL is the primary carrier of cholesterol in the blood. Like VLDL and IDL, the shell of LDL contains apo B-
100 but LDL is lacking the other lipoproteins present in different lipoprotein particles. LDL is responsible 
for delivering cholesterol to peripheral tissues where it interacts with the LDL receptor and is 
internalised. LDL receptor molecules are found on the surface of the cell in areas called coated pits. 
When LDL particles interact with the receptor, the coated pits invaginate to form coated vesicles 
containing the lipoprotein particles. These vesicles then fuse with lysosomes in the cell where esterified 
cholesterol from LDL is hydrolysed to free cholesterol and the apoproteins are broken down to amino 
acids so that both can be used by the cell. The LDL receptor proteins are then recycled and return to the 
surface of the cell in new coated pits (Brown and Goldstein, 1986). 
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The final type of lipoprotein particle is high density lipoprotein (HDL). HDL is the densest of all of the 
lipoproteins and, instead of apo B-100 or apo B-48, contains apo A-I or apo A-II in its hydrophilic shell. 
Nascent HDL is secreted by the liver and intestine as bilayer discs containing apo A and phospholipids. 
The role of these particles is to take up free cholesterol from cell membranes undergoing turnover as 
well as taking up free cholesterol liberated from dead cells and other lipoproteins. An enzyme called 
lecithin cholesterol acyltransferase (LCAT), which circulates with HDL, is responsible for esterifying this 
free cholesterol so it can be incorporated into the lipid core of the mature HDL particle. The esterified 
cholesterol can then be shuttled to VLDL or LDL due to the action of a cholesterol ester transfer protein 
(CETP), which is contained within the HDL particle. 
HDL is responsible for returning excess cholesterol from peripheral tissue to the liver for excretion in a 
process known as reverse cholesterol transport (Glomset, 1968). In this process, surplus cholesterol is 
absorbed from the plasma membrane by a low molecular weight type of HDL called prebeta-1 HDL. The 
efflux of cholesterol is dependent upon the action of a protein called cholesterol efflux regulatory 
protein (CERP). CERP is coded for by the gene ABCA1, a member of the ATP-binding cassette (ABC) 
family (Kane and Malloy, 2012). These genes typically encode proteins which transport substances 
across cell membranes using the energy produced by the hydrolysis of ATP. This excess, free cholesterol 
is esterified by LCAT in the prebeta-1 HDL particle and the majority is transferred to the lower density 
lipoproteins VLDL and LDL before eventually returning to the liver. The uptake of the remaining HDL 
particles by the liver is mediated by the scavenger receptor class B type 1 (SR-B1) (Liadaki et al., 2000). 
 
 
2.1.5 HMG-CoA Reductase 
HMG-CoA is responsible for catalysing the second step in the mevalonate pathway. This is the reduction 
of HMG-CoA to mevalonate which requires two molecules of the cofactor NADPH. The reaction takes 
place in three stages: first HMG-CoA is reduced to mevaldyl-CoA; mevaldyl-CoA then decomposes to 
form mevaldehyde which is then reduced to mevalonate. It is a 97 kD enzyme containing 888 amino acid 
residues and is associated with the ER (Brown and Simoni, 1984) although it has also been found in the 
matrix of peroxisomes (Keller et al., 1986). The N-terminal, ER bound domain consists of eight 
membrane-spanning helices separated by short loops and is encoded by amino acid residues 1-425 
(Roitelman et al., 1992). The remaining 462 residues make up the catalytic domain of the enzyme. This 
region is capable of catalysis without the presence of the ER binding domain. The main function of the 
N-terminal binding domain in the cell is in regulation of the half-life of the enzyme as will be discussed in 
section 2.1.6 (Gil et al., 1985). 
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Figure 2.10. The reduction of HMG-CoA to mevalonate by HMG-CoA reductase.  
In step one, NADPH transfers a hydride ion to HMG-CoA forming mevaldyl-CoA. In step two, mevaldyl-
CoA decomposes, losing CoA thiol, to form mevaldehyde. In step three, a second hydride transfer reduces 
mevaldehyde to mevalonate. 
 
 
The structure of the catalytic domain of HMG-CoA reductase has been solved by x-ray crystallography 
(Istvan et al., 2000). In this structure, the catalytic domains form a tightly associated tetramer with the 
active sites of the enzyme located at the interface of two monomers. The catalytic region of the enzyme 
can be broken down into three different domains. The small N-domain is α-helical and acts as a linker 
between the catalytic domain and the ER bound N-terminal domain of the full enzyme. The large L-
domain and small S-domain make up the enzyme’s active site. The L-domain contains a fold which is 
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prism-shaped with a 27 residue α-helix at its core and unique to HMG-CoA reductase. The S-domain 
inserts into the L-domain to form the NADPH binding site. This creates an α/β sandwich fold that differs 
from the Rossman fold which is commonly found in NAD(P) dependent enzymes. All three of these 
domains are responsible for interacting with other monomers of HMG-CoA reductase when forming the 
active sites of the enzyme through dimerisation. 
 
 
 
Figure 2.11. Ribbon diagrams of human HMG-CoA reductase. 
 (A) The structure of the HMG-CoA reductase tetramer. Dimer 1 consists of monomers 1α (purple) and 1β 
(yellow) and dimer 2 consists of monomers 2α (pink) and 2β (green). (B) The active site of human HMG-
CoA reductase. Residues from monomer α are in yellow and residues from monomer β are in blue. HMG-
CoA is shown in magenta and NADPH is shown in green. This figure is taken from Istvan et al. (2000). 
 
 
The structure of the active site of HMG-CoA reductase has been solved with various combinations of 
substrates and products bound (Istvan et al., 2000). The CoA portion of HMG-CoA binds to the active site 
in an extended conformation with the pantothenic acid region buried deep inside the structure of the 
enzyme, as can be seen in figure 2.11. The interactions between HMG-CoA reductase and CoA are all 
formed by the L-domain of a single monomer with the exception of one interaction with a tyrosine 
residue (Y479) from the N-domain of the adjacent monomer. This single interaction appears to be 
responsible for closing the extended binding site by forming a hydrophobic shield over the adenine base 
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of CoA. In contrast, the majority of the interactions between NADPH and the enzyme originate from the 
S-domain of the second monomer. The crystal structures obtained by Istvan et al. suggest that NADPH 
binding results in a conformational change in the c-terminus of the enzyme which completely closes the 
active site. The HMG domain of HMG-CoA binds to the enzyme in a pocket located between the L-
domain of one monomer and the S-domain of another. It forms interactions with both monomers and 
most importantly binds to the ‘cis-loop’ which bends over the top of the molecule, positioning key 
catalytic residues in their required positions. 
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Figure 2.12. The proposed mechanism of catalysis by HMG-CoA reductase.  
The negatively charged oxygen of mevaldyl-CoA is stabilised by the side chain of K691. The closing of the 
C-terminal flap of HMG-CoA reductase positions H866 close to the CoA thiol allowing it to donate a 
proton in the second step of the reaction. The proximity of E559 to D767 is likely to raise the pKa of the 
glutamic acid sufficiently for its side chain to be protonated. This would allow E559 to act as a proton 
donor for mevaldehyde. D767 also acts to stabilise the side chain of K691 (Istvan and Deisenhofer, 2000). 
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2.1.6 Regulation of Cholesterol Homeostasis 
Due to the potential threats that cholesterol can pose to the body, which will be discussed in section 
2.1.7, cholesterol homeostasis is one of the most tightly regulated biological systems. As the rate-
limiting enzyme in the mevalonate pathway, HMG-CoA reductase is itself one of the most highly 
regulated enzymes known (Goldstein and Brown, 1990). It is subject to control on several levels 
including over its rate of transcription, rate of translation, rate of degradation and level of activity. This 
control is mediated by a number of different molecules and enzymes which also exert control over other 
important proteins involved in cholesterol homeostasis, including HMG-CoA synthase and the LDL 
receptor. The different mechanisms involved have been studied in detail by Michael Brown and Joseph 
Goldstein who were awarded the Nobel Prize for Medicine for their work (Brown and Goldstein, 1986). 
The rate of transcription of the HMG-CoA reductase gene is controlled by the sterol regulatory element 
binding protein (SREBP) pathway. The SREBP is a transcription factor that is associated with the ER or 
nuclear membrane in its inactive state (Wang et al., 1994). The protein consists of an N-terminal 
transcription factor domain and a C-terminal regulatory domain, both cytosolic, separated by two 
membrane spanning helices and a hydrophilic loop projecting into the ER lumen (Nohturfft et al., 1998). 
This means that, in order to enter the nucleus and initiate transcription of HMG-CoA reductase mRNA, 
the transcription factor domain of SREBP must be released from its membrane association. This release 
is controlled by a protein called SCAP (originally standing for SREBP cleavage-activating protein).  
In the presence of cholesterol, SCAP and SREBP are both associated with the ER, with the cytosolic C-
terminal domain of SCAP interacting with the regulatory domain of SREBP (Sakai et al., 1997). However, 
when cellular cholesterol levels drop, the SCAP/SREBP complex moves to the Golgi complex. This 
movement is controlled by the interaction of SCAP with the copII coat protein complex. A sequence of 
six amino acids known as MELADL that is located on a cytosolic loop of the SCAP protein interacts with 
the sec24 component of the copII complex (Sun et al., 2005). The copII complex then causes the 
formation of a vesicle containing the SCAP/SREBP complex by budding from the ER, this ‘copII coated 
vesicle’ then moves on to the Golgi (Rothman and Orci, 1992). Here, the luminal loop of SREBP is cleaved 
by a membrane associated protease called site-1 protease (S1P). This allows the release of the 
transcription factor domain by a second cleavage, in the membrane spanning helix, by site-2 protease 
(S2P) (Brown and Goldstein, 1997). 
In the presence of cholesterol or oxysterol, the SCAP/SREBP complex does not interact with the copII 
complex and remains in the ER membrane. The disruption of SREBP export is mediated by ER retention 
proteins called insigs. When insigs bind to SCAP, the loop of SCAP containing the MELADL sequence, 
which interacts with the copII complex, undergoes a conformational change (Brown et al., 2002). This 
change stops the copII complex from accessing the MELADL sequence and therefore blocks export of 
SCAP/SREBP to the Golgi. Cholesterol and oxysterol stimulate the binding of insigs to SCAP in different 
ways. Cholesterol binds directly to the membrane embedded domain of SCAP to stimulate insig binding 
whereas oxysterols bind to the insig stimulating it to bind to SCAP (Adams et al., 2004). 
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Figure 2.13. Mechanism of regulation of HMG-CoA reductase transcription. 
 When sterol concentration is low, the SCAP-SREBP complex moves to the golgi where the SREBP is 
cleaved enabling it to activate transcription. Cholesterol and oxysterol mediate insig binding to SCAP 
blocking the access of Cop-II to the MELADL region. 
 
 
When SREBP enters the nucleus it binds to a short DNA sequence called a sterol regulatory element 
(SRE). The SRE is located on the 5’ side of the HMG-CoA reductase gene and binding of SREBP activates 
transcription of the gene. SREs have also been identified downstream of the genes for the LDL receptor 
(Sudhof et al., 1987), HMG-CoA synthase (Dooley et al., 1998) and insig-1 (Yabe et al., 2002). This results 
in both an increase in cholesterol biosynthesis and an increase in cholesterol uptake in response to a fall 
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in cellular cholesterol levels. The SREBP activation of insigs means that SREBPs trigger the synthesis of 
their own inhibitor, thus providing a further level of control. 
HMG-CoA reductase and SCAP have similar topologies, each containing a cytosolic, C-terminal domain 
responsible for function as well as eight, membrane-spanning helices. In fact, the membrane spanning 
domains of both proteins bind to insigs in a sterol-controlled manner (Sever et al., 2003b). However, 
whereas they act to stabilise SCAP, insigs are responsible for triggering the rapid degradation of HMG-
CoA reductase. The sterol responsible for the binding of HMG-CoA to insig is 24,25-dihydrolanosterol, 
this is the first intermediate in the mevalonate pathway after lanosterol (see section 2.3). The insig 
molecules which bind to HMG-CoA reductase also associate with a membrane-bound ubiquitin ligase 
called gp78 that, in turn, associates with Ubc7, a ubiquitin conjugating enzyme (Song et al., 2005). These 
two enzymes work together to initiate polyubiquitination of two cytosolic lysine residues in the N-
terminal domain of HMG-CoA reductase. Ubiquitination of the reductase acts as a signal for the protein 
to be extracted from the ER membrane. This is carried out by an ATPase called VCP/p97, which is also 
associated with gp78, and a number of its cofactors (Kostova et al., 2007). The mechanism by which this 
extraction occurs remains unclear although it is known that the nonsterol isoprenoid geranylgeraniol 
increases the rate of extraction (Sever et al., 2003a). Geranylgeraniol is derived from farnesyl 
pyrophosphate which is an intermediate in the mevalonate pathway. Once extracted from the ER 
membrane, HMG-CoA reductase is transported to proteasomes where it is degraded. 
In addition to mechanisms controlling the amount of HMG-CoA reductase present in the cell, the level of 
activity of the enzyme can also be controlled. The activity is controlled through the process of 
phosphorylation. HMG-CoA reductase phosphorylation is carried out by an enzyme called AMP-
activated protein kinase (AMPK) (Omkumar et al., 1994). AMPK is allosterically activated by AMP but not 
by ATP. Since AMP and ATP compete for the same binding site on AMPK, this means that the kinase is 
sensitive to the AMP:ATP ratio in the cell. This property of AMPK means that it becomes activated when 
the cell undergoes periods of metabolic stress (Hardie et al., 2006). In these conditions, AMPK is 
responsible for the phosphorylation of serine 872 of HMG-CoA reductase. This phosphorylation inhibits 
the activity of the reductase and, although the mechanism of inhibition is not known, it is thought that 
this is achieved by either decreasing the NADPH affinity of the enzyme or by stopping the proper closure 
of the C-terminal flap over the active site (Tabernero et al., 1999). When levels of ATP increase again, 
HMG-CoA reductase is dephosphorylated by the enzyme protein phosphatase 2A (PP2A) (Janssens and 
Goris, 2001). This dephosphorylation fully restores the catalytic activity of the reductase. 
The rate of translation of HMG-CoA reductase mRNA is also tightly controlled. This control is known to 
be mediated by a nonsterol isoprenoid (Goldstein and Brown, 1990). However, the identity of this 
molecule and the mechanism by which the rate of translation is controlled is not known, although it is 
likely that the mechanism involves a complex, 5’-untranslated region of the reductase mRNA. 
The combination of all of these mechanisms of control means that the HMG-CoA reductase activity in a 
cell can vary over a 200-fold range. Numerous other enzymes in the mevalonate pathway are controlled 
by the same or similar mechanisms ensuring the cholesterol needs of the cell can be met quickly when 
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required. Modulation of this control by a range of different metabolites found in, or derived from, the 
mevalonate pathway also helps to stop the build-up of undesirable intermediates. 
 
 
2.1.7 Hypercholesterolemia, Atherosclerosis and Coronary Heart Disease 
The insolubility of cholesterol is essential for its function in controlling plasma membrane fluidity. 
However, this insolubility means that cholesterol can be a potentially dangerous and even fatal 
molecule. Accumulation of cholesterol in the cell can have a number of negative consequences.  
Excess free cholesterol can be incorporated into the cell membrane, reducing fluidity to below optimum 
levels. This can have negative effects on membrane proteins, which require a degree of conformational 
flexibility (Yeagle, 1991). This can affect proteins responsible for diverse cellular functions including 
transport and signalling. Reduced membrane fluidity can not only have negative effects for the cell 
membrane but can also affect the membranes of different organelles. High levels of free cholesterol can 
also result in the formation of intracellular cholesterol crystals (Kellner-Weibel et al., 1999). These 
needle-shaped crystals are likely to physically disrupt intracellular structures. Finally, excess free 
cholesterol can be oxidised to oxysterols which may have cytotoxic effects (Brown and Jessup, 1999). All 
of these processes are toxic to the cell and can cause cell death. 
Due to the dangers of the accumulation of free cholesterol, healthy cells are able to regulate their 
cholesterol content as discussed in section 2.6. This is achieved by the inhibition of cellular cholesterol 
synthesis, reduction in uptake of LDL cholesterol and the export of excess cholesterol via lipoprotein 
particles and reverse cholesterol transport. However, while this export of cholesterol from the cell to 
the blood stream is beneficial for the cell, the resulting increase in concentration of plasma LDL can have 
serious consequences. 
Excess plasma LDL undergoes oxidation to form oxidised LDL (oxLDL). The oxLDL is taken up by 
macrophages which are unable to process it. This results in the formation of engorged, cholesterol rich 
foam cells. These foam cells become lodged in the walls of blood vessels leading to an accumulation of 
cholesterol in the lumen. This process is known as atherosclerosis (Levine et al., 1995). The build up of 
cholesterol is called an atherosclerotic plaque and the sizes of these plaques increase over time in 
patients suffering from atherosclerosis. This leads to a narrowing of the blood vessel which can limit the 
blood supply to different tissues. In advanced cases this can lead to ischemia of different tissues and, 
even more seriously, coronary thrombosis of the coronary artery causing heart attacks. In some cases, 
parts of the atherosclerotic plaque can break off causing thromboembolisms such as strokes (Davies et 
al., 1993). 
While LDL is responsible for the negative consequences of high cholesterol levels, HDL plays a crucial 
role in minimising these effects. The primary cholesterol reducing role of HDL is in reverse cholesterol 
transport as discussed in section 2.1.4 (Kane and Malloy, 2012). However, it is also likely that HDL has 
antioxidant capabilities which can help to reduce the amount of oxLDL and therefore slow the 
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development of atherosclerotic plaques. This ability is thought to be conferred by the enzyme 
paraoxonase which is associated with the HDL particle and is able to hydrolyse oxidised phospholipids 
(Navab et al., 1996). It is also possible that HDL has further atheroprotective abilities such as its ability to 
stop oxLDL inhibiting endothelial vasodilation (Stein and Stein, 1999). These protective capabilities mean 
that, as a marker for coronary heart disease risk, the LDL:HDL ratio is used rather than the total plasma 
cholesterol concentration. 
While high cholesterol and atherosclerosis in most patients is caused by poor diet and lack of exercise, it 
can also have a genetic basis. Familial hypercholesterolemia (FH) is typically caused by a mutation in the 
gene encoding the LDL receptor (Brown and Goldstein, 1974), although it can also be caused by a 
mutation in the gene for apo B (Innerarity et al., 1990). Heterozygous sufferers of the disease have one 
faulty copy of the LDL receptor and typically have plasma cholesterol levels of around 300 mg dl-1 
(compared to < 200 mg dl-1 in healthy individuals) (Berg et al., 2002). Heterozygous FH affects 
approximately 1 in 500 people around the world (Rader et al., 2003). The elevated blood LDL levels in 
the disease lead to the deposition of cholesterol, causing nodules called xanthomas, in the skin and 
tendons. More seriously, excess LDL is oxidised to oxLDL leading to the development of atherosclerotic 
plaques and many sufferers of heterozygous FH experience premature cardiovascular disease. 
Homozygous FH is much rarer, affecting only around 1 in 1,000,000 people worldwide. Blood cholesterol 
levels in homozygotes are around 680 mg dl-1 and the majority of sufferers die of coronary artery 
disease as children. 
Murray and Lopez estimated that, in 1990, ischaemic heart disease, i.e. heart disease caused by reduced 
blood flow to the heart muscle, was the leading cause of death worldwide (Murray and Lopez, 1997). In 
developed countries cardiovascular disease is a factor in 38-42 % of deaths (White, 1995), although this 
figure is closer to 15 % in developing nations (Murray and Lopez, 1997). Atherosclerosis caused by high 
cholesterol levels is a major contributor to these conditions and it has been shown that a ten percent 
reduction in cholesterol levels is associated with a reduction in the incidence of coronary heart disease 
of between twenty to thirty percent (Scandinavian Simvastatin Survival Group, 1994). Finding ways of 
successfully reducing the cholesterol levels of patients at risk of coronary heart disease is therefore 
extremely desirable. 
The most effective way to maintain low cholesterol levels is through a healthy diet and regular exercise. 
Low fat diets in particular are recommended to patients with high cholesterol levels although there is 
evidence to suggest that diets rich in unsaturated fats and low in saturated and trans fats help to lower 
the LDL:HDL ratio in the blood (Mensink et al., 2003). Administration of hypolipidaemic drugs has been 
shown as an alternative method of reducing cholesterol levels (Betteridge et al., 1993). These drugs 
include: bile acid binding resins, fibric acid derivatives, HMG-CoA reductase inhibitors, nicotinic acid 
derivatives, probucol and omega-3 marine triglycerides. Inhibitors of HMG-CoA reductase, which are 
known as statins, are proven to reduce coronary heart disease and have fewer adverse effects than 
other hypolipidaemic agents (Scandinavian Simvastatin Survival Group, 1994). 
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 2.1.8 Statins 
The impact of high cholesterol levels on health has been known for some time. The fact that the 
majority of the cholesterol in the body is synthesised de novo means that inhibiting this synthesis is an 
ideal course of treatment for high cholesterol. The role of HMG-CoA reductase in catalysing the rate-
limiting step in cholesterol synthesis made it a ‘prime target for the development of a pharmacological 
intervention’ (Endo, 1985). The first HMG-CoA reductase inhibitor was actually discovered by two 
groups independently in 1976 (Endo and Kuroda, 1976, Brown et al., 1976). Compactin, as it was named, 
was isolated from the fungi Penicillium citrinum and Penicillium brevicompactum.  
Compactin, like all statins, contains an HMG-like moiety connected to a ring system. It is a competitive 
inhibitor of HMG-CoA reductase although it has a 10,000-fold higher affinity for the enzyme than the 
natural substrate, HMG-CoA (Endo, 1985). This high potency and lack of effects on other enzymes made 
statins ideal as a potential treatment for high cholesterol. This led to the discovery of a range of other 
HMG-CoA reductase inhibitors, typically isolated from other species of fungus (Endo, 1979, Albers-
Schonberg et al., 1981). Compactin itself was never marketed as a drug due to adverse effects in animal 
studies. The first statin drug to be approved for use was lovastatin. 
Statins are usually divided into two classes: type 1 statins are derived from fungi and resemble the 
substituted decalin ring structure of compactin whereas type 2 statins are completely synthetic and 
typically contain much larger cyclic groups attached to the HMG-like moiety. The structure of HMG-CoA 
reductase bound to a number of different statins has been solved by x-ray crystallography (Istvan and 
Deisenhofer, 2001). Statins bind to the reductase enzyme in the open, acid conformation rather than 
the lactone form. This conformation closely resembles the HMG region of HMG-CoA, the natural 
substrate of the enzyme. 
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Figure 2.14. Structures of four statin compounds.  
Compactin and simvastatin are type-I statins, both featuring the decalin ring structure. These are 
administered in the cyclic, lactone form. Atorvastatin and rosuvastatin are type-II statins with synthetic 
ring structures. These compounds are administered in an open, carboxylic acid form. 
 
 
Kinetic studies show that statins are competitive inhibitors of HMG-CoA reductase with respect to HMG-
CoA but not with respect to NADPH (Endo et al., 1976). This finding is supported by the statin-bound 
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crystal structures that show the HMG-like moiety of each statin binding to the HMG binding site of the 
enzyme (Istvan and Deisenhofer, 2001). The bulky, hydrophobic regions of the statins do not resemble 
the structure of CoA and the crystal structures show that they do not bind to the CoA binding site. 
Instead, these regions occupy a ‘shallow groove’ which is created by a rearrangement of the C-terminal 
region of HMG-CoA in response to statin binding (Istvan, 2002). There is no interaction between statins 
and the NADPH binding site which further supports the earlier kinetic data. Statins form interactions 
with a number of key catalytic residues including a polar interaction with K691 and a hydrogen bond 
network with K691, E559 and D767. 
 
 
 
Figure 2.15. Mode of binding of (A) Atorvastatin and (B) Rosuvastatin to human HMG-CoA reductase. 
The majority of interactions are ionic or polar and occur in the HMG binding region. Type 1 statins do not 
form the interactions with R590 that are seen in these type 2 statins. Both Atorvastatin and Rosuvastatin 
form interactions with S565 that are not observed with other statin compounds. Rosuvastatin also forms 
a unique interaction with R568. This figure is taken from Istvan & Deisenhofer (2001). 
 
 
A number of statin compounds are available for doctors to prescribe. All perform well in clinical trials 
although the doses required vary for different drugs. The most potent statin compound marketed to 
date is cerivastatin, however, this was withdrawn from sale in 2001 due to an increased risk of serious 
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side effects compared to other statins (Furberg and Pitt, 2001). The most potent statins still available are 
atorvastatin and rosuvastatin. As can be seen in figure 2.15, these two statins form a greater number of 
interactions with the active site of HMG-CoA reductase which is likely to explain their increased binding 
affinity and therefore higher potency. 
Statins are widely prescribed in developed countries. While primarily prescribed for patients suffering 
from high cholesterol levels they are also prescribed to those who have suffered from, or are deemed to 
be at risk of, heart attacks or cardiovascular disease (Ridker, 2003). In fact, in England in 2011, 
Simvastatin was the most widely prescribed medication (NHS, 2012). There were over 57 million 
prescriptions for statins in 2011, which the British Heart Foundation (BHF) estimates to mean that over 
7 million people in the UK are taking statins (British Heart Foundation, 2011). Globally, atorvastatin is 
the biggest-selling pharmaceutical in history (Associated Press, 2011). 
Statins have been proven to reduce mortality, coronary heart disease and strokes in both patients with a 
history of cardiovascular disease and those with raised cholesterol levels (Taylor et al., 2011, 
Scandinavian Simvastatin Survival Group, 1994). However, there remain uncertainties regarding the 
cost-effectiveness of statins for primary prevention of cardiovascular disease, particularly for patients 
deemed to be at low risk (Taylor et al., 2011). While statins are effective in lowering plasma LDL levels, it 
is likely that some of their success in reducing the incidence of cardiovascular disease is through 
pleiotropic effects (Zhou and Liao, 2009). These effects are caused because, by inhibiting HMG-CoA 
reductase, statins also inhibit the synthesis of isoprenoid compounds such as farnesyl pyrophosphate. As 
mentioned in section 2.1.3, isoprenoid compounds are important in post-translational modifications of 
many proteins, especially nuclear lamins such as Rac and Rho (Burridge and Wennerberg, 2004). 
Although the exact mechanisms involved are not understood, studies suggest that statins have a 
positive effect on many areas of the vascular system (Zhou and Liao, 2009). In particular, it is possible 
that statins have several pleiotropic effects on atherosclerotic plaques. These effects include: reduction 
of inflammation of the vascular wall (Vaughan et al., 2000), lipid-independent inhibition of LDL oxidation 
(Wassmann et al., 2001) and plaque stabilisation (Crisby et al., 2001). 
In addition to the suggested pleiotropic effects of statins on the cardiovascular system, there is also a 
possibility that statins have beneficial effects in treating or preventing a number of different conditions. 
These include dementia (Sparks et al., 2006) and several types of cancer (Mandal et al., 2011). However, 
further trials are needed to establish clearly whether or not statins are an appropriate treatment for 
other conditions (McGuinness et al., 2010, Dellavalle et al., 2005). 
Despite the wide range of potential benefits to statin therapy, the drugs also have a number of 
associated side-effects. The most important of these is myopathy which occurs with a frequency of 1.2 
per 10,000 treatment years (Sathasivam and Lecky, 2008). In serious cases, this can result in 
rhabdomyolysis which can be potentially life-threatening, although this is very rare, occurring with a 
frequency of approximately 0.1 per 10,000 treatment years. These negative effects on muscle function 
are due to the reduction in ubiquinone synthesis caused by the inhibition of HMG-CoA reductase 
(section 2.3). Another possible side-effect of statin therapy is liver failure which is dose dependent and 
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extremely rare, occurring with a frequency of 1 per 1,000,000 treatment years (Law and Rudnicka, 
2006). 
 
 
2.1.9 Potential New Inhibitors of HMG-CoA Reductase 
A library of novel statin compounds have been synthesised (Lindsay et al., 2010). These compounds are 
based around the structures of atorvastatin and rosuvastatin. These two statins were chosen as the 
parent compounds as they are the most potent LDL-lowering agents of the statins currently available 
(Shepherd et al., 2003). The compounds are all synthesised with the HMG like moiety in a cyclic lactol 
form, this differs from the typical lactone form often seen in type 1 statins because the ketone is 
reduced to a hydroxyl group. This basic structure has then been modified to produce a library of 
potential HMG-CoA reductase inhibitors as shown in figure 2.16. 
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Figure 2.16. Structures of potential HMG-CoA reductase inhibitors synthesised by Redx Pharma. 
Structures are all based around the parent compounds (A) atorvastatin or (B) rosuvastatin. The 
structures of the wide range of lactol acetal compounds are indicated. The lactone derivatives of 
atorvastatin and rosuvastatin, (C) and (D) respectively, were also synthesised. 
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All of the potential HMG-CoA reductase inhibitors contain a modification at the R1/R3 position indicated 
in figure 2.16, producing lactol acetal compounds. This modification ranges from a methyl group to a 
much larger polyether or substituted phenyl group. The R2/R4 position remains unmodified in many of 
the compounds. Modifications in both positions affect the steric and electronic properties of the original 
compounds which will alter the strength with which they bind to the active site of HMG-CoA reductase.  
The aim of this work is to determine the ability of these new compounds to inhibit HMG-CoA reductase 
in vitro. The inhibitors that perform the best in enzyme assays will then be selected for animal trials in 
order to determine whether or not the inhibitory effects are replicated in vivo.  
 
 
2.2 Results and Discussion 
2.2.1 Initial Screening 
The ability of the compounds described in section 2.1.9 to inhibit the activity of HMG-CoA reductase was 
measured using an enzyme assay. The assay showed the rate of conversion of HMG-CoA to mevalonate 
by measuring the conversion of the cofactor NADPH to NADP, at pH 7.2. The rate of reaction can be 
monitored due to the characteristic UV absorption of NADPH at 340 nm. For every molecule of HMG-
CoA reduced to mevalonate, two molecules of NADPH are oxidised to NADP. NADP does not absorb UV 
light at 340 nm so the total absorption of the reaction mixture falls as the reaction proceeds. When the 
assay is carried out in the presence of an HMG-CoA reductase inhibitor, the rate of catalysis and 
therefore the fall in absorption at 340 nm is smaller, as can be seen in figure 2.17. More potent 
inhibitors of HMG-CoA reductase will produce lower rates of catalysis and therefore smaller decreases in 
absorption. 
Through initial testing of the novel HMG-CoA inhibitors and the parent compounds, atorvastatin and 
rosuvastatin, it was determined that an inhibitor concentration of 50 nM was sufficient to differentiate 
between non-inhibitors and those compounds likely to inhibit HMG-CoA reductase to a similar degree to 
atorvastatin and rosuvastatin. The mean serum statin concentration of patients taking a 20 mg dose of 
atorvastatin is 15 nM (Bjorkhem-Bergman et al., 2011) and statin concentrations in liver cells have been 
shown to be up to twice those in serum (Thelen et al., 2006). 50 nM is therefore a reasonable 
approximation of in vivo concentrations.  
The concentrations of HMG-CoA reductase, HMG-CoA and NADPH were adjusted in order to give a 
constant rate of catalysis over the ten minutes for which the absorption was measured. This ensures a 
more accurate calculation of the rate of reaction. All compounds were tested blind, i.e. the identity of 
each compound was unknown at the point of testing. A minimum of three biological repeats of each 
assay were carried out in a UV/vis microplate spectrophotometer. The assay is described in chapter 7.2. 
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Figure 2.17. Effect of rosuvastatin on the change in UV absorption of the HMG-CoA reductase assay. 
Change in UV absorption at 340 nm of the HMG-CoA reductase assay over time in the absence of an 
HMG-CoA reductase inhibitor and the presence of 50 nM rosuvastatin, a potent HMG-CoA reductase 
inhibitor. This plot shows the raw data from a single assay and negative control experiment. 
 
 
The initial screening assays were carried out with inhibitor concentrations of 50 nM for a period of ten 
minutes. The average rates of reaction for all of the potential inhibitors tested are shown in figure 2.18. 
The rate of reaction was also measured at 50 nM concentrations of the parent compounds atorvastatin 
and rosuvastatin to serve as a comparison. 
All of the organic compounds being tested are insoluble in water so 99.5 % DMSO was used to produce 
inhibitor solutions. As a result of this the initial test assays were carried out in 0.5 % DMSO. A control 
assay involving no inhibitor and a final DMSO concentration of 0.5 % was carried out to determine if the 
presence of DMSO had any significant effect on the rate of reaction compared to a second control 
containing no inhibitor and no DMSO. The results of these experiments are also shown in figure 2.18, 
which shows no significant change in the initial rate of reaction in the presence of 0.5 % DMSO. An 
additional control using denatured HMG-CoA reductase with each compound could also be included to 
confirm that the decrease in absorbance measured was due to the oxidation of NADPH to NADP by the 
enzyme and not directly by the inhibitor. 
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Figure 2.18. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of 39 different potential inhibitor compounds.  
Compounds which were not functional as inhibitors or showed poor inhibition are represented by blue 
bars. Compounds identified as good inhibitors are represented by red bars. The commercially available 
HMG-CoA reductase inhibitors atorvastatin and rosuvastatin are represented by orange bars. All 
inhibitors were tested at a final concentration of 50 nM and with a final DMSO concentration of 0.5 %. 
Negative controls, one containing no inhibitor and 0.5 % DMSO and one containing no inhibitor and no 
DMSO, are represented by green bars. Substrates HMG-CoA and NADPH both have a final concentration 
in the reaction of 200 µM and the HMG-CoA reductase concentration was 10 nM in all assays. Mean 
rates of reaction were calculated from a minimum of three biological repeats and error bars plotted 
show the standard error of the mean. Initial rate of reaction is shown in procedure defined units (p.d.u.) 
as it is calculated from absorption measurements which have no units.  
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Initially, 39 potential inhibitors were tested using the method outlined. Around 20 of these compounds 
appear to inhibit the activity of HMG-CoA reductase in vitro, as can be seen in figure 2.18. Of these 20 
compounds, 16 caused inhibition of the enzyme at a concentration of 50 nM to a level at least 
approaching that caused by atorvastatin at the same concentration. These included eight atorvastatin 
lactol acetals and seven rosuvastatin lactol acetals in addition to the atorvastatin lactone. 
The lactone forms of statin compounds are not expected to bind to the active site of HMG-CoA 
reductase in their cyclic form. Under physiological conditions they are hydrolysed enzymatically to form 
the extended, carboxylic acid conformation (Corsini et al., 1995). This allows some statins to be 
administered in their lactone form as pro-drugs (Todd and Goa, 1990). The structures of atorvastatin 
and rosuvastatin bound to HMG-CoA reductase show the compounds binding in their acid conformation 
(Istvan and Deisenhofer, 2001). The fact that the atorvastatin lactone shows inhibition of the enzyme in 
this experiment was therefore not predicted. The assay was carried out at pH 7.2 which is not high 
enough to cause chemical hydrolysis of the lactone. If the result obtained from the assay is accurate 
then this suggests one of two things: either an interaction with the enzyme is in some way responsible 
for causing the opening of the lactone ring or atorvastatin is able to inhibit HMG-CoA reductase in its 
closed, lactone conformation. 
Many of the lactol acetal variations were synthesised using both atorvastatin and rosuvastatin as the 
parent compounds.  The results of the assay show that, in many cases, if an atorvastatin lactol acetal 
inhibits HMG-CoA reductase then its corresponding rosuvastatin lactol acetal will also inhibit the 
enzyme. The majority of the compounds lacking modifications in the R2/R4 position (as indicated in 
figure2.16) and containing only simple, alkyl substituents in the R1/R3 position showed no inhibition or 
poor inhibition at a concentration of 50 nM. Several compounds lacking R2/R4 modifications but with 
larger, cyclic substituents attached to the acetal oxygen showed inhibition in testing, although the 
presence of a substituent group in the R2/R4 position appears to be linked to in vitro inhibition. There 
was particularly good agreement between the ability of the equivalent atorvastatin and rosuvastatin 
lactol acetals to inhibit HMG-CoA reductase. 
Some compounds with nicotinoyl esters in the R2/R4 position also appear to inhibit HMG-CoA reductase 
at concentrations of 50 nM. These compounds were designed with the nicotinoyl ester as it is known 
that, under physiological conditions, these groups are metabolised to form nicotinic acid (Salvi et al., 
1997). Nicotinic acid, or niacin as it is also known, has long been established to have lipid lowering 
effects which are achieved by inhibiting the breakdown of lipids stored in adipose tissue (Altschul et al., 
1955). A recent trial testing the effects of niacin therapy on patients already taking simvastatin indicated 
an increase in serum HDL levels and a decrease in serum LDL and triglyceride levels (Boden et al., 2011). 
Unfortunately this trial was ended early due to an increase in the incidence of strokes which was 
subsequently shown to be statistically insignificant. 
As previously mentioned, existing statin drugs are known to bind to HMG-CoA reductase with their HMG 
like moiety in the extended, acid conformation. In all of the compounds tested in this assay, the HMG 
like moiety is in a closed, lactol form. There is some evidence that, under physiological conditions, 
lactols are oxidised to form their corresponding lactones (Nicoll-Griffith et al., 1999). In the case of statin 
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compounds the lactone ring would then undergo enzymatic ring opening allowing them to bind to HMG-
CoA reductase in the extended form (Corsini et al., 1995). However, the conditions under which this 
assay was carried out are unlikely to cause such reactions to occur. The assay lacks any of the enzymes 
which would be responsible for these conversions in the human body so these cannot cause oxidation or 
ring opening. In addition to that, the assay is carried out at pH 7.2 which is certainly too close to neutral 
to allow the ring opening of a lactone. This means that, either the lactol rings are opening via some 
other mechanism or the compounds are binding in their cyclic conformations. 
Acetals are stable but exist in equilibrium with their corresponding hemiacetals in the presence of 
water. The lactol acetals tested in this work could, potentially, therefore form two different hemiacetals 
depending upon their relative stabilities. In one scenario the lactol form of the compound would be 
formed effectively removing the modification at the R position of all compounds, as shown in scheme 
(A) in figure 2.19. Following its formation, the lactol can then open to form a hydroxyaldehyde which is 
similar in structure to the open acid form taken by statin drugs but lacking a hydroxyl group. The 
practicalities of such ring opening would be that only the different R2/R4 substituents would have any 
effect upon the difference in inhibition caused between different compounds. However, only three 
different groups are present in that position across all of the compounds tested, namely hydroxyl, 
benzyl ether and nicotinoyl ester. While both of the nicotinoyl esters tested inhibited HMG-CoA 
reductase, only some of the hydroxyl and benzyl ether compounds were inhibitors while others were 
not. In addition to this, the lactol forms of the atorvastatin and rosuvastatin were also tested using the 
assay and neither compound inhibited HMG-CoA reductase. This result rules out the possibility of 
hydroxyaldehydes being the functional inhibitors in these compounds.  
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Figure 2.19. Potential ring opening reactions of lactol acetal compounds.  
Acetals exist in equilibrium with their corresponding hemiacetal. In the case of the potential HMG-CoA 
reductase inhibitors tested here, this equilibrium could first result in the formation of (A) the 
corresponding lactol or (B) the corresponding hydroxy-hemiacetal. Lactols often exist in equilibrium with 
their open, hydroxyacetone form as shown in scheme (A). The possible extended conformations are (C) 
hydroxyacetone produced by scheme (A) or (D) hydroxy-hemiacetal produced by scheme (B). The 
extended acid conformation of existing statin drugs is shown in (E). R3 is atorvastatin or rosuvastatin, R1 
and R2 are the sites of variation in the compounds tested in this work. 
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The other possible reaction that could take place involving formation of a hemiacetal results in the 
formation of a hydroxyhemiacetal. This reaction is shown in scheme (B) in figure 2.19 and causes the 
lactol ring to open. Again, this open form of the lactol ring is very similar to the open acid form of statin 
drugs, varying only in the presence of a hemiacetal functional group in place of the carboxylic acid. 
However, unlike the lactol ring opening discussed above, the modifications at both the R1/R3 and R2/R4 
positions should be present in the open form. This could account for the inhibition results which do not 
support the hydroxyaldehyde being formed. 
If the potential inhibitors do indeed form the hydroxyhemiacetal, then it is likely their modes of binding 
are similar to those observed for existing statin drugs in crystal structures with HMG-CoA reductase 
(Istvan and Deisenhofer, 2001). The significant difference between the hydroxyhemiacetals and the 
extended acid conformation of the statins is the replacement of the carboxylic acid group with a 
hemiacetal. This is likely to alter the interactions between the inhibitors and the enzyme active site 
although the hydroxyhemiacetals still contain polar oxygen atoms in similar positions so may still be able 
to form similar interactions with the enzyme. Any other differences in binding modes are likely to be due 
to the structural variation in the lactol acetal compounds. 
If the inhibitors do bind in a conformation similar to that of the open acid statins, then any group added 
in the R1/R3 position is likely to be in close proximity to R590, S684, K692 and K735 in the active site of 
HMG-CoA reductase. However, the majority of the groups found at this position in the compounds 
showing inhibition are relatively large and are unlikely to fit easily into an area of the active site that 
would already be rather crowded. This means that any conformation of the inhibitors that does bind to 
HMG-CoA reductase would probably require any group in the R1/R3 position to be oriented away from 
the HMG binding region of the enzyme. This may allow new inhibitor-enzyme interactions not present in 
the binding of existing statin compounds. Such interactions may be stronger if the R1/R3 group of the 
inhibitor contains polar groups as present in the lactol 2,4-dimethoxyphenyl acetals and lactol 2,4,6-
trifluorophenyl acetals, for example. 
The role played by modifications in the R2/R4 position is less clear if the inhibitors are binding in the 
hydroxyhemiacetal form. All of the substituents present in this position contain large, six-membered 
aromatic rings. The size of these groups makes it unlikely that the hydroxyhemiacetals would be able to 
bind with this particular group in a similar conformation to that observed for the equivalent group in 
existing statins. Binding in such a conformation would almost certainly disrupt other interactions 
between the inhibitor and the HMG binding site. Any binding conformation would also have to minimise 
the interactions between the aromatic group substituent and the larger aromatic rings of the statin 
structure. 
Another possibility is that the compounds are binding to HMG-CoA reductase in their cyclic, lactol 
conformations. This is possible as the relative distances between the oxygen atoms in the structure will 
not be too dissimilar to the distances between the carboxylic acid and hydroxyl groups in the extended 
acid conformation of the existing statin compounds. However, the ring structure limits the range of 
conformations that may be adopted by a given compound. This may explain the fact that the 
compounds with polar substituents are more likely to inhibit HMG-CoA reductase as their polar groups 
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are able to form stronger interactions with the active site of the enzyme. However, those compounds 
containing an additional benzyl or nicotinoyl group in the R2/R4 position would be unlikely to adopt a 
suitable binding conformation as any flexibility in their structures is limited. 
Figure 2.18 appears to show that two of the compounds tested actually enhance the rate of catalysis by 
HMG-CoA reductase. Assuming that these results are accurate and that the compounds being tested are 
free of contamination which could account for this then the most likely explanation for this 
phenomenon would be allosteric enhancement of the enzyme. This would mean that the compounds 
are binding to a site in the enzyme that is distinct from the active site. Allosteric activators or inhibitors 
have been described for several enzymes (Volkman et al., 2001, Chen et al., 2010), although no allosteric 
activators have previously been described for HMG-CoA reductase. Further investigation of the nature 
of the interaction between the compounds which appear to show activation and the enzyme is needed, 
perhaps through crystallographic studies, in order to determine whether or not allosteric activation is 
truly occurring in these cases. This is discussed further in section 6.1. 
A limitation of this assay is that these possible conformations of the compounds may not represent the 
forms that they take under physiological conditions. This is certainly true of the lactone compounds and 
the nicotinoyl compounds as they are known to undergo enzymatic modifications which would not be 
possible in the conditions of the assay. Similarly, benzyl ethers present in other compounds have been 
known to be removed by metabolic enzymes (Miller et al., 2000). Additionally, there is a possibility that 
all of the lactol acetal compounds may be oxidised to form either the atorvastatin or rosuvastatin 
lactones that would then undergo an enzymatic ring-opening reaction. Effectively this would result in all 
of the potential inhibitors acting as prodrugs for their parent compounds, atorvastatin or rosuvastatin. It 
is therefore important that the mode of binding of the inhibitors is determined before drawing firm 
conclusions from the results of the assay. Should the compounds prove to be prodrugs for other, active 
compounds in vivo, they may possibly display improved pharmacokinetic properties compared to other 
statin compounds. This may allow lower doses to be used in treatment of high cholesterol which may 
result in lower costs or a reduction in side-effects. 
The assay used seems to serve as an effective technique to assess whether or not the compounds are 
inhibitors of HMG-CoA reductase. Ideally, the initial rates of reaction for each compound could be used 
to identify trends within the library of compounds in order to gather further information about their 
modes of binding to the enzyme. This could potentially be used for more targeted inhibitor design if, for 
example, the addition of larger groups in certain positions caused an increase or decrease in the initial 
rate of catalysis at 50 nM inhibitor. Unfortunately no such trends can be identified in the data generated 
by this work. This is likely to be due to the limited sensitivity of the assay so other approaches would be 
required if such trends were to be identified. This is discussed in more detail in section 6.1. 
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2.2.2 Calculation of IC50 Values 
Following the initial screening of potential HMG-CoA reductase inhibitors, IC50 values were calculated 
for those compounds selected as inhibitors. The IC50 of an inhibitor is the concentration of inhibitor that 
inhibits the activity of a process by 50 %. In the case of this assay, the IC50 is the concentration of 
inhibitor at which the initial rate of reaction is 50 % between its minimum and maximum values. In order 
to calculate this, the assay was repeated over a range of inhibitor concentrations from 1 nM to 50 nM. A 
graph of initial rate of reaction against inhibitor concentration was plotted for each inhibitor and a 
sigmoidal curve fitted to the data using a least squares regression method. Each curve was fitted to a 
Boltzman function in the form: 
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Where y is the initial rate of reaction, x is the inhibitor concentration, A1 is the initial rate of reaction at 
minimal inhibition, A2 is the initial rate of reaction at maximal inhibition, x0 is the IC50 and dx is the 
concentration range over which inhibition changes from minimal to maximal. In each case the initial rate 
of reaction with no inhibitor was used as an estimate A1. A2 was estimated from a plot of the initial rates 
of reaction against the concentration of inhibitor. The estimated values of x0 and dx were calculated by 
least squares regression. 
IC50 values were calculated for the sixteen compounds identified as inhibitors by the initial screening 
assay carried out at 50 nM inhibitor. In addition to this, IC50 values were calculated for atorvastatin and 
rosuvastatin.  The initial rates of reaction data and the fitted curves are shown in appendix A. 
The IC50 values calculated for atorvastatin and rosuvastatin are 7 nM and 4 nM, respectively. The IC50 
values found in the literature for these compounds are 8 nM for atorvastatin and 5 nM for rosuvastatin 
(Istvan and Deisenhofer, 2001). This shows that the method used for calculating IC50 values in this work 
provides reasonably accurate results although may slightly underestimate the true values. As can be 
seen in table 2.1 the IC50 values of the compounds tested vary although the majority of compounds 
have IC50 values lower than that of atorvastatin. Calculation of the IC50 values serves as a further level 
of screening before the compounds are put forward for use in in vivo testing. 
Compounds with lower IC50 values are more desirable medicines as they require a smaller dose to 
achieve the same effects as a similar compound with a higher IC50 (Copeland, 2005). For many drugs 
this is particularly desirable as administering a lower dose can reduce the effects of any dose-dependent 
side effects. However, the majority of side effects of statin drugs are not dose dependent since they 
occur due to the reduction in synthesis of various molecules synthesised by the mevalonate pathway. 
Liver failure is the main dose-dependent side effect of statins although this is extremely rare so 
discovery of statins with IC50 values significantly lower than those already available is unlikely to have a 
significant effect upon its incidence. 
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Compound Number IC50 / nM 
IB/13/1 6 
IB/19/1 1 
IB/20/1 2 
IB/21/1 2 
IB/26/1 4 
IB/28/1 1 
IB/29/1 5 
IB/32/1 4 
IB/56/1 4 
IB/57/1 1 
IB/60/1 1 
IB/61/1 2 
IB/62/1 5 
IB/66/1 12 
IB/67/1 4 
Atorvastatin Lactone 4 
Atorvastatin 7 
Rosuvastatin 4 
Table 2.1. IC50 values of compounds identified to be inhibitors of HMG-CoA reductase after screening 
at 50 nM inhibitor.  
Values are the concentration of inhibitor at which HMG-CoA reductase activity i is 50 % between its 
minimum and maximum values, calculated over a range of inhibitor concentrations between 1 nM and 
50 nM. Also included are the IC50 values of atorvastatin and rosuvastatin calculated by the same 
method. 
 
 
There are some limitations in these IC50 values. As discussed above, it is likely that these values are 
subject to an error of somewhere in the region of ±2 nM. This reduces the opportunity to identify trends 
within IC50 values and limits the application of the data beyond acting as a second level of screening. 
However, the IC50 values easily identify those compounds with an IC50 in the region of the IC50s of 
atorvastatin and rosuvastatin and those that clearly have a higher IC50 value. Part of the error is due to 
the range of concentrations of inhibitor that were tested. For example, in the case of the atorvastatin 
methyl nicotinoyl ester the IC50 value appears to be approximately 1 nM. However, the lowest inhibitor 
concentration used in the calculation is 1 nM. This means that the real IC50 may conceivably be one or 
more orders of magnitude lower and this could be determined by increasing the range of concentrations 
tested. The assay was not carried out at lower inhibitor concentrations as it was felt that the results 
obtained provided a good enough estimation of the IC50 value to identify the most suitable candidates 
for further testing. This is supported by the fact that the IC50 values calculated for atorvastatin and 
rosuvastatin using this method are with 1 nM of the published IC50 values. It is also possible that the in 
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vitro IC50 values will not necessarily be related to the in vivo IC50 values due to the likelihood of 
enzymatic modifications to the compounds as described in section 2.2.1. 
 
 
2.2.3 Molecular Modelling of HMG-CoA Reductase Inhibitor Binding 
Prior to the in vitro testing, the potential interactions between some of the compounds and HMG-CoA 
reductase had been modelled at the University of Liverpool. The results of this modelling suggested that 
the rosuvastatin analogues would have similar binding energies to rosuvastatin and that the atorvastatin 
analogues would bind with similar energies to atorvastatin. This modelling was carried out assuming 
that the inhibitors would be in the ring-open hemiacetal conformation and calculated two different 
docking energies, one for each enantiomer, for each compound. Of the compounds modelled, IB/6/2 
and IB/7/2 were expected to bind poorly to HMG-CoA reductase and only one enantiomer of IB/21/1 
was expected to bind to the enzyme. As the results in figure 2.18 show, IB/6/2 and IB/7/2 do not inhibit 
HMG-CoA reductase although IB/21/1 does. All of the other compounds modelled were predicted to 
bind to the enzyme although clearly several of them do not show inhibition in this assay. 
Molecular modelling, such as that carried out for these compounds, has a number of limitations. In the 
case of these compounds, as has been discussed in section 2.2.1, the mode of binding is not known. The 
models assume that binding will occur in the hemiacetal conformation but binding may also be 
occurring in the cyclic, lactol acetal form. In addition to this, the modelling relies on existing structures 
of the enzyme when it is bound to existing statin drugs, particularly the parent compounds atorvastatin 
and rosuvastatin. As these compounds are almost certainly binding in a different conformation to the 
carboxylic acid forms observed in these structures, it is possible that the mode of binding and the shape 
of the active site will vary to some degree. 
Despite the limitations of this modelling, it could be used, along with experimental data, in order to 
create more accurate models for other compounds. The results of this assay have some value in this as 
they show which compounds inhibit HMG-CoA reductase well and which do not appear to cause any 
inhibition. The IC50 values also provide a guide to the relative binding strength of each inhibitor. The 
most important step in improving molecular modelling would be to confirm the binding conformations 
of those compounds which inhibit the enzyme. In addition to this, determining the binding affinities of 
these compounds using a technique such as isothermal titration calorimetry would offer a direct 
experimental comparison for the calculated docking energies. This would allow refining of the model to 
enable more accurate prediction of the binding of other compounds and is discussed in more detail in 
section 6.1. 
Accurate modelling is extremely useful as it allows the properties of compounds to be analysed before 
the compound itself has even been synthesised. This can save time and money as compounds predicted 
to show no interaction with the enzyme will not be synthesised or tested. Additionally, if the model is 
improved enough, molecular modelling could replace the need for carrying out in vivo studies in 
animals. This would also require accurate modelling of interactions with other molecules in order to 
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predict side-effects accurately. An effective molecular modelling system could potentially reduce the 
time and costs involved in drug discovery considerably. 
 
 
2.2.4 Testing of Other Inhibitors 
Following on from the initial inhibitor testing described in sections 2.2.1 and 2.2.2, a further group of 
compounds was synthesised (Lindsay et al., 2010). These consisted of a number of new lactone acetal 
compounds not previously tested, as well as purified enantiomers of those compounds identified as 
inhibitors in the initial screening. The initial rate of catalysis by HMG-CoA reductase in the presence of 
50 nM of inhibitor was calculated using the same method as described in section 2.2.1. The results of 
this are shown in figure 2.20. 
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Figure 2.20. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of 18 different potential inhibitor compounds. 
 Compounds which were not functional as inhibitors or showed poor inhibition are represented by blue 
bars. Compounds identified as inhibitors are represented by red bars. The commercially available HMG-
CoA reductase inhibitors atorvastatin and rosuvastatin are represented by orange bars. All inhibitors 
were tested at a final concentration of 50 nM and with a final DMSO concentration of 0.5 %. Negative 
controls, one containing no inhibitor and 0.5 % DMSO and one containing no inhibitor and no DMSO, are 
represented by green bars. Substrates HMG-CoA and NADPH both have a final concentration in the 
reaction of 200 µM and the HMG-CoA reductase concentration was 10 nM in all assays. Mean rates of 
reaction were calculated from a minimum of three biological repeats and error bars plotted show the 
standard error of the mean. Initial rate of reaction is shown in procedure defined units (p.d.u.) as it is 
calculated from absorption measurements, which have no units. 
 
 
Of the 18 new compounds tested, 13 of them were determined to inhibit HMG-CoA reductase to a 
similar degree to atorvastatin and rosuvastatin at concentrations of 50 nM. Six of these compounds are 
new compounds not tested in the earlier experiments and seven are purified enantiomers of 
compounds previously identified as inhibitors of HMG-CoA reductase. Interestingly, three of the ten 
purified enantiomers tested did not appear to inhibit HMG-CoA reductase. This suggests that the 
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compounds are binding to the enzyme in a manner which preserves their stereocentre. This means that 
they cannot be binding in the extended acid conformation or the extended aldehyde conformation as 
these forms are lacking the chiral carbon atom. Binding in the cyclic, lactol acetal, conformation or the 
extended hemiacetal conformation would both allow for the differences in inhibition between the 
stereoisomers. 
 
 
Compound IC50/nM 
IB/83/1/4 3 
IB/87/1/2 2 
IB/87/1/3 7 
IB/89/1T 8 
ED/05/01B 13 
ED/05/01T 5 
ED/05/02T 10 
ED/06/2 6 
ED/07/2 8 
ED/09/02 28 
ED/11/02 3 
SH/II/87A 34 
TD/I/31A 9 
Table 2.2. IC50 values of 13 HMG-CoA reductase inhibitors. 
 Values are the concentration of inhibitor at which HMG-CoA reductase activity is 50 % between its 
maximum and minimum values calculated over a range of inhibitor concentrations between 1 nM and 50 
nM. 
 
 
The IC50 values of the 13 compounds from this group which are inhibitors of HMG-CoA reductase are 
shown in table 2.2. As with the first group of compounds, the majority of these compounds have IC50 
values similar to those of the parent compounds, atorvastatin and rosuvastatin. This suggests that they 
may be active in similar doses in vivo. Two pairs of separated enantiomers have had their IC50 values 
calculated in this work. In both cases, the IC50 value is different for each enantiomer further supporting 
the idea that the compounds are binding to the enzyme in a manner which preserves the differences in 
stereochemistry.  
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2.3 Conclusions 
Many of the compounds tested inhibit HMG-CoA reductase at clinically useful concentrations 
(McTaggart et al., 2001) having similar in vitro profiles to the currently used statins atorvastatin and 
rosuvastatin. The experiments were able to select a further batch of compounds for use in further 
testing. Had time allowed, in vitro testing of the toxicity of the compounds to cultured human cells could 
also have been carried out by assaying cell viability using a dye such as resazurin, as described in section 
6.1. However, as in vivo animal testing experiments had already been arranged, it was not possible for 
such an experiment to be conducted 
The animal testing that was carried out “demonstrated the potential for superiority over existing best-
in-class drugs.” This demonstrates that the testing carried out is an effective way of selecting effective 
inhibitors for further testing. A potential drawback of this type of assay is the possibility that modified 
versions of the compounds may be responsible for inhibition in vivo. However, the positive results 
obtained from the animal testing suggest that, even if this is the case, the experiments used are still a 
good indicator of such activity. 
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Chapter 3 
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3. Antibacterial Activity of Novel Fluoroquinolones 
 
3.1 Introduction 
3.1.1 Fluoroquinolones 
The fluoroquinolones are a group of broad-spectrum, synthetic antibacterial compounds and are part of 
the wider, quinolone family. The first quinolone was discovered inadvertently as a by-product of the 
synthesis of chloroquine, an antimalarial agent. This compound, nalidixic acid, was discovered to have 
moderate antibacterial activity against gram-negative bacteria (Lesher et al., 1962) and was first 
approved for medicinal use in 1967. In addition to its limited activity, nalidixic acid also proved to 
undergo high serum protein binding and caused rapid appearance of resistant bacteria (Hane and Wood, 
1969). Further first generation quinolone compounds were developed including oxolinic acid, piramidic 
acid and pipemidic acid. These compounds typically have a greater potency against gram-negative 
bacteria and, in the case of pipemidic acid, activity against Pseudomonas aeruginosa which is not 
observed for nalidixic acid. The addition of the piperazine ring to form pipemidic acid was also shown to 
cause some activity against gram-positive bacteria (Jacoby and Hooper, 2012). The first fluoroquinolone, 
flumequine, was patented in 1973. This compound is a first generation quinolone compound which 
showed an even greater potency against gram-positive bacteria (Appelbaum and Hunter, 2000). These 
compounds, where still in use, are primarily used in treating urinary tract infections (UTIs) in humans 
and also have some veterinary uses. 
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Figure 3.1. The general structure of quinolone compounds and the structures of three first generation 
quinolone antibacterial drugs. 
 All compounds contain the quinolone nucleus and the sites of potential structural variation are 
numbered in the general structure. 
 
 
Norfloxacin was the first second generation quinolone to be produced. Like all later generation 
quinolone compounds, norfloxacin is a fluoroquinolone and combines the fluorine at position six found 
in flumequine with the piperazine ring found in pipedimic acid. The combination of these two structural 
features results in increased potency against both gram-negative and some gram-positive bacteria. 
Despite its improved potency, the pharmacokinetic profile of norfloxacin means that it is only used as a 
last resort in treating infections. However, following the patenting of norfloxacin in 1978 a large number 
of new fluoroquinolones were introduced. Many of these drugs, such as pefloxacin, ciprofloxacin and 
ofloxacin, are still in clinical use today. These other second generation fluoroquinolones are absorbed 
much more readily by the gastrointestinal tract, making them much more effective at fighting systemic 
infections. To this day, ciprofloxacin remains the most potent fluoroquinolone agent against gram-
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negative bacteria. Despite their improvement upon first generation quinolones, these antibacterial 
drugs are still not potent enough against gram-positive bacteria to be used clinically against respiratory 
infections so are still used primarily in the treatment of UTIs (Appelbaum and Hunter, 2000). 
Ciprofloxacin can also be used in the treatment of gastrointestinal tract infections. However, while the 
development of resistance to these agents is not as rapid as development of resistance to nalidixic acid, 
resistance to second generation quinolones is still a problem in certain bacterial species, particularly 
Staphylococcus aureus and P. aeruginosa. 
 
 
 
Figure 3.2. The structures of four second generation fluoroquinolone compounds.  
All compounds contain the basic quinolone nucleus in addition to a fluorine at position 6 and a piperazine 
ring at position 7. Ofloxacin exists as a mixture of two enantiomers and its stereocentre is indicated. 
 
 
The third generation, or ‘respiratory’, fluoroquinolones were developed specifically for increased activity 
against gram-positive bacteria. These compounds include levofloxacin, grepafloxacin and sparfloxacin. 
They typically have a much broader spectrum of activity which includes Streptococci, particularly 
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Streptococcus pneumoniae, as well as some anaerobes. However, the activity of third generation 
fluoroquinolones against S. aureus remains limited and their improvement in activity against 
fluoroquinolone-resistant S. aureus is not great enough to be clinically useful (Appelbaum and Hunter, 
2000). Levofloxacin is the functional enantiomer of the second generation fluoroquinolone ofloxacin and 
shows improved activity when administered as the single enantiomer compared to the racemic mixture 
present in ofloxacin. The other third generation fluoroquinolones are similar in structure to the second 
generation compounds, often with very minor modifications responsible for their improved activity. 
Unlike the second generation drugs, the activity of these compounds is sufficient to treat respiratory 
tract infections. 
 
 
 
Figure 3.3. The structures of four third generation fluoroquinolones. 
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The fourth generation of fluoroquinolone compounds shows, perhaps, the greatest improvement over 
earlier generations. These compounds include clinafloxacin, gemifloxacin, sitafloxacin and moxifloxacin. 
All of these compounds show a similar level of activity against gram-negative bacteria to ciprofloxacin, 
making them some of the most effective fluoroquinolones at fighting infections caused by gram-
negative species, although their activity against non-fermentative species such as P. aeruginosa remains 
poor. In addition to this activity, the fourth generation compounds show very good activity against a 
range of gram-positive bacteria including S. pneumoniae, Haemophilus influenza and Chlamydia 
pneumoniae. Many of the compounds, in particular sitafloxacin and clinafloxacin, also have increased 
activity against anaerobes. Another improvement seen in these compounds is the slower development 
of resistance to their action. 
 
 
 
Figure 3.4. The structures of four fourth generation fluoroquinolones. 
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3.1.2 Type II DNA Topoisomerases 
Fluoroquinolone antibiotics function by inhibiting the action of bacterial type II topoisomerases. These 
enzymes are essential for regulating DNA topology, especially during replication (Kubo et al., 1979). 
There are two different types of type II topoisomerase: DNA gyrase and DNA topoisomerase IV. DNA 
gyrase is able to introduce negative supercoils into the bacterial chromosome and is also responsible for 
unwinding DNA at the replication fork (Brown and Cozzarelli, 1979). Topoisomerase IV, on the other 
hand, is responsible for decatenating the daughter chromosome from the parent prior to cell division 
(Peng and Marians, 1993) in addition to relaxing negative supercoils (Zechiedrich et al., 2000). In order 
to achieve this, type II topoisomerases introduce and stabilise a double-strand break in the DNA allowing 
one strand to pass through the other in an ATP dependent manner. This is in contrast with type I 
topoisomerases which only break a single strand of DNA in order to regulate its topology (Lima et al., 
1994). 
Type II topoisomerases are tetrameric with gyrase being made up of two GyrA subunits and two GyrB 
subunits and topoisomerase IV containing two ParE and two ParC subunits. The GyrB and ParE domains 
consist of a GHKL ATPase domain and a Toprim domain which is a Rossman fold capable of coordinating 
magnesium ions. The GyrA and ParC domains contain a 5Y-catabolite gene activator protein (5Y-CAP) 
domain as well as a variable C-terminal domain. Like domains form dimer interfaces which are known as 
gates and are responsible for controlling the movement of DNA by the enzyme. There is significant 
sequence homology between gyrase and topoisomerase IV enzymes and the two different type II 
topoisomerases of Escherichia coli share 40 % sequence identity (Ullsperger and Cozzarelli, 1996). Such 
identity is not seen in the C terminal domains of the enzymes which are likely to be responsible for 
substrate recognition (Corbett et al., 2004). While the crystal structure of a complete type II 
topoisomerase has not been solved, several different partial structures exist which give a good insight 
into the structure and catalytic mechanism of the tetramer (Laponogov et al., 2009, Bellon et al., 2004, 
Morais Cabral et al., 1997). A schematic representation of the different domains present in type II 
topoisomerases is shown in figure 3.5. 
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Figure 3.5. The domain structure of bacterial DNA gyrase.  
The N-gate is formed by the ATPase domains, which are shown in light blue (GHKL subdomains) and pink 
(transducer subdomains). The DNA gate is formed by the Toprim domains, which are shown in red, and 
the 5Y-CAP domains, shown in green. The tower domains are shown in purple and the variable, C-
terminal domains in orange and the C-gate is shown in dark blue. 
 
 
Type II topoisomerases modify DNA via the ‘two-gate mechanism’ (Roca and Wang, 1994). The ‘gates’ 
involved are the N-gate which is created at the interface of the N-terminal domains of GyrB or ParE, the 
DNA gate which is formed by the GyrA-GyrB-DNA interface in gyrase and the ParC-ParE-DNA interface in 
topoisomerase IV and the C-gate or exit gate at the interface of the C-terminal region of GyrA or ParE. 
The gate (or ‘G’) segment of DNA associates with the enzyme at the interfaces of the N-termini of the 
GyrA dimer and the Toprim domain of GyrB (Bax et al., 2010). During DNA association, approximately 
130 base pairs wrap around the enzyme, particularly the variable C-terminal domains, supporting the 
hypothesis that these domains are involved in target recognition (Orphanides and Maxwell, 1994). 
Following association of the G segment, a second segment of DNA, the ‘T’ segment, associates with the 
N-gate of the enzyme. The primary role of gyrase is to introduce supercoils to a single DNA molecule so 
the T segment in such cases will be from the same DNA molecule as the G segment. Topoisomerase IV, 
in addition to a role in regulating supercoiling of DNA, is also responsible for decatenating daughter 
chromosomes from parent DNA, in which case the T segment and G segment would come from different 
DNA molecules. The N-gate is situated above the G segment, positioning the T segment in the optimum 
position to be passed through the G DNA strand (Heddle et al., 2004). 
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Association of the DNA T segment to the N-gate of a type II topoisomerase enzyme facilitates ATP 
binding to the ATPase domain of GyrB or ParE. ATP binding triggers a conformational change in these 
subunits which effectively traps the T segment in position above the DNA G segment by closing the N-
gate of the enzyme (Brino et al., 2000). The closing of the N-gate triggers asymmetric double strand 
cleavage of the DNA G segment. The strands are cleaved four base pairs apart and the overhanging ends 
form phosphotyrosyl bonds with tyrosine residues in the GyrA or ParC breakage-reunion domains. These 
tyrosine residues are essential for catalysis and are highly conserved (Laponogov et al., 2010, Morais 
Cabral et al., 1997). At this point, the ATPase domain hydrolyses ATP, passing the DNA T segment 
through the double stranded break in the G segment. Once the T segment has passed through the 
break, the G segment is religated triggering the opening of the C gate and therefore release of DNA 
(Williams and Maxwell, 1999). In the absence of ATP, gyrase is able to catalyse DNA relaxation which is 
effectively the reverse of the supercoiling reaction (Gellert et al., 1977). 
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Figure 3.6.The reaction mechanism of type II topoisomerases.  
The yellow subunit represents the GyrB/ParE domain, the dark blue subunit represents the N-terminal 
domain of GyrA/ParC and the orange subunit represents the C-terminal domain. The DNA G-segment is 
represented by the green bar and the DNA T-segment by the purple bar. The small circles represent 
bound ATP (red) and unbound ADP (black). The progression through the mechanism is indicated by blue 
arrows and direction of conformational change is indicated by black arrows. ΔL is the change in linking 
number of the substrate DNA. 
58 
 
The crystal structure of the ParC breakage-reunion domain and ParE Toprim domain of S. pneumoniae 
has been solved with levofloxacin, moxifloxacin and clinafloxacin bound (Laponogov et al., 2009, 
Laponogov et al., 2010). These structures all show the fluoroquinolone compounds intercalating 
between the nucleotides of the cleaved DNA G segment. Specifically, binding is in the gap adjacent to 
the nucleotides which are bound to Tyr188 in ParC. The structure with bound Moxifloxacin shows the 
cyclopropane group of the drug in close proximity to Ser79 and Asp83 in the active site of the enzyme. 
The bicyclic group at position seven of moxifloxacin stacks against the fourth nucleotide on the opposite 
DNA strand. The structure also shows the carboxylic acid and ketone groups, which are conserved across 
the vast majority of quinolones, in close proximity to Gly77, Asp78 and Arg117. However, despite its 
strong influence on the potency of the fluoroquinolones, the fluorine at position six of the structure is 
oriented away from both the protein and DNA, suggesting its influence on inhibition to be due to 
electronic effects (Laponogov et al., 2009). The structure of topoisomerase IV with bound levofloxacin 
reveals a similar mode of binding, with the cyclic nucleus of the fluoroquinolone intercalating the 
cleaved DNA. However, in this structure the carboxylic acid group is seen to coordinate to Ser79 and 
Arg117 through a “highly-mobile” hydrogen-bonded water molecule (Laponogov et al., 2010). 
 
 
 
Figure 3.7. Moxifloxacin binding to DNA topoisomerase IV from S. pneumoniae.  
The enzyme active site is shown in cartoon representation. Moxifloxacin is shown in red and the DNA G-
segment is shown in green. The active site tyrosines which are bound to the cleaved DNA are shown in 
orange. Ser79 and Asp83, involved in quinolone binding, are shown in yellow. This image is taken from 
Laponogov et al.(2009). 
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The binding of fluoroquinolones to type II topoisomerases prevents religation of the DNA G segment, 
thus forming a stable quinolone-enzyme-DNA complex. This has a bacteriostatic effect as it blocks DNA 
replication and cell growth. Fluoroquinolones also have bactericidal effects which are not fully 
understood but act via different mechanisms depending upon the specific fluoroquinolone. The 
bactericidal effects of some quinolones can be blocked by the addition of the protein synthesis inhibitor 
chloramphenicol. This indicates that the quinolone-enzyme-DNA complex triggers the synthesis of a 
“suicide factor” which is responsible for cell death (Drlica et al., 2008). Other fluoroquinolone 
compounds cause chloramphenicol insensitive cell death. This bactericidal mechanism is typically 
observed in compounds containing cyclopropyl and methoxy groups. It is likely that this mechanism 
requires the action of peroxide as the accumulation of hydroxyl radicals has been observed in cells 
undergoing this process (Wang and Zhao, 2009). 
Fluoroquinolones are known to inhibit both DNA gyrase and DNA topoisomerase IV. However, which of 
these enzymes is the primary target depends upon the strain of bacteria and the fluoroquinolone in use. 
Typically, in gram negative bacteria, gyrase is the more susceptible enzyme, whereas, in gram positive 
bacteria, topoisomerase IV is more susceptible. This difference in preference goes some way to 
explaining why many fluoroquinolones tend to show high levels of potency against either gram negative 
or gram positive species but rarely both. The structure of a particular fluoroquinolone can have some 
influence on the target in a given bacterial strain. For example, S. pneumoniae is a gram positive 
bacterial species in which topoisomerase IV is the most susceptible target for fluoroquinolones. 
However, fluoroquinolones with a benzenesulfonylamido group at position seven show a preference for 
DNA gyrase in this organism. Addition of halogen or methoxy groups at position eight of the 
fluoroquinolone structure has also been observed to have a similar effect (Alovero et al., 2000). 
 
 
3.1.3 Structure Activity Relationships 
Since the discovery of nalidixic acid, several thousand different quinolone compounds have been 
synthesised. This has led to a good understanding of the structure activity relationships for each part of 
the molecule. The carbonyl group in position 4, the carboxyl group in position 3 and the 2-3 double bond 
are all essential for antibacterial activity. The close proximity of these groups to the substituent in 
position 2 limits the range of modifications that can be made while still retaining activity and hydrogen 
has been shown to be by far the optimal group. These features are responsible for interactions with the 
topoisomerase DNA gates as shown in the structures described in section 2.2 (Laponogov et al., 2010). 
The 3-carboxyl group is also important in bacterial uptake as it is ionised at physiological pH. The final 
essential structural feature of these drugs is the fluorine in position 6. The addition of this group to the 
first generation quinolone compounds was associated with a greater than ten-fold increase in DNA 
gyrase inhibition and up to a 100-fold improvement in minimum inhibitory concentration (MIC). As can 
be seen in figure 3.7, this group does not directly interact with the enzyme or the bound DNA. It is likely 
that the highly electronegative fluorine modulates the electron density of the aromatic quinolone ring 
allowing more effective base stacking when it is intercalating the cleaved DNA (Laponogov et al., 2009). 
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Figure 3.8. Core structure of quinolone compounds showing sites of modification. 
 
The other positions of the quinolone structure are much more tolerant to modifications and this has 
enabled the huge range of structures and corresponding activities that can be seen in the quinolone 
family. Compounds with a number of different substituents in position 1 have been synthesised. These 
modifications have an effect on both the potency and pharmacokinetics of the compounds. One of the 
most commonly added groups in this position, particularly in later generation fluoroquinolones, is a 
cyclopropyl group. This group has been shown to provide optimum in vitro activity, with 2,4-
diflurophenyl and t-butyl groups also improving activity to a lesser degree. The 2,4-difluorophenyl 
group, which is present in temafloxacin, also improves the in vivo efficacy of the compound and provides 
a slight improvement against gram positive bacteria and anaerobes. These groups are all more bulky 
than the ethyl groups found in nalidixic acid and other first generation quinolones and have been shown 
to interact directly with topoisomerase IV, which accounts for the improvement in activity against gram 
positive species (Laponogov et al., 2009). 
Substitutions at position 5 have been associated with improved activity against gram positive bacteria, 
although any improvements are minor if not present in addition to suitable substitutions in other 
positions, particularly position 1 (Domagala, 1994). Large, bulky substituents in position 5 cause a 
dramatic decrease in potency (Domagala et al., 1993). This is likely to be due to the proximity of this 
position to the essential, enzyme binding groups in positions 3 and 4, with bulky groups likely to 
interfere with this binding. Small amino, hydroxyl and methyl groups in this position are associated with 
an increase in in vitro potency. Amino groups, as present in sparfloxacin are responsible for the greatest 
increase in potency. However, these groups also have a negative effect on the MIC of a compound, so 
many fluoroquinolones simply retain a hydrogen in this position. 
The type of substituent in position 7 can have an influence on the potency, spectrum and 
pharmacokinetics of a quinolone compound. As discussed in section 3.1.1, the addition of a piperazine 
ring in this position in pipedimic acid was, along with the addition of fluorine in position 6, one of the 
key developments in producing clinically useful fluoroquinolones. The majority of later generation 
compounds contain either a piperazine or pyrrolidine ring in position 7, although these rings are often 
substituted. Piperazine rings, which are present in levofloxacin and sparfloxacin, are associated with 
improved potency against gram negative bacteria and also an increase in in vivo activity (Sanchez et al., 
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1988). Amino pyrrolidine groups, found in clinafloxacin and sitafloxacin amongst others, are associated 
with improved potency against gram positive bacteria. The pyrrolidine ring in gemifloxacin is substituted 
with both a 3-aminomethyl group and a 4-methyloximino group. These substituents have been shown to 
increase further the potency of the compound against gram positive bacteria as well as improving the 
serum half life of the drug. It has also been shown that increasing the length of the alkyl chain in this 
compound increases the gram positive activity further although this is associated with a decrease in 
activity against gram negative bacteria (Appelbaum and Hunter, 2000). The presence of a basic nitrogen 
as the position 7 substituent is associated with an increase in membrane permeation of the compound. 
This is because, at physiological pH, the group will be protonated and therefore the fluoroquinolone will 
be zwitterionic. 
The substituent at position 8 is important for the in vivo efficacy of the compound. Strictly speaking, 
quinolones have nitrogen in the aromatic ring in this position although the more common, pyridine-β-
carboxylic acid derivatives are still described as quinolones. The optimum groups in this position for in 
vivo efficacy are N, CF and CCl, although CF, CCl and COMe groups also show improved activity against 
anaerobes (Domagala, 1994). Unfortunately, the presence of a halogen, particularly chlorine, at this 
position is strongly associated with phototoxicity which is an issue in compounds such as clinafloxacin 
and sparfloxacin. Methoxy groups in this position are also associated with an increase in activity against 
anaerobes but compounds with this group, such as moxifloxacin and gatifloxacin, do not appear to carry 
the risk of phototoxicity (Appelbaum and Hunter, 2000). 
 
 
3.1.4 Side Effects of Fluoroquinolones 
The majority of quinolones in clinical use produce adverse reactions in between two and ten percent of 
cases. The majority of these reactions are minor and affect the central nervous system (CNS), the 
gastrointestinal (GI) tract and the skin, although more serious reactions do occur in some cases. GI 
effects are the most common and are reported with all fluoroquinolones. These effects range from 
nausea and anorexia to abdominal pain, vomiting and diarrhoea. The exact cause of these effects is 
unknown although it is likely to be due to GI irritation or a CNS effect (Norrby, 1991). CNS effects are the 
second most common and can range from dizziness and headaches to sleep disorders, delirium and 
convulsions. Two possible pathways have been suggested to account for these effects. Some 
fluoroquinolones are known to bind to GABAA receptors in the brain. This stops gamma-aminobutyric 
acid (GABA), the natural ligand of the receptor, from binding and causes stimulation of the CNS. This 
effect is most common with fluoroquinolones containing piperazine rings in position 7 and also occurs 
when pyrrolidine rings are found in the same position. Substitution of these rings decreases the ability 
of the compounds to bind to GABAA and the degree of in vivo brain penetration also plays a role in the 
level of binding(Takayama et al., 1995). Adverse skin reactions typically occur due to phototoxicity, 
which is discussed in section 3.1.3, or allergic reactions causing histamine release (Ball and Tillotson, 
1995). More serious skin problems are extremely rare. 
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Many fluoroquinolone compounds have been withdrawn from clinical use due to side effects which are 
specific to or more common with particular drugs. In very rare cases, fluoroquinolones have been known 
to cause sudden cardiac death and a condition called torsades de pointes which is characterised by an 
increased QT interval. These effects are more common with the fluoroquinolone grepafloxacin which 
has subsequently been withdrawn from use (Ball, 2000). Gatifloxacin has been withdrawn from use due 
to an increased incidence of hypo- and hyperglycaemia (Park-Wyllie et al., 2006) and levofloxacin has 
also been associated with dysglycaemia although it remains in use (Aspinall et al., 2009). Temafloxacin 
and trovafloxacin are known to cause severe immunologically mediated adverse reactions. This is due to 
the 2,4-difluorophenyl groups present in position 1 of these compounds. These effects range from fever, 
jaundice and haemolysis to, in severe cases, renal failure and hepatitis. Trovafloxacin has also been 
known to cause eosinophilic hepatitis with liver necrosis and even the need for liver transplantation in 
the most extreme cases (Chen et al., 2000). Neither of these two drugs remains in use. A final, rare class 
effect of fluoroquinolones is tendinitis, typically of the Achilles tendon. In some cases this can lead to 
the tendon rupturing although this effect is more common in the elderly and patients already taking 
corticosteroids (Dekens-Konter et al., 1994). 
Fluoroquinolones have also been shown to have some inhibitory activity against mammalian 
topoisomerase II. This activity is observed in all quinolones but each compound has a characteristic 
concentration above which inhibition occurs. The groups present in positions 1, 7 and 8 have been 
shown to be the most important in determining the degree of interaction with the mammalian enzyme 
(Elsea et al., 1993). For position 1, the strongest interactions are observed in compounds with a 
cyclopropyl substituent although t-butyl groups also show high activity. Substitution of the cyclopropyl 
ring, as seen in sitafloxacin, is able to reduce this effect. In position 7, pyrrolidine rings are responsible 
for the greatest activity but any compounds containing cyclic, nitrogen containing groups show activity 
(Wentland et al., 1993). In position 8, fluorine, chlorine or methoxy groups cause the greatest level of 
interaction with mammalian topoisomerase with a CH in that position causing the lowest activity. 
Interaction with the mammalian topoisomerase II enzyme is linked with cytotoxicity (Elsea et al., 1993). 
 
 
3.1.5 Mechanisms of Fluoroquinolone Resistance 
A major problem for all antibacterial drugs is the development of bacterial resistance to their effects 
(Andersson and Levin, 1999). The emergence of strains resistant to many different types of drug is a 
particular concern in hospital environments as infections caused by such strains are becoming 
increasingly difficult to treat. Fluoroquinolones are no different to other antibacterials in this respect 
and several different mechanisms of resistance to these compounds have been identified (Drlica et al., 
2012). 
Permeability based resistance to fluoroquinolones is an issue in gram negative bacteria. These bacteria 
contain protein channels called porins which are responsible for uptake of certain hydrophilic molecules. 
Fluoroquinolone resistance in certain gram negative bacteria has been associated with a deficiency in 
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certain porin proteins including OmpF in E. coli and D2 in P. aeruginosa (Michea-Hamzehpour et al., 
1991). In E. coli, permeability based quinolone resistance can also be associated with chloramphenicol 
and tetracycline resistance. This occurs because of a mutation in the marA gene of the multiple 
antibiotic system and leads to a downregulation of ompF mRNA and therefore a decrease in the number 
of OmpF porin channels (Cohen et al., 1988). 
Efflux based resistance is a significant issue for fluoroquinolones with many compounds acting as 
substrates for one or more different efflux pump proteins. Several different families of efflux pumps 
have been identified including the ATP-binding cassette (ABC) superfamily, the resistance-nodulation-
division (RND) superfamily, the major facilitator (MF) superfamily, the small multidrug resistance (SMR) 
family and the multi-drug and toxic compound extrusion (MATE) family. Gram negative bacteria typically 
express several different efflux pumps, at least 37 different pumps have been identified in E. coli, for 
example, and virtually all species have at least one pump that is able to export certain quinolones. Due 
to the range of structural variation in fluoroquinolone compounds, generalising with regards to efflux 
mediated resistance can be difficult. Gatifloxacin has actually been shown to inhibit certain efflux pumps 
in ciprofloxacin resistant strains of P. aeruginosa. If both compounds are used together their synergistic 
effects produce antibacterial activity against the resistant strains (Pankey and Ashcraft, 2005). Many 
efflux pumps are known to play a role in the export of multiple drug types, for example the AcrAB-TolC 
system in E. coli. This RND system exports several different antibacterials including β-lactams, 
tetracycline and chloramphenicol. E. coli strains deficient in the AcrAB proteins of this system are known 
to be hypersensitive to some fluoroquinolones but many fluoroquinolone resistant strains overexpress 
AcrA (Hirakawa et al., 2008). This results in decreased cellular accumulation of many antibacterials, 
potentially causing resistance to several different drugs. This phenomenon is also observed in certain 
resistant strains of P. aeruginosa where up to six different fluoroquinolone exporters from the RND 
superfamily are overexpressed leading to multidrug resistance (Kriengkauykiat et al., 2005). 
Efflux based resistance is also a common problem in gram positive bacteria. In these bacteria, the MF 
and SMR families are most commonly associated with fluoroquinolone resistance. In S. aureus, NorA, an 
MF family efflux pump, as well as certain MATE pumps are involved in quinolone export. These systems 
are regulated by the mgrA and mepA genes, respectively. In resistant strains, mutant alleles of these 
regulatory genes, leading to overexpression of the efflux pumps, are frequently found (Truong-Bolduc et 
al., 2006, Kumaraswami et al., 2009). The NorA equivalent in S. pneumoniae, PmrA, is known to export 
ciprofloxacin and norfloxacin although compounds with bulky substituents in position 7 of their 
structures, such as sitafloxacin and moxifloxacin, as well as substituents other than hydrogen in position 
8, are less susceptible to efflux (Beyer et al., 2000). It is possible to use fluoroquinolones in combination 
with efflux pump inhibitors such as reserpine; these inhibitors, however, are rarely broad enough in 
their spectrum of action to sufficiently increase MIC. The effects of efflux inhibitors are further limited 
due to the ability of fluoroquinolones to induce overexpression of certain ABC family exporter proteins 
(Marrer et al., 2006). 
Plasmid mediated fluoroquinolone resistance mechanisms have also been discovered in recent years. 
One such mechanism involves the role of topoisomerase protecting proteins. These proteins are known 
as Qnr (Quinolone resistance) proteins and were first identified in Klebsiella pneumoniae. QnrA from this 
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bacterium is a 218 amino acid protein characterised by pentapeptide repeats containing leucine or 
phenylalanine every fifth residue. A similar protein, MfpA, was discovered in Mycobacterium smegmatis 
and was shown to be similar in size, shape and electrostatics to B DNA (Hegde et al., 2005). These 
proteins bind specifically to the GyrA and GyrB subunits of DNA gyrase and the ParC and ParE subunits 
of topoisomerase and reverse fluoroquinolone inhibition, even when fluoroquinolones are in a 1000-
fold excess (Tran et al., 2005a, Tran et al., 2005b). This reversal of inhibition is likely to be due to an 
alteration of the DNA binding properties of topoisomerase enzymes rather than a direct effect upon 
quinolone binding and is able to increase the MIC of a compound up to 100-fold. Another mechanism of 
plasmid mediated resistance is via quinolone modifying enzymes such as aac(6’)-lb-cr. This enzyme 
acetylates unsubstituted nitrogen atoms in the piperazinyl ring in position 7 of fluoroquinolones leading 
to an increase in MIC (Robicsek et al., 2006). 
The most common mechanism of quinolone resistance occurs via mutations in bacterial type II 
topoisomerase enzymes. Resistance causing mutations typically occur in a narrow region known as the 
quinolone-resistance-determining region. In E. coli gyrA the most effective mutations are of ser83 and 
asp87, two residues which are highly conserved across GyrA and ParC domains. As seen in the structure 
of S. pneumoniae these residues are heavily involved with quinolone binding (Laponogov et al., 2010). 
Mutations have also been identified in gyrB and parE in fluoroquinolone resistant strains although these 
are less effective that gyrA/parC mutations. In gyrB these mutations are typically found in the GyrA 
recognition helix so may affect the activity of the enzyme rather than directly affecting quinolone 
binding (Fass et al., 1999). 
Selection of fluoroquinolone resistant mutants occurs in what is known as the mutant selection window. 
This is the fluoroquinolone concentration range between the MIC and the mutant prevention 
concentration (MPC). The MPC is defined as the MIC of the least fluoroquinolone susceptible mutant. If 
the fluoroquinolone concentration is within this window, growth of susceptible bacteria is inhibited but 
growth of resistant bacteria is not (Baquero and Negri, 1997). This effectively enriches the bacterial 
population with resistant mutants. In order for growth to occur above the MPC, two or more resistance 
mutations must be acquired, which is rare. Widespread quinolone resistance is likely to have been 
facilitated by prescription of the drugs for inappropriate infections and at doses that are within the 
mutant selection window (Lautenbach et al., 2003). This is a particular problem with fluoroquinolone 
use in animals (Aarestrup et al., 2000). Selection of mutants with efflux based resistance is a problem 
not only for future fluoroquinolone use but for the use of other antibiotics which are also exported from 
cells via the same mechanisms. In fact, one study has shown that an overall decrease in fluoroquinolone 
use in one hospital was associated with a significant decrease in the rates of methicillin-resistant 
Staphylococcus aureus (MRSA) (Parienti et al., 2011). 
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3.1.6 New Fluoroquinolone Compounds 
A number of novel fluoroquinolone derivatives have been synthesised (Murray et al., 2012), the general 
structures of which are shown in figure 3.9 below. These compounds are based upon the existing 
fluoroquinolone compounds levofloxacin and pefloxacin. The only site of modification is in position 1 of 
the quinolone nucleus. The aim of the work undertaken here is to assess the in vitro activity of these 
compounds against a selection of non-fluoroquinolone resistant bacterial strains. These are 
Enterococcus faecalis, a gram positive bacterium found in the gastrointestinal tract, S. aureus, a gram 
positive bacterium found as part of the skin flora of many humans, and P. aeruginosa, a gram negative 
species found in soil and skin flora. All of these bacteria are capable of causing infections in humans that 
can, in some cases, be life threatening. The primary target of fluoroquinolones in S. aureus is 
topoisomerase IV whereas the primary target in P. aeruginosa is gyrase. Both gyrase and topoisomerase 
IV have been identified as fluoroquinolone targets in E. faecalis (Kanematsu et al., 1998).  
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Figure 3.9. The structures of novel fluoroquinolone compounds synthesised by Redx Pharma Ltd. 
Compounds are based upon (A) levofloxacin and (B) pefloxacin with variations all occurring at position 1 
of the fluoroquinolone nucleus. 
 
 
3.2 Results and Discussion 
The potential antibacterial compounds were tested for their activity against a range of bacteria using the 
Kirby-Bauer disk diffusion technique (Bauer et al., 1966). Different concentration solutions of each 
compound were applied to filter paper disks before being placed upon Mueller-Hinton agar plates which 
had been inoculated with Mueller-Hinton ‘top’ agar containing different bacterial culture to produce 
growth of a bacterial lawn. After being incubated at 37 °C for 18 hours, zones of activity could be 
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measured around the disks. These zones are regions of no bacterial growth and are easily identifiable as 
the agar in these zones is translucent rather than the opaque covering produced by the bacterial lawn. 
 
 
 
Figure 3.10. Size of zones of activity of levofloxacin and pefloxacin mesylate with four different 
bacterial strains.  
Data was obtained using the Kirby-Bauer disk diffusion method with a range of different amounts of two 
commercially available fluoroquinolone compounds. Results for Levofloxacin are shown in blue and 
results for pefloxacin mesylate are shown in red. The diameters of zones of activity shown are the means 
of three biological replicates. Error bars are the standard error of the mean and results which lack error 
bars do so due to all replicates being identical to the nearest millimetre. 
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In initial testing, the parent compounds, levofloxacin and pefloxacin mesylate, showed clear zones of 
antibacterial activity around the discs containing higher amounts of the compounds. At the very lowest 
antibacterial concentrations no activity was observed, which suggests that the zones of no bacterial 
growth are due to the activity of the antibacterial compounds rather than any contamination introduced 
during the experiment. The results also show a clear decrease in the size of the zones of activity as the 
amount of antibacterial decreases. This can be seen in figure 3.11. 
Based upon these initial results, it was decided to test the novel fluoroquinolone compounds using discs 
containing 10 ng, 100 ng, 1000 ng and 10000 ng of each. It was not possible to test significantly higher 
masses due to the small amounts of each compound that were provided. A positive control of 100 ng 
levofloxacin was included on each plate as this mass showed activity against all bacterial strains. Five 
novel fluoroquinolones and a 3-formyl levofloxacin derivative were tested by this method and the 
results are shown in tables 3.1 – 3.6. The plates produced during the experiments are shown in appendix 
B. Each compound was tested against each strain of bacteria twice and concordant results were 
obtained for all compounds. 
 
 
 Diameter of Zone of No Bacterial Growth / mm 
 P. aeruginosa E. faecalis S. aureus SH1000 S. aureus Newman 
Mass of 
Compound 
/ ng 
Plate 1 Plate 2 Plate 1 Plate 2 Plate 1 Plate 2 Plate 1 Plate 2 
10 0 0 0 0 0 0 0 0 
100 0 0 0 0 0 0 0 0 
1000 0 0 0 0 0 0 0 0 
10000 7 7 7 8 7 8 8 8 
Control 7 8 7 8 7 8 8 10 
Table 3.1. Diameters of zones of no growth around discs of filter paper soaked in different masses of a 
3-formyl levofloxacin derivative placed of plates inoculated with four different bacteria. 
Discs of filter paper soaked with different masses of a 3-formyl levofloxacin derivative dissolved in 5 μl of 
DMSO are placed onto Mueller-Hinton agar (21 g l-1 Mueller-Hinton broth, 1.5 % (w/v) agar) plates 
inoculated with Mueller-Hinton top agar (21 g l-1 Mueller-Hinton broth, 0.7 % (w/v) agar) mixed with 
different strains of bacteria which are incubated at 37 °C for 18 hours. The control used is 100 ng of 
levofloxacin. 
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 Diameter of Zone of No Bacterial Growth / mm 
 P. aeruginosa E. faecalis S. aureus SH1000 S. aureus Newman 
Mass of 
Compound 
/ ng 
Plate 1 Plate 2 Plate 1 Plate 2 Plate 1 Plate 2 Plate 1 Plate 2 
10 0 0 0 0 0 0 0 0 
100 0 0 0 0 0 0 0 0 
1000 0 0 0 0 0 0 0 0 
10000 0 0 0 0 0 0 0 0 
Control 8 7 8 7 7 7 11 8 
Table 3.2. Diameters of zones of no growth around discs of filter paper soaked in different masses of 
fluoroquinolone derivative number one placed of plates inoculated with four different bacteria. 
Discs of filter paper soaked with different masses of fluoroquinolone derivative number one dissolved in 
5 μl of DMSO are placed onto Mueller-Hinton agar (21 g l-1 Mueller-Hinton broth, 1.5 % (w/v) agar) 
plates inoculated with Mueller-Hinton top agar (21 g l-1 Mueller-Hinton broth, 0.7 % (w/v) agar) mixed 
with different strains of bacteria which are incubated at 37 °C for 18 hours. The control used is 100 ng of 
levofloxacin. 
 
 
 Diameter of Zone of No Bacterial Growth / mm 
 P. aeruginosa E. faecalis S. aureus SH1000 S. aureus Newman 
Mass of 
Compound 
/ ng 
Plate 1 Plate 2 Plate 1 Plate 2 Plate 1 Plate 2 Plate 1 Plate 2 
10 0 0 0 0 0 0 0 0 
100 0 0 0 0 0 0 0 0 
1000 0 0 0 0 0 0 0 0 
10000 0 0 0 0 0 0 0 0 
Control 8 7 8 7 7 7 9 8 
Table 3.3. Diameters of zones of no growth around discs of filter paper soaked in different masses of 
fluoroquinolone derivative number two placed of plates inoculated with four different bacteria. 
Discs of filter paper soaked with different masses of fluoroquinolone derivative number two dissolved in 
5 μl of DMSO are placed onto Mueller-Hinton agar (21 g l-1 Mueller-Hinton broth, 1.5 % (w/v) agar) 
plates inoculated with Mueller-Hinton top agar (21 g l-1 Mueller-Hinton broth, 0.7 % (w/v) agar) mixed 
with different strains of bacteria which are incubated at 37 °C for 18 hours. The control used is 100 ng of 
levofloxacin. 
 
70 
 
 Diameter of Zone of No Bacterial Growth / mm 
 P. aeruginosa E. faecalis S. aureus SH1000 S. aureus Newman 
Mass of 
Compound 
/ ng 
Plate 1 Plate 2 Plate 1 Plate 2 Plate 1 Plate 2 Plate 1 Plate 2 
10 0 0 0 0 0 0 0 0 
100 0 0 0 0 0 0 0 0 
1000 0 0 0 0 0 0 0 0 
10000 0 0 0 0 0 0 0 0 
Control 8 8 7 7 7 8 9 8 
Table 3.4. Diameters of zones of no growth around discs of filter paper soaked in different masses of 
fluoroquinolone derivative number three placed of plates inoculated with four different bacteria. 
Discs of filter paper soaked with different masses of fluoroquinolone derivative number three dissolved in 
5 μl of DMSO are placed onto Mueller-Hinton agar (21 g l-1 Mueller-Hinton broth, 1.5 % (w/v) agar) 
plates inoculated with Mueller-Hinton top agar (21 g l-1 Mueller-Hinton broth, 0.7 % (w/v) agar) mixed 
with different strains of bacteria which are incubated at 37 °C for 18 hours. The control used is 100 ng of 
levofloxacin. 
 
 
 Diameter of Zone of No Bacterial Growth / mm 
 P. aeruginosa E. faecalis S. aureus SH1000 S. aureus Newman 
Mass of 
Compound 
/ ng 
Plate 1 Plate 2 Plate 1 Plate 2 Plate 1 Plate 2 Plate 1 Plate 2 
10 0 0 0 0 0 0 0 0 
100 0 0 0 0 0 0 0 0 
1000 0 0 0 0 0 0 0 0 
10000 0 0 0 0 0 0 0 0 
Control 8 8 7 7 7 8 9 8 
Table 3.5. Diameters of zones of no growth around discs of filter paper soaked in different masses of 
fluoroquinolone derivative number four placed of plates inoculated with four different bacteria. 
Discs of filter paper soaked with different masses of fluoroquinolone derivative number four dissolved in 
5 μl of DMSO are placed onto Mueller-Hinton agar (21 g l-1 Mueller-Hinton broth, 1.5 % (w/v) agar) 
plates inoculated with Mueller-Hinton top agar (21 g l-1 Mueller-Hinton broth, 0.7 % (w/v) agar) mixed 
with different strains of bacteria which are incubated at 37 °C for 18 hours. The control used is 100 ng of 
levofloxacin. 
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 Diameter of Zone of No Bacterial Growth / mm 
 P. aeruginosa E. faecalis S. aureus SH1000 S. aureus Newman 
Mass of 
Compound 
/ ng 
Plate 1 Plate 2 Plate 1 Plate 2 Plate 1 Plate 2 Plate 1 Plate 2 
10 0 0 0 0 0 0 0 0 
100 0 0 0 0 0 0 0 0 
1000 0 0 0 0 0 0 0 0 
10000 0 0 0 0 0 0 0 0 
Control 8 8 7 7 7 7 8 8 
Table 3.6. Diameters of zones of no growth around discs of filter paper soaked in different masses of 
fluoroquinolone derivative number five placed of plates inoculated with four different bacteria. 
Discs of filter paper soaked with different masses of fluoroquinolone derivative number five dissolved in 
5 μl of DMSO are placed onto Mueller-Hinton agar (21 g l-1 Mueller-Hinton broth, 1.5 % (w/v) agar) 
plates inoculated with Mueller-Hinton top agar (21 g l-1 Mueller-Hinton broth, 0.7 % (w/v) agar) mixed 
with different strains of bacteria which are incubated at 37 °C for 18 hours. The control used is 100 ng of 
levofloxacin. 
 
 
One of the compounds tested, the 3-formyl levofloxacin derivative, showed a small zone of activity 
against each bacterial strain around the disc containing 10000 ng. These were significantly smaller than 
the zones of activity produced by the same mass of each of the parent compounds. This result is 
supported by previous work which showed that 3-formylquinolones display in vitro activity against 
S. aureus and P. aeruginosa. However, levofloxacin is expected to be over 100 times more potent than 
its 3-formyl derivative and pefloxacin is expected to be up to 30 times more potent than its 3-formyl 
derivative (Kondo et al., 1988). 
This study of 3-formylquinolone activity also investigated the in vivo activity of the levofloxacin and 
pefloxacin derivatives (Kondo et al., 1988). The ED50 values calculated in this study show that the 3-
formyl derivatives are approximately twice as effective in vivo as the parent fluoroquinolones. Under 
physiological conditions, 3-formylquinolones are oxidised to their corresponding carboxylic acid (Racker, 
1955). This means that the 3-formyl derivatives of levofloxacin and pefloxacin will be converted to 
levofloxacin and pefloxacin in vivo. This means that the increase in in vivo activity must be due to 
improved pharmacokinetic properties of the 3-formyl compounds. It is likely that the improvement 
comes as a result of improved absorption of the drug when it is administered orally, which is supported 
by the serum concentration data produced (Kondo et al., 1988). 
As can be seen from tables 3.1 – 3.6, none of the remaining five compounds tested showed any activity 
against any of the bacterial strains at the quantities tested. This result is expected to some degree, due 
to the structures of the compounds. These compounds varied from the structures of the parent 
compounds levofloxacin and pefloxacin only by the group present in position 1 of the structure. In 
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nearly all known, functional fluoroquinolone compounds a carboxylic acid group is found in this position 
and this group is known to be heavily involved in binding to type II topoisomerases (Laponogov et al., 
2010, Laponogov et al., 2009). With the exception of the aldehyde compounds, these new 
fluoroquinolones all contain groups that are substantially bulkier than a carboxylic acid group. These 
groups are likely to interfere with the interaction between the compound and the binding site serine or 
arginine residues involved in quinolone binding. 
It is also possible that the other compounds tested would be metabolised to the parent compounds 
levofloxacin and pefloxacin under physiological conditions. This is certainly likely to be true for the 
compounds containing imine ether compounds which are known to be converted to carbonyl groups in 
vivo (Foley et al., 2009). For the compounds tested in this experiment, this would result in the formation 
of the 3-formylquinolone compounds which would, of course, subsequently be oxidised to the 
carboxylic acids of the parent compounds. The metabolism of the other groups is less likely to result in 
formation of levofloxacin or pefloxacin. The β-diketone compounds are likely to be converted to 
alcohols via the actions of β-diketone hydrolases (Grogan, 2005) and carbonyl reductases. These 
possible products are unlikely to be active against topoisomerases as the remaining substituents in 
position 3 will be too bulky for enzyme binding to occur. In addition to this, β-diketone hydrolases are 
also found in bacteria including Pseudomonas species so if a metabolic product did have topoisomerase 
inhibiting activity then this may be seen in in vitro testing. The metabolic products of the compounds 
containing aromatic groups in position 3 are also likely to be too bulky for effective topoisomerase 
binding. 
 
 
3.3 Conclusion 
The lack of in vitro activity displayed by these compounds was deemed sufficient to end these trials. 
Despite this, further testing at higher concentrations may reveal that certain compounds do display in 
vitro activity. Unfortunately, due to the small amounts of each compound that were provided for these 
experiments, it was not possible to test the compounds at significantly higher amounts. However, any 
positive results obtained by such experiments would be limited in their usefulness because any 
fluoroquinolone-topoisomerase interactions causing the activity are unlikely to occur under 
physiological conditions. If these compounds were to be investigated further, the most useful approach 
would be to carry out in vivo testing, as described in section 6.2. 
It is unlikely, however, that any of these compounds would offer an improvement in activity against 
fluoroquinolone resistant bacterial strains. Any improvement in activity over its parent compound 
offered by a compound would almost certainly be due to its pharmacokinetic properties. The 
pharmacodynamics of the compounds would be identical to those of the parent compounds, as the new 
fluoroquinolones are expected to behave as prodrugs. If metabolic reactions are able to form an active 
compound, then these must happen before the drug enters the bacterial cell. Effectively, the prodrug 
would be converted to its parent compound, either levofloxacin or pefloxacin, and its activity from that 
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point onwards would be the same as that parent. If a bacterial strain is resistant to levofloxacin or 
pefloxacin then, whatever the mechanism of that resistance, it will remain resistant to any prodrug 
which does not show activity in vitro.
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4. Development of a Biodegradable Shampoo Sachet 
4.1 Introduction 
4.1.1 Shampoo Packaging in Developing Countries 
Developing countries with rapidly growing economies such as Brazil, Russia, India and China (BRIC 
countries) are potentially huge new markets for many global brands. These countries currently have a 
great imbalance in the distribution of wealth with large proportions of the population living in poverty. 
However, over this decade, it is estimated that the distribution of wealth in developing countries will 
change, resulting in a significant increase in the purchasing power of many people (Unilever, 2012a). 
This increase in disposable income means that people are more likely to consider purchasing cosmetic 
products, such as shampoos, in addition to other products which were not previously affordable for 
them. However, when large volume product sizes similar to those available in the UK were first 
introduced in India, they sold poorly as they still remained too expensive for the budgets of the majority 
of customers. 
A solution to this problem was provided by Indian company CavinKare, who began selling shampoo in 
small sachets in 1983. These sachets allowed consumers to purchase shampoo as and when it was 
required, rather than having to make a comparatively expensive, one-off purchase for a large volume 
bottle. This is important in a country where almost one third of the population lives on less than $1.25 
per day (World Bank Group, 2012). These sachets are sold for as little as 1 rupee (Unilever, 2012a) which 
is the equivalent of just over 1 penny in the UK. The contents of these sachets are often meted out very 
carefully by the customers and in some cases a single sachet of shampoo can last an entire family for a 
whole week. Not only are sachets an affordable solution for low income customers but they are also a 
more efficient way of packaging shampoo compared to larger bottles and produce less waste by weight 
per millilitre of product (Unilever, 2012b). 
Unfortunately, the countries in which sachets are a popular product typically have poor infrastructure 
for waste removal and recycling. The majority of sachets sold end up in landfill, are discarded as litter or 
are washed into the sewage system. Sachets are typically manufactured from polyethylene coated with 
aluminium foil. These materials are degraded extremely poorly by the environment and can take 
decades to break down (Mumtaz et al., 2010). This results in the production of large amounts of waste 
and can easily lead to blockages of sewers and water ways. As well as the clear environmental impact, 
the blockage of sewers can potentially cause public health issues. This is coupled with the 
embarrassment and negative commercial impact experienced by the shampoo manufacturers as large 
amounts of waste bearing their branding are created. A method of reducing this waste and its 
associated problems is therefore highly desirable from the point of view of both the manufacturer and 
consumer. 
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4.1.2 Initial Concept for a Biodegradable Shampoo Sachet 
The work described in the next two chapters had the aim of creating a solution to the problems caused 
by shampoo sachet waste, specifically by producing a prototype of a biodegradable shampoo sachet. 
Ideally the prototype should lead to 0 % residual solid waste after degradation with all mass being 
eventually converted to carbon dioxide and water. In addition to being completely biodegradable, the 
sachet must also make use of existing, commercially available materials and be commercially viable. The 
initial concept for this work involves the use of a bilayer system of two different materials, with an 
enzyme contained between them. The outer layer will be made from cellulose, a biodegradable 
polysaccharide, and the enzyme used will be a cellulase in order to enhance the rate of cellulose 
breakdown. The inner layer of the bilayer will be made from polyvinyl alcohol (PVOH). This material will 
remain intact when the sachet contains shampoo but, once the contents have been used, the PVOH will 
break down when it comes into contact with water, activating the cellulase and triggering the 
breakdown of the outer layer. 
 
 
 
Figure 4.1. The initial bilayer concept for a biodegradable shampoo sachet.  
The outer layer (1), shown in blue, will be made from a cellulose material and the inner layer (2), shown 
in green, will be made from PVOH. Cellulase enzyme will be held between the two layers and will be 
activated when the inner, PVOH, layer is broken down by water. 
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4.1.3 Cellulose 
Cellulose is the most common organic molecule on Earth. It is found in plants, algae and oomycetes and 
is secreted by some bacteria. The cell walls of plant cells are synthesised from cellulose which makes up 
approximately 33 % of all plant matter. Cellulose has a host of different uses and is the major 
constituent of many fibres such as cotton and linen as well as synthetic cellulose fibres such as Rayon. 
Cellulose is used in many laboratory processes with microcrystalline cellulose being used as a medium 
for thin-layer chromatography as well as being used to manufacture filter paper. As well as these 
applications, cellulose can be made into films for use as packaging materials. These different cellulosic 
materials vary in their degree of crystallinity with cotton being 70 % crystalline and most commercially 
available celluloses being 30-70 % crystalline. The huge range of uses of cellulose means that an 
estimated 1010 to 1011 tonnes are synthesised and destroyed every year (Hon, 1994). Cellulose is 
insoluble in water but biodegradable via the action of cellulolytic enzymes. 
 
 
 
Figure 4.2. The structure of cellulose I.  
Cellulose consists of chains of glucose molecules linked by β-1,4-glycosidic bonds. In the cellulose I 
allomorph, the glucose chains are organised in a parallel arrangement and extensive networks of 
hydrogen bonds can be seen between chains represented by dotted lines. In cellulose II, the chains are 
found in an antiparallel arrangement. The repeating unit of cellulose is cellobiose. 
78 
 
Research leading to the discovery of the structure of cellulose formed the foundation of the discipline of 
polymer science (Hon, 1994). The molecule consists of unbranched, linear chains of D-glucose molecules 
joined by β-1,4-glycosidic bonds. Each glucose residue in a cellulose chain is rotated through 180° with 
respect to the previous residue and an extensive network of hydrogen bonds is formed both within 
individual chains and between different chains. Cellulose exists as two different allomorphs, called I and 
II, the structure of cellulose I is shown in figure 3.2. In cellulose I, the chains of glucose residues are 
parallel with respect to each other (Koyama et al., 1997) whereas, in cellulose II, the chains are 
antiparallel (Kuga et al., 1993). There are two different suballomorphs of cellulose I known as Iα and Iβ. 
While these typically exist together in natural cellulose microfibrils, cellulose Iα is associated more with 
bacteria and algae whereas cellulose Iβ is more commonly produced by plants. Cellulose II is produced 
by solubilisation of cellulose I followed by reprecipitation (Brown Jr, 1999) and is the most stable 
allomorph (Ranby, 1952). 
Cellulose is synthesised by enzymes called cellulose synthases. These synthases are plasma membrane 
associated proteins and, in plants, are found in hexameric “rosette” structures in the membrane (Kimura 
et al., 1999). The active sites of the synthase monomers are found in the cytosolic portion of the protein. 
There, they are able to attach glucose molecules to the end of a growing microfibril which is 
translocated across the membrane as it extends (Pear et al., 1996). Higher plants often contain multiple 
cellulose synthase genes which share conserved structures with each other and also bacterial cellulose 
synthases. Arabidopsis contains at least ten different cellulose synthase genes (Holland et al., 2000). 
 
 
4.1.4 Cellulolytic Enzymes 
Cellulolytic enzymes are produced by a variety of fungi, bacteria and termites. Bacterial cellulases 
typically exist as multi-enzyme complexes containing enzymes with a range of different specificities 
(Bayer et al., 1996). Fungi also secrete multiple different cellulolytic enzymes in order to achieve optimal 
cellulose breakdown (Tomme et al., 1995). Different types of cellulolytic enzymes include 
endoglucanases, exoglucanases and β-glucosidases. Endoglucanases are able to cleave the β-1,4-
glycosidic bonds within individual cellulose chains producing smaller cellulose fragments with more 
exposed ends. Exoglucanases, such as cellobiohydrolase, work processively from the end of an individual 
cellulose chain cleaving individual glucose molecules or small polysaccharides such as cellobiose or 
larger cellodextrins. These smaller molecules are then broken down into individual glucose molecules by 
the action of β-glucosidases such as cellobiase. The filamentous fungus Trichoderma reesei contains at 
least four cellulolytic enzymes including two cellobiohydrolases, four endoglucanases and one cellobiase 
(Medve et al., 1998). In addition, many of these enzymes are also present in different isoforms due to 
differential glycosylation (Enari and Niku-Paavola, 1987). 
 
79 
 
 
Figure 4.3. Domain structure of exoglucanases enzymes.  
The cellulose binding domain (red) binds to an individual cellulose fibre and moves processively along it. 
The following catalytic domain (blue) cleaves cellobiose and cellodextrins from the end of the fibre. The 
linker region is shown in yellow and the direction of movement is shown by the arrow. 
 
 
Cellulolytic enzymes typically contain two distinct domains separated by a flexible, glycosylated linker 
(Tomme et al., 1995). One of the domains is a cellulose binding domain and the other contains the 
catalytic region of the enzyme. Strong adsorption of the cellulose binding domain onto the cellulose 
substrate is essential for a good rate of hydrolysis (Klyosov, 1990). Similar, two-domain structures have 
been observed in enzymes which hydrolyse other naturally occurring polysaccharides such as starch and 
chitin (Coutinho and Reilly, 1994, Blaak and Schrempf, 1995). The structures of cellulose binding 
domains are highly conserved within different taxonomic groups (Tomme et al., 1995). In the case of 
exoglucanase enzymes, the cellulose binding domains move processively along the cellulose substrate 
(Teeri et al., 1998). 
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The rate of cellulose hydrolysis by cellulolytic enzymes depends on a number of different factors, most 
of which impact on the ability of the enzymes to access the surface of the cellulose. These factors 
include surface area and degree of crystallinity (Mosier et al., 2005). The rate of enzymatic hydrolysis 
has been observed to decrease over time as the reaction proceeds (Yang et al., 2006). A number of 
different explanations have been suggested for this, including changes in the degree of crystallinity and 
polymerisation present in the cellulose (Eriksson et al., 2002). Cellulolytic enzymes are also known to 
undergo product inhibition which would also explain this decrease in rate. A recent study has shown 
that hydrolysis can be halted due to exoglucanases blocking each others’ progress along the tangled 
cellulose fibres (Igarashi et al., 2011). These factors mean that it is often necessary for high 
concentrations of cellulolytic enzymes to be used in order to achieve a satisfactory rate of hydrolysis. 
 
 
 
Figure 4.4. Enzymatic hydrolysis of cellulose.  
Cellulose chains are broken down into smaller units by the actions of endoglucanases and exoglucanases. 
These units are further broken down into individual glucose molecules by the action of β-glucosidases. All 
enzymes are subject to product inhibition as indicated. 
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4.1.5 Problems with Cellulose as a Packaging Material 
While cellulose can be broken down efficiently by cellulolytic enzymes, there are a number of other 
factors which must be considered regarding the suitability of cellulose as a packaging material for 
shampoo sachets. Not least of these is the method of sachet construction. Plastics made from fossil 
fuels, such as polyethylene, can be heat sealed. This allows an effective seal to be created by applying 
heat to a thin region around the edge of the sachet. This process, however, cannot be used on cellulose. 
Therefore, in order to construct a sachet from cellulose, an alternative method of sealing must be used. 
 
 
 
Figure 4.5. Method of construction for bilayer sachet.  
A border of cellulose is left exposed around the sachet edge allowing the application of adhesive. The 
single sheet of material can then be folded over leaving a complete sachet. The top is left open to allow 
contents to be inserted. Sachet’s were constructed by Joshua Swann at the University of Sheffield, 
Department of Chemistry. 
 
 
Use of an adhesive is the best alternative for creating a sealed sachet from cellulose film. The 
construction of a completed bilayer sachet is shown in figure 4.5 although at this stage sachet 
construction used only the cellulose film with no PVOH applied. Use of an epoxy resin adhesive 
successfully sealed the cellulose sachet, however, further testing of the sachet by Joshua Swann at the 
University of Sheffield, Department of Chemistry revealed that the sachet leaked through both the 
edges of the construction and the surface of the cellulose. This is likely to be due to interactions 
between the epoxy and the cellulose. The cellulose film used became easily stress cracked and was 
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observed to be brittle around the regions of adhesive application. Further testing of other adhesives 
revealed that ST6093G, a polyurethane adhesive, had the most favourable interaction with the cellulose. 
This adhesive is also biodegradable which is essential for the manufacture of a fully biodegradable 
prototype. 
Another problem with cellulose film is the degree of permeability. This is important as the sachet will be 
holding a liquid. The permeability is measured by the moisture vapour transmission rate (MVTR) which 
shows the rate at which water can evaporate through a material. The MVTR of simple cellulose film is 
approximately 360 g/ m2/ 24 hrs which is equivalent to the loss of 0.75 g of water per day for a sachet 
3 cm x 5 cm. This is much too high to be useful as the sachets must be stored for long periods of time in 
commercial use.  
An alternative commercially available cellulose film consists of simple cellulose with the addition of an 
additional thin coating on one side. The intended purpose of the additional layer is to allow heat sealing 
of the cellulose. However, for the construction of a biodegradable sachet this cannot be used for heat 
sealing as it would result in a barrier being positioned between the cellulose and the cellulolytic 
enzymes. Instead, the heat seal layer will form the outer layer of the sachet, simply offering a barrier 
against the excess evaporation of water from within the sachet. Indeed, the MVTR of this material is 
approximately 30 g/ m2/ 24 hrs which is around ten times lower than that of the simple cellulose film 
tested previously. However, a significant issue introduced by the use of the coated cellulose film as the 
heat seal layer is not biodegradable. 
 
 
4.1.6 Polyvinyl Alcohol 
PVOH is commercially produced by the hydrolysis of polyvinylacetate (PVA), as shown in figure 4.6. Fully 
hydrolysed PVOH is highly crystalline with strong hydrogen bonding and will only dissolve in 
temperatures exceeding 60 °C (Verall et al., 2010). The hydrogen bonding present in partially hydrolysed 
PVOH is weaker, producing a less crystalline material which is soluble in water at temperatures below 
10 °C. The difference in hydrogen bonding between fully hydrolysed and partially hydrolysed PVOH can 
be seen in figure 4.7. PVOH is used in a wide variety of commercial settings. In the health care sector, 
contaminated laundry in hospitals is stored in bags made from PVOH. This allows the bag and its 
contents to be placed into a washing machine where the bag will dissolve when it comes into contact 
with warm water. This reduces the exposure of laundry staff to the contaminated laundry. PVOH is used 
as a packaging material in the agricultural sector where it is used to store feedstock and fertiliser 
supplies. The PVOH packaging is contained within a further layer of polyethylene or polypropylene, 
however, meaning that the packaging is not biodegradable. 
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Figure 4.6. Synthesis of polyvinyl alcohol by hydrolysis of polyvinylacetate. 
 
 
The majority of current uses for PVOH involve the storage of solids although one common product using 
PVOH to store a liquid is that of Persil ‘capsules’. These ‘capsules’ contain laundry detergent and are 
placed directly into the washing machine drum where they dissolve during the wash cycle. As the only 
current PVOH material used commercially to store liquids, the detergent was removed from some Persil 
‘capsules’ by Joshua Swann and replaced with a typical shampoo formulation. Within two minutes, the 
PVOH packaging began to lose its strength and after ten minutes shampoo was escaping from the 
damaged material. Closer investigation of the formulation of detergent intended for use in the 
‘capsules’ revealed that it was approximately 97 % organic solvent. Typical shampoos contain closer to 
75 % water explaining the rapid breakdown of PVOH. In order for PVOH to successfully store a liquid, 
that liquid must ideally contain less than 10 % water. 
There are a number of proposed solutions to the problem of storing high water content liquids in PVOH. 
Modifications to the PVOH backbone are described in the patent literature as is the incorporation of wax 
into the PVOH film (Padget et al., 2002, Verall et al., 2010). However, these modifications to PVOH only 
serve to reduce the rate of breakdown by water rather than stopping it all together. In order for the 
bilayer concept to work properly, a PVOH film which is stable in the presence of shampoo but which 
breaks down in the presence of water is required. Additionally, PVOH with such modifications is not 
commercially available. 
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Figure 4.7. Intermolecular hydrogen bonding of polyvinyl alcohol.  
Compound (A) has a higher degree of hydrolysis and forms a larger number of intermolecular hydrogen 
bonds compared to (B) which has a lower degree of hydrolysis. Breakdown of PVOH occurs when the 
strength of hydrogen bonding to water is greater than the strength of intermolecular hydrogen bonding. 
 
 
A further possible method of increasing the stability of PVOH is by the addition of a salt to the shampoo 
formulation. The stability of PVOH depends upon intermolecular hydrogen bonding between polymer 
chains. When water is present, the hydrogen bonding network is disrupted as PVOH chains form 
hydrogen bonds with water molecules instead. Addition of a salt to the water encourages water 
molecules to form a hydration cage around the added ions which prevents them from disrupting the 
intermolecular hydrogen bonding. The effects of adding different concentrations of different salts have 
been further investigated by Joshua Swann and were found to reduce the rate of PVOH breakdown. 
However, the shampoo used in the tests became saturated with salt before breakdown could be 
stopped completely. In addition to this, some salts interacted directly with the PVOH causing alterations 
in its structural properties. Addition of salts to the shampoo formulation can have an effect on the 
properties of the shampoo, for example causing a reduction in the amount of lather produced, which is 
undesirable as it reduced the quality of the product. 
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One final solution for reducing the rate of breakdown of PVOH in the presence of liquids is to 
concentrate the shampoo formulation used. While this approach is effective in preventing breakdown of 
PVOH it has associated problems. In order to produce a shampoo formulation with a low enough water 
content to completely prevent PVOH breakdown, approximately 90 % of the water present must be 
removed. This is an issue for consumers in developing countries. As mentioned in section 4.1.1, 
customers often do not have sufficient income to purchase high volume products and, also, carefully 
regulate the use of a single sachet to last a family for several days. If the volume of a sachet was kept 
constant but contained concentrated shampoo, this would inevitably lead to a price increase which may 
well be out of the range that many customers can afford. Highly concentrated shampoo is, also, 
significantly more difficult to use sparingly which would be an issue for those families forced to make a 
single sachet last for a prolonged period of time. 
 
 
4.1.7 Bilayer Films 
Successful incorporation of cellulolytic enzymes into sachets is essential for the biodegradation of 
cellulose. In the initial concept outlined in section 4.1.2, the enzymes are placed between the PVOH and 
cellulose layers. The enzymes used in the cellulose breakdown assays described in section 4.2 are all in 
aqueous solution. This means that, were they to be placed between the two layers, they would instantly 
begin to degrade the outer, cellulose layer. These enzymes are also commercially available in solid form 
although incorporation of the solid enzyme between the layers would almost certainly result in an 
uneven distribution and therefore uneven breakdown. In order to avoid either of these problems, it was 
decided that the enzyme would be incorporated into an additional ‘bonding’ layer, as shown in figure 
4.8. 
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Figure 4.8.  Structure of ‘bilayer’ packaging material with additional bonding layer.  
Coated cellulose film is used for the outer layer and a PVOH which is insoluble in shampoo but soluble in 
water is used for the inner layer. The bonding layer is an additional layer of PVOH and acts as an 
adhesive between the inner and outer layers. The bonding layer incorporates cellulolytic enzymes. 
 
 
Ideally, the bonding layer will break down slowly as this will increase the contact time between the 
cellulose and the cellulolytic enzymes resulting in more efficient degradation of cellulose. A further 
benefit of a slow rate of breakdown for this layer is the fact that it will act to keep the enzymes within 
the sachet for as long as possible. Were the bonding layer to break down quickly it would leave the 
cellulolytic enzymes free in solution where they could easily be lost were the open sachet to be inverted. 
The inner PVOH layer requires a material which is insoluble in the presence of shampoo but readily 
soluble in water.  
A number of films were produced by Joshua Swann consisting of the outer layer of coated cellulose with 
an attached bonding layer. This is achieved by producing a solution of PVOH and adding cellulolytic 
enzymes before casting this mixture onto the non-coated surface of the cellulose film. The different 
types of PVOH used in the production of these films varied in both their degree of hydrolysis and their 
molecular weight. These properties affect the rate of breakdown of PVOH so should allow the slowest 
rate of breakdown to be determined. The different PVOH types used are shown in table 4.2.  
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4.2 Results and Discussion 
4.2.1 Determination of Optimum Cellulolytic Enzymes 
In order to measure the activity of different cellulolytic enzymes a two step assay was used. The 
methodology is described in section 7.4 but the basic steps involved are: 
1. Digestion of 10 mg of cellulose substrate by cellulolytic enzymes for 20 hours at 37 °C. 
2. Hexokinase/Glucose-6-phosphate Dehydrogenase assay with the supernatant from step one as 
substrate for one hour at 25 °C. 
Glucose produced from cellulose in step one undergoes the following reaction in step two of the assay. 
 
 
Figure 4.9. The conversion of glucose to 6-phosphoglucomo-δ-lactone. 
The reaction proceeds via glucose-6-phosphate and is catalysed by hexokinase and glucose-6-phosphate 
dehydrogenase. 
 
 
As shown in figure 4.9, the reaction in step two of the assay requires the conversion of NADP to NADPH. 
As with the assay used in chapter two, this allows the reaction to be monitored by UV spectroscopy as 
NADPH has a characteristic absorption at 340 nm while NADP does not. The number of moles of NADP 
converted to NADPH is equal to the number of moles of glucose converted to 6-phosphoglucomo-δ-
lactone. The assay was allowed to proceed to its end point, i.e. until all glucose had been converted to 6-
phosphoglucomo-δ-lactone. 
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Three different commercially available products were considered in this work: cellulase from 
Trichoderma reesei, cellulase from Aspergillus species and cellobiase from Aspergillus niger. These 
enzymes are crude extracts from the fungal cells and contain a mixture of different enzymes and 
isoforms. In order to determine the optimum combination of enzymes for the highest rate of 
degradation of cellulose, the assay was carried out using various enzyme combinations and 10 mg of 
Whatman filter paper as a substrate. Each enzyme was used individually as well as a number of different 
mixtures of two, or all three enzymes to determine the most efficient combination. The combinations 
tested are shown in table 4.1. 
 
 
Enzyme Mixture Units of Cellulase from 
Trichoderma reesei 
Units of Cellulase from 
Aspergillus species 
Units of Cellobiase 
from Aspergillus niger 
A 10 0 0 
B 0 63 0 
C 0 0 3 
D 5 32 0 
E 5 0 2 
F 0 32 2 
G 3 21 1 
H 4 25 1 
I 7 16 0 
J 2 47 0 
Table 4.1. Combinations of cellulolytic enzymes used for optimization of cellulose breakdown. 
 
 
For each enzyme mixture, two negative controls were carried out: one with no cellulolytic enzyme 
added to the reaction, and one with no filter paper added to the reaction.  This ensured that any change 
in absorbance observed was due to the action of the enzyme or enzymes breaking down the cellulosic 
substrate. The absorbance values obtained are shown in appendix C.1. 
In order to determine the extent of the breakdown of the substrate, the mass of glucose present in step 
two of the assay was calculated using the glucose standard curve in appendix C. Due to the large 
amounts of glucose produced by some of the reactions, it was necessary to dilute the supernatant from 
step one of the assay in some cases to ensure that the reactants in step two did not become limiting. All 
results shown in this chapter have been converted to masses of glucose using the following equation: 
4
3
1028.9
1097.1y
x  
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Where x is the mass of glucose produced and y is the change in absorbance at 340 nm in step two of the 
assay. 
 
 
 
Figure 4.10. Mass of glucose produced after 20 hours from 10 mg of Whatman filter paper by different 
combinations of cellulolytic enzymes. 
 The composition of each enzyme mixture is given in table 4.1. 
 
 
As can be seen in figure 4.10, when the different enzymes are used individually they breakdown only a 
small fraction of the cellulose present. Of the three individual enzymes, the cellulase from T. reesei is 
most effective. Cellobiase from A. niger causes virtually no breakdown of cellulose alone but when used 
in addition to the cellulase from T. reesei, as in enzyme mixtures E, G and H, the breakdown of cellulose 
is greatly enhanced. As these results show, a mixture of cellulase from T. reesei and cellobiase from 
A. niger is the most effective at breaking down cellulose from those tested. This enzyme mixture was 
selected for use in all further assays. The results suggest that close to complete digestion of the cellulose 
filter paper substrate is taking place within 20 hours with this enzyme mixture. 
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The number of units used is based upon the supplied concentrations of commercially available enzymes. 
Despite the concentrations of cellulose from A. niger in this experiment being significantly higher than 
that of the other two enzymes, the low rates of breakdown observed mean that it is unnecessary to test 
the enzyme at more similar concentrations. 
 
 
4.2.2 Breakdown of Cellulose Films 
The assay was repeated using the same conditions and enzyme mixture E but with alternative cellulosic 
substrates. The raw data and controls for this experiment are shown in appendix C.2 and the results 
shown in figure 4.11 have been converted to masses of glucose produced in 20 hours. These results also 
suggest complete, or near complete breakdown of the substrate into glucose is taking place within the 
time-frame. In the case of the cellulose film used, this is important as it will form the outer layer of the 
prototype biodegradable shampoo sachet. 
 
 
 
Figure 4.11. The mass of glucose produced from 10 mg of different cellulosic substrates after 20 hours 
digestion with cellulolytic enzymes.  
The results of the digestion of other cellulosic substrates are included as a comparison. Assay conditions 
are identical to those outlined previously. 
 
 
0 2000 4000 6000 8000 10000 12000 
Simple Cellulose Film 
Coated Cellulose Film 
Microcrystalline Cellulose 
Whatman Filter Paper 
Mass of glucose produced in 20 hours / μg 
91 
 
As these results show, the addition of the coating to the cellulose film has no significant impact on the 
level of breakdown taking place within 20 hours. As observed for the other substrates, the cellulose 
appears to break down completely in this time scale. 
In order to confirm that complete breakdown was occurring within 20 hours, the time scale of the 
digestion (step one of the assay as outlined in section 4.2.1) was increased. The results of this are shown 
in figure 4.12 and confirm that no further glucose is produced by the digestion within this time frame. 
 
 
 
Figure 4.12. The mass of glucose produced from 10 mg of coated cellulose film after different periods 
of digestion with cellulolytic enzymes. 
 
 
Following complete breakdown of the cellulose present in the film, the heat seal layer remains present 
in the enzyme solution. The layer is very thin compared to the overall thickness of the film and is not 
recognisable as a layer of film following cellulase digestion. While the remaining layer means that a 
shampoo sachet made from this film would not be entirely biodegradable, the small amount of waste 
produced by a sachet would still offer a considerable improvement upon the current situation. In 
addition to the reduction in total waste, the fragility of such a thin layer means that it would be unlikely 
to cause obstructions to water courses. 
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4.2.3 Breakdown of Bilayer Films 
The breakdown of the films consisting of cellulose and a bonding layer of PVOH containing cellulolytic 
enzymes, as constructed by Joshua Swann, was measured using the assay outlined in section 4.2.1. 
Sections of these films contained 10 mg of cellulose in addition to the PVOH layer and the enzyme 
loading was 0.7 units of cellulolytic enzyme per mg of cellulose, as used in the earlier assays. One film 
was constructed with a lower enzyme concentration of 0.04 units of cellulolytic enzyme per mg of 
cellulose in the same ratio as described in section 4.2.1. For these experiments the negative control 
containing no cellulose substrate used a piece of PVOH film made from the same type of PVOH and with 
the same enzyme loading as the bilayer film being tested. The second negative control was a bilayer film 
containing no enzyme. The amount of degradation of these films in 20 hours at 37 °C is shown in figure 
4.13. 
Each film was constructed from the coated cellulose film that was tested in section 4.2.2. The 
differences between the bilayer films are caused by the different type of PVOH used for the bonding 
layer. These varied in both molecular weight and the percentage of hydrolysis as shown in table 4.2. In 
addition to creating films with each type individually, some mixtures of different types were also used. 
 
 
Type Molecular Weight / gmol-1 Percentage Hydrolysis 
4-88 31,000 88 
8-88 67,000 88 
40-88 205,000 88 
4-98 27,000 98 
6-98 47,000 98 
10-98 61,000 98 
20-98 125,000 98 
28-99 145,000 99 
Table 4.2. Different types of PVOH used for prototype bonding layers.  
Types with 88 % hydrolysis are considered partially hydrolysed and types with 98 % hydrolysis and above 
are considered fully hydrolysed. 
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Figure 4.13. The mass of glucose produced from 10 mg of coated cellulose film in 20 hours when 
attached to a bonding layer of polyvinyl alcohol containing cellulolytic enzymes.  
Each film contained a different type of PVOH in the bonding layer and three of the films contained a 
mixture of PVOH types. The mass of glucose produced in 20 hours from cellulose film is included by way 
of comparison. The concentration of enzyme was 0.7 units per mg of cellulose in all experiments except 
for ’28-99 Low Enzyme Concentration’ which had an enzyme concentration of 0.04 units per mg of 
cellulose. 
 
 
The results show that all films containing the higher enzyme concentration undergo close to complete 
breakdown within 20 hours. This shows that all of the PVOH types are breaking down quickly enough to 
liberate the contained cellulolytic enzymes within a short enough time frame to allow the enzymes to 
fully digest the cellulose substrate. This conclusion is supported by experimental observations. Once the 
film is immersed in water and agitated, the appearance of the PVOH and enzyme layer begins to alter 
and the two layers (cellulose and bonding layer) delaminate. The enzymes used in producing the film 
have a distinct colour and this colour can be observed to transfer from the PVOH bonding layer into 
solution within a short time period. This means that none of the PVOH types tested fulfilled the aim of 
prolonging the contact time of the cellulolytic enzymes with cellulase. 
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4.2.4 Effect of Enzyme Concentration on Rate of Breakdown 
While packaging materials such as cellulose and PVOH are relatively cheap, enzymes are comparatively 
expensive. Shampoo sachets are sold at prices lower than two pence in developing countries so an 
entire sachet and its contents cost significantly less than this in order to remain commercially viable for 
the manufacturer. Based upon the prices charged by Sigma-Aldrich, a 3 cm x 5 cm sachet with an 
enzyme loading of 0.7 units of enzyme per mg of cellulose would contain approximately ten pence 
worth of enzymes. This is clearly far too high for a commercially viable product so a lower enzyme 
loading must be used. The rate of breakdown of coated cellulose film by different concentrations of the 
cellulase/cellobiase mixture was monitored using the same assay, as described in section 7.5. 
 
 
 
Figure 4.14. Number of days taken for complete degradation of coated cellulose film by different 
concentrations of cellulolytic enzymes.  
Different concentrations are indicated by their cost when purchased from Sigma-Aldrich. The cellulolytic 
enzyme used was a mixture of five parts cellulase from T. reesei and 2 parts cellobiase from A. niger as 
described in section 4.2.1. Error bars displayed are ±0.5 days as samples were analysed after multiples of 
24 hours. 
 
 
Figure 4.14 shows the rates of breakdown of coated cellulase at different enzyme concentrations. When 
the cost of the enzyme is 1 penny for a 3 cm x 5 cm sachet the time for breakdown is approximately 
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eleven days. Purchasing of enzymes in bulk quantities can allow a decrease in cost to as little as 10 % of 
the cost of small scale purchases. If this is possible for these enzymes then this could lower the cost to 
around 0.1 pence per sachet for a degree of enzyme loading sufficient to break down all of the cellulose 
present in eleven days. However, this experiment was still carried out in a closed system with excess 
water ensuring the maximum possible rate of degradation and no loss of enzyme. In a real world 
situation, eleven days gives plenty of opportunity for enzyme to escape from the sachet thus increasing 
the time for complete breakdown. 
 
 
4.3 Conclusions 
The initial concept of this work, as outlined again in figure 4.15, involves the production of a bilayer 
material with a cellulosic outer layer and a PVOH inner layer with cellulolytic enzymes contained 
between the layers. Ideally, the PVOH inner layer would remain intact while in contact with shampoo 
but break down when in contact with water. This would allow the material to be used to construct a 
biodegradable shampoo sachet which is stable when full of shampoo. After the shampoo has been used 
the sachet can be filled with water, breaking down the PVOH and activating the cellulolytic enzymes 
which in turn break down the cellulose outer layer. As the work presented here shows, however, there 
are a number of barriers to this concept. 
The cellulose outer layer itself proved to be a poor material for storage of liquids due to a high MVTR. 
This fact necessitated the addition of an extra, non-biodegradable coating to the outside of the sachet. 
This extra layer, although successful in significantly reducing the MVTR, did not reduce it sufficiently to 
make the cellulose film an appropriate packaging material for shampoo. Due to the layer being non-
biodegradable, its addition also results in a failure to meet the aim of creating a completely 
biodegradable sachet. 
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Figure 4.15. The initial bilayer concept for a biodegradable shampoo sachet.  
The outer layer (1), shown in blue, will be made from a cellulose material and the inner layer (2), shown 
in green, will be made from PVOH. Cellulase enzyme will be held between the two layers and will be 
activated when the inner, PVOH, layer is broken down by water. 
 
 
The internal PVOH layer also has associated issues. In order for the concept to work as intended, the 
internal layer must be completely stable when in contact with shampoo, but break down in contact with 
water at a rate high enough to facilitate the degradation of cellulose within an acceptable time frame. 
The high water content of shampoo, however, is sufficient to break down PVOH extremely rapidly. 
Potential modifications of the PVOH structure or shampoo formulation are able to reduce this rate of 
break down but not stop it completely. The only approach suitable for stopping the breakdown is that of 
concentrating the shampoo although this has issues from a commercial point of view as it affects the 
affordability of a sachet. 
The most successful element of the initial concept was the cellulolytic enzymes. A combination of 
cellulase from T. reesei and cellobiase from A. niger was shown to break down cellulose rapidly at 37 °C. 
This temperature is higher than the temperatures likely to be experienced by discarded sachets 
although the rate of degradation at the concentration investigated is high enough to suggest 
degradation will still occur rapidly in cooler conditions. Experiments with lower enzyme concentrations 
demonstrate that cellulose can be broken down within an acceptable time-frame at an economically 
viable cost. 
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The main limitation of the assay used in estimating rates of degradation is the fact that the entire 
experiment is carried out in a closed system. This ensures that the enzyme, substrate and water remain 
in constant contact. When a complete sachet is filled with water and discarded, there are ample 
opportunities for the escape of these elements. The water could easily escape from the sachet before 
the PVOH has broken down and activated the cellulolytic enzymes, preventing degradation. Worse still, 
the PVOH could break down, liberating the enzymes followed by the resulting enzyme solution escaping 
from the sachet. This would remove any possibility of enzymatic degradation. 
Another issue associated with the enzymes used was how best to contain them between the two layers. 
The use of a PVOH ‘bonding layer’ was intended to maximise contact time between the enzymes and 
the cellulose surface. However, the results show that this layer breaks down too quickly to achieve this 
effect. Importantly, the PVOH, almost instantly, delaminates from the cellulose film. This removes the 
contact between the enzymes and the surface which they are there to break down and, also, makes it 
easy for the enzymes to escape from the sachet environment completely. 
While in theory the ‘bilayer’ concept could lead to the production of a completely biodegradable 
shampoo sachet, in practice there are too many problems preventing development of a successful 
prototype. Two simple layers swiftly become four layers that are not all biodegradable and are still too 
porous to store liquids. The biggest single issue though, is the requirement for a material for the inner 
layer which is soluble in water but stable in shampoo. Until such a material is developed a bilayer 
cellulosic sachet will remain merely an interesting concept. 
While the experiments carried out represent an ideal environment for cellulose breakdown compared to 
the environmental conditions likely to face a discarded shampoo sachet, they still identify these issues 
which are inherent to the concept. Had the inherent issues not been identified, experiments testing the 
materials in environmental conditions would have been an important stage in the sachet development. 
Despite these issues, a number of other biodegradable packaging materials are available, two of which 
are described in section 6.3. Of the two, the most likely candidate for the successful manufacture of a 
biodegradable shampoo sachet is polyhydroxyalkanoate (PHA) film. This is discussed in more detail in 
chapter 5. 
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Chapter 5 
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5. Suitability of Polyhydroxyalkanoates as Biodegradable Packaging 
Materials 
5.1 Introduction 
5.1.1 Polyhydroxyalkanoates 
 
 
 
Figure 5.1. Structure of Polyhydroxyalkanoates.  
When R is CH3, the polymer is poly(3-hydroxybutyrate). 
 
 
Polyhydroxyalkanoates (PHAs) are aliphatic polymers produced naturally by some bacterial cells. PHA 
production occurs in response to unbalanced growth conditions in which there is an excess carbon 
source but a lack of another nutrient, typically nitrogen. Depending upon the type of bacteria, the 
excess carbon is converted to either 3-, 4- or 5-hydroxyalkanoyl-CoA (Steinbuchel et al., 1995). These 
monomers are then condensed into PHA polymers between 0.05 and 20 MDa via the action of PHA 
synthase enzymes. PHA is stored in water insoluble granules in the cytoplasm of the bacterial cell. 
Within 48 hours of synthesis beginning, these granules can account for up to 90 % of the dry weight of 
the cell and are clearly visible by phase contrast light microscopy (Sudesh and Abe, 2010). 
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Figure 5.2. Bacterial synthesis of poly(3-hydroxybutyrate) from acetyl-CoA.  
This pathway exists in many species of bacteria and all of the enzymes involved have been purified and 
characterised. 
 
 
The most common type of PHA is poly(3-hydroxybutyrate) or P(3HB). This polymer is also commonly 
known simply as PHB as it was the first PHA to be discovered and remained the only known variant for 
some time (Lemoigne, 1926). Currently, over 150 different types of HA monomers are known to be 
incorporated into PHAs. This demonstrates the broad specificities of PHA synthase enzymes (Sudesh and 
Abe, 2010). The majority of these monomers are only found in what are termed ‘unnatural PHAs’. 
Natural PHAs which, as the name suggests, occur naturally in bacteria, only ever contain a limited 
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number of different monomers. Most bacteria are only able to produce unnatural PHAs when they are 
grown in a medium containing a source of carbon structurally related to the unnatural HA monomer. 
Examples of monomers which are found exclusively in unnatural PHAs include: 4-hydroxybutyrate (4HB), 
3-hydroxyvalerate (3HV) , 3-hydroxyhexanoate (3HHx) and 4-hydroxyoctanoate (Doi et al., 1989). PHA 
synthases have even been demonstrated to polymerise polylactic acid monomers (Taguchi et al., 2008). 
PHA synthase enzymes have thus far proven difficult to crystallise so their structure and exact 
mechanism of action are unknown. What is certain is their ability to polymerise insoluble, high 
molecular weight polymers at room temperature (Gerngross et al., 1994). 
PHAs are divided up into two categories depending upon the number of carbon atoms in their HA 
monomers. Monomers containing six carbon atoms or fewer are found in short chain length (SCL) PHAs 
and monomers containing between six and fourteen carbon atoms are found in medium chain length 
(MCL) PHAs. PHA synthase enzymes are always specific to either SCL or MCL PHAs. Typically a bacterial 
species will only produce either SCL or MCL polymers depending upon the synthase it contains. The 
scope for variation in the structure of a PHA allows the production of polymers with a wide variety of 
physical properties. Generally speaking, the longer the monomer carbon chain, the closer the properties 
of the polymer are to an elastomer (Rai et al., 2011). PHA found in granules in bacterial cells is 
amorphous but commercially produced PHAs are highly crystalline. Electron micrographs of a 
commercially available PHA are shown in figure 5.3. The surface of the commercially produced PHA is 
highly regular and non-porous. 
 
 
 
Figure 5.3. Scanning electron micrographs of a commercially produced polyhydroxyalkanoate.  
The PHA shown is EM10020, produced by Ecomann films. Electron micrographs were produced by Chris 
Hill, University of Sheffield, Department of Biomedical Science. 
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5.1.2 Commercial Production of PHAs 
The most common commercially available PHAs are P(3HB) and copolymers of 3HB. The most common 
monomers found in these copolymers with 3HB are 4HB, 3HV and 3HHx. Production typically requires 
growth of PHA producing bacteria in large bioreactors for between 24 and 96 hours (Chen et al., 2001). 
This can be carried out via a two-stage cultivation in which the bacteria are grown on a nutrient rich 
medium before being transferred to a limited medium or, more commonly, for large scale production, a 
one stage cultivation with only a limited medium used. This process can be expensive and slow and also 
requires an abundant carbon source (Braunegg et al., 2004). A range of different carbon sources has 
been used in the industrial production of PHAs. These include sugars, whey, molasses, triglycerols and 
starch. Selection of a suitable carbon source is essential to keep production costs as low as possible 
since this accounts for up to 50 % of the overall production costs (Lynd et al., 1999). Glucose and sucrose 
are the most commonly used although plant oils and fatty acid derivatives were found to be cheaper, 
renewable and give a higher PHA yield (Loo et al., 2005). Palm oil by-products and used cooking oil can 
also be used as carbon sources. Gram for gram, plant oils give almost double the yield of glucose when 
used as a carbon source (Akiyama et al., 1995). 
In order to further increase the efficiency of commercial PHA production a number of biotechnological 
approaches have been used. Over-expression of PHA synthase genes in natural PHA producers has little 
effect on the PHA yield (Suriyamongkol et al., 2007, Wang and Lee, 1997a) and expression of PHA 
synthase genes in recombinant E. coli was also ineffective, as PHA yields tended to be lower than those 
in natural PHA producers (Lee, 1994, Wang and Lee, 1997b). PHA synthase genes have also been 
expressed in plants such as maize and Arabidopsis. Growing plants is considerably cheaper than growing 
bacteria by fermentation. However, high yields of PHA are often associated with growth defects which 
limit the commercial potential of PHA production (Poirier et al., 1992). More recently, individual PHA 
synthetic enzymes have been purified. These may offer an alternative, in vivo, approach to PHA 
production. Production of the required substrate materials, however, is difficult and the enzymes are 
not very stable (Cho et al., 2012). 
Once PHA has accumulated in the bacterial cells it must be extracted. At the laboratory scale, solvent 
extraction is the method of choice. This requires large amounts of chlorinated solvents such as 
chloroform and isoamilic alcohols such as methanol (Nonato et al., 2001). This process is hazardous to 
the environment and very expensive so unsuitable for use on an industrial scale. Cell solubilisers such as 
sodium hypochlorite can also be used to extract PHA although these methods can damage the polymer, 
causing as much as 50 % reduction of molecular weight. Mixtures of different chemicals and solvents 
have been investigated and all give varying yields, purities and reductions in PHA molecular weight (Choi 
and Lee, 1999). The most efficient way of extracting PHA from bacterial cells is by heat shock followed 
by enzymatic solubilisation of non-PHA biomass. This process achieves greater than 90 % purity and 
yield and causes no damage to the molecular weight of the PHA. As no chemicals are required for this 
method it also has a lower associated cost (Kapritchkoff et al., 2006). Extraction of PHA from plants is 
complicated and often a combination of mechanical processes and solvent or enzyme extraction is 
required (Noda, 1997). 
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5.1.3 Enzymatic Degradation of PHAs 
All PHA synthesising bacteria also produce two types of PHA depolymerase: intracellular and 
extracellular. Intracellular depolymerases allow the bacteria to liberate the carbon stored in intracellular 
PHA granules. Legionella pneumophila is able to survive for over 600 days with stored P(3HB) as its only 
available carbon source (James et al., 1999). The majority of PHA producing organisms produce and 
store P(3HB) and P(3HB) depolymerases are known to break down P(3HB) into its constituent 3HB 
monomers. 3HB is converted to acetyl-CoA as shown in figure 5.4. Acetyl-CoA is subsequently able to 
enter the tricarboxylic acid (TCA) cycle where it serves as an energy source (Uchino et al., 2007). Like 
PHA synthases, intracellular PHA depolymerases show specificity for certain PHAs and are always, at 
least, specific to either SCL- or MCL-PHA. Intracellular PHA depolymerases are active only against the 
amorphous PHAs found inside bacterial cells and are unable to break down crystalline, commercially 
produced PHAs. 
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Figure 5.4. The P(3HB) cycle in bacteria as proposed by Uchino et al. (2007).  
Enzymes involved are indicated by underlining. 
 
 
PHA molecules are too large to enter bacterial cells so, in order to gain access to carbon from 
extracellular sources of PHA, PHA synthesising bacteria also produce extracellular PHA depolymerases. 
The rate of PHA breakdown by extracellular depolymerases depends on a number of factors. These 
include environmental factors such as temperature, moisture level, pH and nutrient supply. Such factors 
affect the growth of the degrading bacteria, the production and secretion of depolymerase enzymes and 
the activity of those enzymes. The nature of the PHA substrate also has a significant effect on rate of 
break down with polymer composition, degree of crystallinity and surface area all being important 
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factors (Sudesh and Abe, 2010). Extracellular PHA depolymerases, like intracellular depolymerases and 
synthases, are specific to either SCL- or MCL-PHAs. However, certain species of bacteria produce 
multiple extracellular depolymerases with different specificities. Pseudomonas lemoignei is known to 
produce six different depolymerase enzymes (Jendrossek, 2001). Production of PHA depolymerases is 
usually suppressed when suitable, soluble carbon sources are present, however, extracellular 
depolymerase expression is not dependent upon stored PHA suggesting that regulation does not occur 
via induction (Jendrossek et al., 1993a). 
Many extracellular PHA depolymerases have been purified and all consist of a single polypeptide chain 
between 26,000 and 63,000 Da in molecular weight. These enzymes all exhibit a high degree of stability 
over a range of temperature, ionic strength and pH although the optimum pH of depolymerase is 
typically between 7.5 and 9.8 (Jendrossek et al., 1993b, Saito et al., 1989). Many SCL-PHA 
depolymerases have been shown to have a similar two-domain structure to that observed in 
endoglucanases enzymes (discussed in section 4.1.4). The two domains are a catalytic domain and a 
PHA-binding domain joined by a flexible linker. Some depolymerases do not contain a PHA binding 
domain although the catalytic domains of all of these enzymes are highly conserved (Hisano et al., 
2006). The active site of the catalytic domain in PHA depolymerases contains a lipase box pentapeptide, 
[Gly-X1-Ser-X2-Gly]. This motif is found in almost all known serine hydrolases including lipases, esterase 
and serine-proteases (Jaeger et al., 1999). In P(3HB) depolymerases, the serine of this motif forms a 
catalytic triad with highly conserved aspartate and histidine residues. It is proposed that, in addition to 
substrate binding, the PHA-binding domains and linker region may play a role in the disruption of the 
polymer structure in crystalline substrates (Sudesh and Abe, 2010). It is likely that PHA depolymerases 
have both endo and exohydrolase activity. 
 
 
5.1.4 Biodegradation of PHAs 
A range of data is available regarding the rate of biodegradation of various commercially produced PHA 
films. These are typically P(3HB)  or copolymers of 3HB. Biodegradation is predominantly caused by 
bacteria although some fungi also produce PHA depolymerase enzymes (Kim et al., 2000). PHA 
degrading bacteria have been isolated from “soil, compost, aerobic and anaerobic sewage sludge, fresh 
and marine water, estuarine sediment and air” (Sudesh and Abe, 2010). These bacterial species include 
both aerobes and anaerobes and are present in almost every ecosystem both terrestrial and aquatic. 
A study in Indonesia monitored the rate of breakdown of P(3HB) and a copolymer of 3-hydroxybutyric 
acid and hydroxyvaleric acid (P(3HB-co-HV)) in different conditions in the tropical climate (Akmal et al., 
2003). The results can be seen in tables 5.1 and 5.2 and, as they show, there is considerable variation in 
the rate of degradation depending upon the type of PHA film and the conditions in which 
biodegradation is taking place. Other work provides further data on rates of biodegradation which, 
again, vary based upon the conditions used and the composition of the PHA (Luo and Netravali, 2003, 
Rudnik and Briassoulis, 2011, Gutierrez-Wing et al., 2010). 
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Medium Average Weekly Percentage 
Mass Loss 
Estimated Time for Complete 
Degradation/Weeks 
Sewage Sludge 3.6 28 
Soil 1.9 53 
Lake Water 1.5 67 
Sea Water 0.8 125 
Table 5.1. Rate of mass loss of poly(3-hydroxybutyrate) in different environmental conditions.  
Data taken from Akmal et al. (2003). 
 
 
Medium Average Weekly Percentage 
Mass Loss 
Estimated Time for Complete 
Degradation/Weeks 
Sewage Sludge 17.8 6 
Soil 6.7 15 
Lake Water 3.2 32 
Sea Water 2.7 37 
Table 5.2. Rate of mass loss of a copolymer of 3-hydroxybutyrate and 3-hydroxyvalerate in different 
environmental conditions. 
Data taken from Akmal et al. (2003). 
 
 
The work described in this chapter aims to assess the rate of breakdown of a commercially available 
PHA, EM10020, produced by Ecomann Films. This data will then be used to assess the suitability of this 
film as a packaging material for use in shampoo sachets sold in developing countries. A full analysis of 
the need for such materials can be found in section 4.1.1. The approach for development of a 
biodegradable sachet made from cellulose described in the previous chapter involved the use of 
cellulolytic enzymes. This had a number of problems associated with it so for PHAs the focus will be on 
its innate biodegradability rather than the use of depolymerase enzymes. 
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5.2 Results and Discussion 
5.2.1 Breakdown of PHA films in Soil 
The rate of breakdown of PHA film in different soils was determined by measuring the mass loss over 
time. A range of soils were used in these experiments in order to simulate a range of environmental 
conditions. The methods used in this experiment are described in section 7.6. An agricultural loam was 
collected from farmland in Lincolnshire as a general, fertile soil. In addition to this, sand was collected 
from the beach at Skegness as well as a sandy soil from sand dunes at near-by Gibraltar Point. In 
addition to this a saline soil was collected from a salt marsh also at Gibraltar Point. 
 
 
 
Figure 5.5. Locations of soil sample collection.  
Reproduced from Ordnance Survey map data by permission of the Ordnance Survey © Crown copyright 
2010. 
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Figure 5.6.  Experimental set-up for breakdown experiments.  
Each bag contains 300 g of soil and a 3 cm x 3 cm piece of EM10020 PHA film. The straw allows aeration 
to the sample. 
 
 
The soil was air-dried to constant mass and divided between several polythene bags before distilled 
water was added to achieve the desired moisture content. Each bag contained 300 g of soil and one 
3 cm x 3 cm piece of EM10020 PHA film. Moisture contents of 9 %, 17 % and 20 % were used for each 
soil with each individual experiment carried out in triplicate. The samples were incubated at 25 °C and 
each week were removed from the soil, washed and dried to constant mass before being photographed. 
Any water lost from the soil due to evaporation was replaced and the pieces of PHA film replaced and 
returned to the incubator. The rate of degradation was measured by monitoring the percentage of mass 
lost from each PHA sample. 
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Figure 5.7. Mass loss of EM10020 samples over time in four different soils (fertile soil, sand, sandy soil 
and saline soil) with A) 9% moisture, B) 17% moisture and C) 20% moisture. 
 Samples were buried in soil and incubated at 25 °C with aeration. Samples were removed weekly, 
washed, dried and weighed before being returned to the soil and incubation. Each soil type was tested 
three times at each moisture content. Error bars show the standard error of the mean. Where error bars 
are missing, this is due to two of the samples in those conditions disintegrating to such a degree that it 
was no longer possible to recover them from the soil. 
 
 
As can be seen in figure 5.7, the rate of degradation of PHA shows considerable variation based upon 
the soil type in which it is placed and the moisture content of that soil. As moisture content increases, so 
does the rate of degradation. The rates of degradation observed for all soils with 9 % moisture content 
are very low. Negative controls of sterilised soils would be required to determine whether the 
breakdown observed is biodegradation by bacteria and fungi, or is simply occurring due to chemical or 
physical degradation from the soil. However, the most rapid degradation takes place in fertile soil which 
would be expected if biodegradation was taking place due to the nutrient content of the soil being more 
supportive of bacterial and fungal growth and therefore greater production of PHA depolymerase 
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enzymes. However, PHA in this soil loses only around 10 % of its mass in 10 weeks, the equivalent of 
approximately two years for complete degradation. The slowest rate of degradation, for the soils with 
9 % moisture content, was observed in sand. Samples in these conditions would not fully breakdown for 
approximately six years. 
 
 
Soil Type Percentage 
Moisture Content 
Average Weekly 
Percentage Mass Loss 
Estimated Time for 
Complete 
Degradation/Weeks 
Fertile soil 9 1.0 102 
Sandy Soil 9 0.4 250 
Sand 9 0.3 324 
Saline Soil 9 0.7 152 
Fertile soil 17 1.6 65 
Sandy Soil 17 0.8 128 
Sand 17 1.0 97 
Saline Soil 17 2.9 36 
Fertile Soil 20 5.5 18 
Sandy Soil 20 6.5 13 
Sand 20 3.6 27 
Saline Soil 20 9.6 11 
Table 5.3. Estimated time for complete breakdown of EM10020 film in different soil types with varying 
moisture contents.  
Estimates are based on the rate of breakdown calculated from the data in figure 5.7. 
 
 
By photographing samples each week, it was possible to observe changes to the appearance of the films 
over time. Those samples in fertile soil appeared to have more localised areas of degradation. This effect 
was visible, after two or three weeks, as small, opaque, white, crystalline areas in the film samples, as 
can be seen in figure 5.8(A). Later in the experiments, as further degradation had occurred, these areas 
were more prone to split, leaving holes or tears in the material. This phenomenon was less apparent in 
the other soil types where a more even pattern of degradation was observed, as seen in figure 5.8(B). 
Samples placed in sandy soil were more prone to splitting than those in sand and saline soil. 
For some samples which had lost a relatively large proportion of their masses, it became no longer 
possible to recover every piece of the sample where parts had broken away. Despite this, the area of the 
remaining pieces was never so small as to account for all of the recorded mass loss. It is possible to 
disregard the loss of very small pieces of PHA as these are unlikely to cause any of the environmental 
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issues associated with non-degradable packaging materials and will continue to break down at the same 
rate as the larger pieces. 
An increase in soil moisture content was associated with an increase in rate of degradation for all soil 
types. If biodegradation is occurring, this is expected over the range of moisture contents investigated as 
an increase in water available in the environment would facilitate greater bacterial and fungal growth. 
Interestingly, the rate of breakdown in saline soil was observed to be faster than that in fertile soil at 
both 17 % moisture and 20 % moisture. This was surprising as it was assumed that soil with a high salt 
content would be less suitable for bacterial growth than nutrient-rich, agricultural soil. The reason for 
the higher-than-expected rate could be due to a number of factors. Firstly, the types of bacteria present 
in the saline soil could be different to those present in agricultural soil. If the saline soil naturally 
contains a higher percentage of PHA producing bacteria this would account for a difference in rate of 
biodegradation. This is possible as it is known that a number of halophilic bacteria produce PHA 
depolymerases (Rodriguez-Valera and Lillo, 1992). The result could also be explained if the bacteria 
responsible for PHA biodegradation were the same in both saline and fertile soils. Should this be the 
case it could be that the bacteria grow more successfully in saline conditions and thus produce more 
PHA depolymerase. An alternative explanation in this situation would be that similar amounts of PHA 
depolymerase were being produced in both soil types but the conditions in the saline soil were more 
favourable leading to a faster rate of breakdown. If biodegradation is not occurring, the differences in 
rate of breakdown between soils may be due to differences in the chemical composition of the soil. 
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Figure 5.8. The appearance of samples of EM10020 after breakdown in different conditions. 
A) Before any breakdown has occurred, B)Fertile soil with 17 % moisture, this sample has lost 20 % of its 
original mass, C)Sand with 17 % moisture, this sample has lost 10 % of its original mass, D)Saline soil 
with 17 % moisture, this sample has lost 33 % of its original mass, E)Lake Water ‘B’, this sample has lost 
69 % of its original mass. 
 
 
Samples in the soils with 17 % moisture content showed less evidence of the localised degradation 
observed in those samples with 9 % moisture. Tears and splits were still seen most frequently in the 
samples in fertile soil (figure 5.8(A)) but less frequently than in those samples in fertile soil with 9 % 
moisture content. This could be due to the higher moisture content ensuring more even bacterial 
growth throughout the sample rather than it being localised to particular areas. 
Samples in soils with 20 % moisture content, however, were much more prone to tearing than samples 
at either of the lower moisture contents. This is almost certainly due to the much higher rates of 
degradation observed in these samples. In fact, after seven weeks six of the nine samples placed in 
fertile soil, sandy soil and saline soil had disintegrated into many small pieces. These pieces ranged from 
approximately 5 mm2 to approximately 50 mm2. Due to the small sizes of some of the fragments it was 
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subsequently impossible to effectively recover the entire sample from the soil. However, as described 
previously, due to the small sizes of the pieces which could not be recovered, the associated mass loss is 
not necessarily significant. After nine weeks, all of the samples in these three soil types had 
disintegrated. Previous work on the composting of PHA films suggests that disintegration is likely to 
occur when approximately 30 %, by mass, of the film is remaining (Luo and Netravali, 2003). However, 
the increased mechanical strain of repeated sample removal, washing, drying and reburying may 
account for why the samples in this experiment began to disintegrate even before this level of 
degradation was reached. 
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Figure 5.9. Mass loss of EM10020 samples over time in A) fertile soil, B)  sandy soil, C) sand and 
D) saline soil with three different moisture contents (9 %, 17 % and 20 %).  
Samples were buried in soil and incubated at 25 °C with aeration. Samples were removed weekly, 
washed, dried and weighed before being returned to the soil and incubation. Each soil type was tested 
three times at each moisture content. Error bars show the standard error of the mean. Where error bars 
are missing, this is due to two of the samples in those conditions disintegrating to such a degree that it 
was no longer possible to recover them from the soil. Data shown is the same as that shown in figure 5.7. 
 
 
As can be seen in figure 5.9, the rate of degradation increased in each soil as moisture content 
increased. The extent of this increase was quite different for different soils and moisture contents. For 
example, the increase in rate of degradation in sandy soil when the moisture content increased from 
9 % to 17 % is relatively small, equating to roughly a halving of the time for complete breakdown (table 
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5.3). In contrast, the equivalent increase in moisture content in saline soil (Figure 5.9) results in an 
almost five-fold increase in rate of degradation. Interestingly, the increase in rate between 17 % 
moisture and 20 % moisture in all soils was greater than the increase observed between 9 % moisture 
and 17 % moisture. 
 
 
 
Figure 5.10. Mean estimated time for complete breakdown of EM10020 film at different moisture 
contents.  
Points are the mean estimated time of breakdown for all samples at given moisture contents as shown in 
table 5.3. 
 
 
Further analysis of the rates of breakdown in each individual soil reveals no obvious trends based upon 
the data collected so far. However, if the mean rate of breakdown for all soils at given moisture content 
is calculated then a clear trend can be seen (figure 5.10). Experiments which investigated a larger range 
of moisture contents would need to be gathered in order to make any firm conclusions about this 
relationship, in particular: how moisture content affects rate of breakdown outside the range 
investigated here. 
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5.2.2 Breakdown of PHA Films in Water 
The breakdown of PHA film was monitored by following the loss of mass over time. A range of different 
water samples was used. Sea water, river water and lake water were collected as they represent the 
main sources of water in the environment. Water was also collected from a second lake in order to show 
possible variations in PHA breakdown. Two different samples were collected from the second lake 
(Lakeside). A negative control of boiled lake water from Lakeside was also tested. Experiments were 
carried out in 1 l sample jars each containing 500 ml of water and a 3 cm x 3 cm piece of PHA film (figure 
5.12). The samples were incubated at 25 °C and every week were removed, washed and dried to 
constant mass. They were then photographed and replaced into the water samples before being 
returned to the incubator. The rate of degradation was measured by monitoring the percentage of mass 
lost from each PHA sample. The full methodology is described in section 7.7. 
 
 
 
Figure 5.11. Locations of water sample collection.  
Reproduced from Ordnance Survey map data by permission of the Ordnance Survey © Crown copyright 
2010. 
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Figure 5.12. Experimental setup for breakdown experiments.  
Each jar contained 500  ml of water and a 3 cm x 3 cm piece of EM10020 PHA film. Holes were drilled in 
the lid to allow aeration. 
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Figure 5.13. Mass loss of EM10020 samples over time in five different water samples (sea water, river 
water and three different lake water samples).  
Samples were incubated at 25 °C with aeration. Samples were removed weekly, washed, dried and 
weighed before being returned to the water and incubation. Each water type was tested in triplicate. The 
error bars shown are the standard error of the mean. 
 
 
As can be seen in figure 5.13, the rate of breakdown of PHA films varies greatly in different water types. 
Two of the three lake water samples showed extremely slow breakdown of the film, not significantly 
different to the breakdown observed in the negative control. These rates are equivalent to around three 
years for complete degradation to occur (table 5.4). In contrast, one of the lake water samples showed 
an extremely high rate of PHA breakdown, similar to that observed in saline soil with 20 % moisture 
(table 5.3). Samples in sea water showed a relatively slow rate of breakdown although this was still 
roughly twice as fast as the slowest rate observed in the lake water samples. Samples in river water are 
expected to breakdown completely within approximately six months. This result is interesting as 
previous work has suggested that PHAs should break down more rapidly in lake water than in sea water 
(Akmal et al., 2003). 
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Water Type Average Weekly Percentage 
Mass Loss 
Estimated Time for Complete 
Degradation/Weeks 
Sea Water 1.2 85 
River Water 4.1 25 
Lake Water 0.5 187 
Lake Water B 10.0 11 
Lake Water B 2 0.7 156 
Table 5.4.  Estimated time for complete breakdown of EM10020 film in different soil types with 
varying moisture contents. 
Estimates are based on the rate of breakdown calculated from the data in figure 5.13. 
 
 
Degradation of PHA samples in water occurred very evenly. In contrast to the breakdown of the film in 
soils, samples placed in water remained largely intact even when they have lost a large proportion of 
their mass. When the samples have lost only a small proportion of their mass, they are almost 
indistinguishable from samples which have not started to biodegrade. As the extent of breakdown 
increases, the films become more translucent (figure 5.8(D)) but are noticeably not as fragile as films 
which have reached a similar level of breakdown in soil. 
 
 
5.2.3 Mechanical Testing of Degraded PHA Films 
A further experiment was planned to investigate the effects of degradation on the mechanical 
properties of the PHA film. Strips of PHA film approximately 2 cm x 5 cm were used in these 
experiments. Three different environments were chosen in which to carry out the breakdown of these 
strips. A new sample of agricultural soil was collected from Howbrook near Sheffield and water from 
Lakeside Doncaster was collected as this had produced a high rate of degradation in the previous 
studies. As a control, some of this lake water was boiled for 30 minutes to provide a third set of 
conditions. The strips of PHA were split between a number of bags and samples jars and incubated at 
30 °C in order to maximise the rate of degradation. The methods used are described in section 7.8. 
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Figure 5.14. Mass loss of EM10020 samples over time in soil, lake water and boiled lake water.  
Samples were buried in soil or submerged in water and incubated at 25 °C with aeration. 
 
 
As shown in figure 5.14, the rate of degradation in soil was very high. In fact, after four weeks the strips 
had begun to break apart quite severely, as can be seen in figure 5.15(C). As a result of this, it is very 
likely that the PHA recovered after four and six weeks was not all that remained of each strip. As the 
strips were labelled only at each end, only those fragments which could be directly identified as 
belonging to a particular strip were dried and weighed. After eight weeks only very small fragments of 
PHA could be recovered from any of the bags of soil so the experiment was stopped. This result supports 
the previous results of composting studies which also showed that large-scale disintegration should 
occur when approximately 30 % of the original mass of PHA is remaining (Luo and Netravali, 2003). 
Unfortunately, the higher than expected rate of breakdown of the samples in soil meant that 
mechanical testing was no longer possible. The photographs in figure 5.15 show the extent to which the 
PHA strips had broken down, even after two weeks. This amount of degradation would have meant that 
any force applied to the strips would have immediately resulted in them breaking apart. 
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Figure 5.15. The breakdown of strips of EM10020 film after incubation at 30 °C in fertile soil with 20 % 
moisture content. 
Samples were removed from the soil after A)0 weeks, B)2 weeks, C)4 weeks, D)6 weeks. 
 
 
The samples incubated in lake water, conversely, broke down at a much slower rate than expected 
based upon the results in figure 5.13 (‘Lake Water B’). In fact, the rate of degradation was only slightly 
greater than that in control experiment. Even after ten weeks the strips had lost, on average, less than 
10 % of their mass. Again this limited any possible findings from mechanical testing as the range of 
breakdown was extremely small. However, this result did highlight the differences in rate of degradation 
between different environments, even if those environments are both found in the same lake. 
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5.2.4 Potential Use of PHA in Shampoo Packaging 
There are a number of limitations in the experiments carried out in this work. First of all, the 
degradation was all carried out in the laboratory so could not be a true representation of environmental 
conditions. In real-world conditions bacterial growth nutrients would be constantly returned to soil or 
aquatic systems, whereas, in these experiments once any nutrients had been used up they would not be 
replenished. The amounts of soil used in the experiments were much larger than the amounts of PHA 
film buried in them in order to try to minimise this effect but for reasons of practicality (i.e. available 
incubator space and mass of large quantities of soil) the amount of soil that could be used was limited. 
This could cause a decrease in bacterial and fungal growth over the course of the experiment which 
could, in turn, lead to a decrease in the rate of breakdown of the PHA films. Such a phenomenon can 
possibly be seen occurring in some of the conditions investigated particularly ‘sea water’ in figure 5.13 
and ‘sandy soil’ and ‘sand’ with 9 % moisture in figure 5.7. In order to confirm whether or not this is the 
case, an experiment in which samples would be buried in the natural environment or submerged 
directly in lake, sea or river water and monitored regularly, as described in section 6.4. 
The process of removing, washing, drying and replacing the PHA samples also creates some issues with 
this work. First of all, the samples are out of the soil environment for approximately six hours every 
week while these processes are carried out. This means that for 3.6 % of the time the samples are not 
undergoing degradation. Additionally, the process of washing removes any bacteria or fungi that have 
built up on the surface of the film over the previous week. When the film is replaced in the soil, the 
population of bacteria and fungi must re-establish itself and begin to produce PHA depolymerases once 
more. This will, again, represent a period of time when degradation is either not taking place or is taking 
place at a lower rate. These limitations mean that the rate of degradation being observed is almost 
certainly lower than would take place in an equivalent environment. Repeating some of the experiments 
with more samples in a similar manner to the degradation for mechanical testing experiments described 
above could provide an estimate of exactly how much higher the rate of degradation could be. 
The experiments were all carried out at a constant temperature and, in the case of the soils, constant 
moisture content. This does not take into account fluctuations that may occur in real-world conditions. 
Temperatures in India vary greatly throughout the country, as do levels of rainfall. It is likely that, rather 
than experiencing a constant rate of degradation, a shampoo sachet made from PHA would break down 
at a range of speeds depending on where it had been discarded and what time of year it was as well as a 
host of other factors. There is also no guarantee that a fertile agricultural soil in India would contain 
similar bacteria and fungi to the fertile soils used in this work. Extensive field studies would need to be 
carried out across India to determine what the true rates of degradation would be in the environment 
there. Even if these were carried out, however, it is extremely likely that a range of rates just as large as, 
if not larger than, the range observed in this work would be obtained. 
The soil and water samples used for these experiments were collected in December. The typical 
environmental temperatures at this time of year are significantly lower than the 25 °C used for 
incubation in these experiments. It is possible that any microbes present in the soil may be better 
adapted to lower temperatures so will not grow optimally at 25 °C. However, it is also likely that this 
temperature will have the effect of increasing the rates of growth of many microbes present. It has also 
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been observed that soil microbe populations vary seasonally (Wolsing and Prieme, 2004) so it is possible 
that, at different times of the year, the microbe population present at the same sites at different times 
of year may be more effective at breaking down PHA. Despite these possibilities, the low rates of 
breakdown observed still suggest that PHA is an unsuitable material for the construction of a 
biodegradable sachet. 
NMR spectroscopy experiments carried out by Joshua Swann at the University of Sheffield Department 
of Chemistry revealed that EM10020 is a copolymer of 3HB and 4HB containing approximately 20 % 
4HB. P(3HB-co-4HB) is an interesting material as it has been shown that the rate of enzymatic 
degradation is highly dependent upon the proportion of 4HB present. The highest rate of degradation is 
observed for polymers containing approximately 15 % 4HB. The rate of degradation falls sharply at 
either side of this value and at 20 % 4HB, is reduced by roughly half (Sudesh and Abe, 2010). This 
suggests that just a small modification in the composition of the polymer could result in a significant 
increase in the rate of degradation. 
The MVTR of EM10020 was also measured and was found to be 23 g/ m2/ day at 25 °C. This is 
considerably lower than the MVTR of simple cellulose and even lower than the coated cellulose also 
investigated. Unfortunately, this value remains too high for the long term storage of liquids. The long 
term ultraviolet (UV) and humidity stability of EM10020 was investigated using a weathering simulation 
system. This revealed that, if exposed to UV light and humidity for a prolonged period, as is likely to be 
experienced by a shampoo sachet on display in a shop in India, the film begins to become brittle and 
crack. This again makes it unsuitable for the long term storage of liquids. 
Ecomann film retails at £5000 per tonne. Based on a shampoo sachet size of 3 cm x 5 cm this works out 
at approximately 0.1 p per sachet. This would be considerably cheaper to produce than the previous, 
enzyme based proposal would have been, as it accounts for the entire cost of the sachet material. As the 
PHA film breaks down without any additional agents being present, it would also be much simpler to 
manufacture a complete sachet. 
 
 
5.3 Conclusions 
These experiments show that P(3HB-co-4HB) films break down in a range of different conditions. 
However, the rate of degradation varies greatly from 0.3 % per week to 10 % per week. While the higher 
rates of degradation would be ideal for a biodegradable shampoo sachet, the lower rates represent a 
time for total breakdown of up to six years. These timescales would offer little solution to many of the 
problems faced due to the current, non-biodegradable sachets. 
Additional control experiments in sterilised samples of each soil and water type used are required to 
determine whether the degradation observed is true biodegradation or is occurring due to chemical or 
physical processes. However, should the final products of breakdown be biomass and water, the 
breakdown observed would still fulfil the initial requirements of the material as described in chapter 4. 
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It is important to note that the experiments described in this chapter were not carried out in 
environmental conditions. In particular, breakdown experiments were carried out at a constant 
temperature with limited quantities of soil and water. The results obtained are sufficient to show that 
the rate of breakdown of the EM10020 film investigated is too variable for it to be a suitable packaging 
material. The value of carrying out experiments in environmental conditions in the UK is limited as a 
biodegradable shampoo sachet would be sold in India or other developing countries in which 
environmental conditions would differ significantly.  
There is the potential to produce a huge range of different PHA materials with different properties, all of 
which would degrade at different rates. This could be an area of further investigation and may produce 
materials with higher rates of degradation. As discussed in section 5.2.4, a small change such as 
adjusting the fraction of the second monomer in a copolymer could have a large effect on the rate of 
degradation. However, any such improvement in the rate of breakdown would also require an 
improvement in properties such as the MVTR and UV stability if PHAs were to be a suitable material for 
a shampoo sachet in the long term. 
It is clear from the work undertaken investigating the properties of current biodegradable materials that 
no currently commercially available products are suitable for the production of shampoo sachets. In 
order to tackle the problem of sachet waste in the short term then an alternative solution must be used. 
One such solution may involve the creation of a partially biodegradable sachet. If the bulk of the sachet 
was made from a biodegradable film, such as a PHA, it could potentially be coated with a thin layer of a 
material such as aluminium foil which would reduce the MVTR and increase the UV stability of the 
sachet. Degradation of the bulk of the mass of the sachet would result in a decrease in waste mass and 
volume. Provided the coating layer could be made thin enough, this would be mechanically weak 
enough once the remainder of the sachet had degraded that it would not cause blockages of sewers and 
water courses. The downside of this approach if PHAs were used is that coating one side of the film 
would reduce the rate of degradation considerably by reducing access to the surface of the PHA for PHA 
depolymerases. 
Another solution is to find a way to encourage people not to discard their waste sachets. Such an 
approach is currently in use by Unilever and relies upon the conversion of sachet waste into fuel via a 
process known as pyrolosis (Unilever, 2012b). This allows people to sell their used sachets back to 
Unilever who can then use the fuel produced to power their plants. This process recovers approximately 
60 % of the energy stored within the sachet which is a significant improvement when the alternative is 
the entire sachet going to waste.
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6. Future Work 
6.1 Small Molecule Inhibitors of HMG-CoA Reductase 
While the method of calculation of IC50 values described in section 2.2.2 provided a sufficiently accurate 
estimate for this work, an increase in the range of concentrations of each compound investigated would 
improve the accuracy. A range of concentrations spanning a number of orders of magnitude both higher 
and lower than the concentrations investigated would produce data which could be plotted on a graph 
of initial rate of reaction against the logarithm of the inhibitor concentration. Using a least-squares 
regression method, this data could then be fitted to a sigmoidal curve in the form: 
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Where y is the initial rate of reaction, x is the inhibitor concentration, A1 is the initial rate of reaction at 
minimal inhibition, A2 is the initial rate of reaction at maximal inhibition, x0 is the IC50 and p is the 
gradient of the linear part of the curve. 
Other further experiments could be carried out in order to better understand the mechanism of 
inhibition taking place in the assay. As mentioned in section 2.2.3, the use of isothermal titration 
calorimetry would enable binding energies to be calculated directly and accurately (McKinnon et al., 
1984). This technique is able to directly measure the energy change, at constant temperature, as an 
inhibitor is titrated against the enzyme. This data would be likely to be accurate enough to identify any 
correlation between gradations in structural properties, i.e. increasing size of groups added in the R1/R3 
position, and binding energy. This could improve the selection of the most effective inhibitors as well as 
potentially allowing more targeted design and molecular modelling of future HMG-CoA reductase 
inhibitors. 
In order to carry out isothermal titration calorimetry, or any of the other experiments described in this 
section, it would first be necessary to produce a supply of HMG-CoA reductase. This can be achieved by 
amplifying the catalytic portion of the human HMG-CoA reductase gene and cloning this into a plasmid 
containing a glutathione S-transferase (GST) protein. This plasmid can be transformed into E. coli leading 
to the production of a GST-fusion protein. The tagged protein can then be purified using affinity 
chromatography before the GST-tag is removed using a protease. HMG-CoA reductase can be further 
purified using anion-exchange chromatography (Istvan et al., 2000). 
Another important piece of further work would be to determine in what conformation the inhibitors 
bind to HMG-CoA reductase. One way of doing so would be to use 13C-NMR, which would indicate 
changes in the environment of carbon atoms in the inhibitors under experimental conditions. An issue 
with this technique would be producing a clearly identifiable signal for the inhibitor. This may require a 
very high inhibitor concentration which may result in undesirable reactions occurring and thus 
producing less reliable results. 
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A more reliable method of determining the binding conformation of the inhibitors would be X-ray 
crystallography. For this technique, co-crystals of the catalytic portion of HMG-CoA reductase and each 
inhibitor would be produced. The diffraction pattern of these crystals could be used to calculate the 
structure of the inhibitor-enzyme complex (Istvan et al., 2000). This would have the further advantage 
over 13C-NMR of showing not only the inhibitor conformation but how each molecule interacts with the 
enzyme. This would also be very useful in identifying which structural features of the inhibitors were 
involved in binding, allowing better targeted design of future compounds. X-ray crystal structures would 
be particularly useful when refining molecular models of compound binding as this data could be used 
to further refine the current models that have been used. 
As discussed in section 2.2.4, in vitro testing of the toxicity of the inhibitors tested would also be a useful 
further experiment to carry out. This can be done using the reagent resazurin, which fluoresces under 
reducing conditions. Viable cells maintain reducing conditions in the cytosol so when resazurin is added 
to cultured human cells and incubated at 37 °C it fluoresces. In order to test for the cytotoxicity of the 
inhibitors used in this experiment, cultured cells can be incubated in a solution of each different 
inhibitor before subsequently being incubated with resazurin. If the cultured cells do not fluoresce, or 
fluoresce to a lesser extent than cells that have not been incubated with the inhibitor, this would 
indicate that the inhibitor is cytotoxic (Fields and Lancaster, 1993). 
Following elucidation of a compound’s binding mechanism and confirmation that it is not toxic to 
human cells in vitro, the next stage of investigation would be to carry out in vivo testing in animals. Such 
experiments would allow an assessment of the pharmacokinetic and pharmacodynamic properties of a 
compound. Due to the nature of these compounds, as discussed in section 2.2.1, it is important to 
investigate the conformation that they take when they reach their sites of action. If the compounds are 
converted to the parent compounds, atorvastatin or rosuvastatin, by the time they reach cells then any 
improvement offered can only be in pharmacokinetic properties. This could be due to, for example, a 
longer elimination half-life or improved targeting to liver or intestinal cells which are the primary sites of 
cholesterol biosynthesis (Berg et al., 2002). However, if the compounds reach cells in a different form 
and still inhibit cholesterol biosynthesis in vivo, this could be via a novel mechanism. 
Initial testing of the compounds at concentrations of 50 nM in sections 2.2.1 and 2.2.4 identified three 
compounds that appear to enhance the initial rate of conversion of HMG-CoA to mevalonate (IB/6/2, 
IB/12/1 and ED/05/02B). Further investigation of these compounds would also be of interest. The assay 
used in chapter 2 could be repeated using a strong inhibitor such as rosuvastatin with one of the three 
rate enhancing compounds added to the reaction. If rosuvastatin has a similar effect on the rate of 
reaction as in the absence of the rate enhancing compound, this would suggest that any enhancement 
was due to allosteric effects. However, if the rate in the presence of both inhibitor and activator was 
higher than that in the presence of only inhibitor, this would suggest that the rate enhancement is 
caused by some interaction at the active site of the enzyme. This could be further investigated by 
carrying out x-ray crystallography on a complex of HMG-CoA reductase and a rate enhancing compound. 
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6.2 Antibacterial Activity of Novel Fluoroquinolones 
It would be desirable to test the compounds investigated in chapter 3 using the same disc-diffusion 
technique but with larger amounts of each compound. However, as discussed in section 3.3, any positive 
results obtained would be of limited use as the mechanism of activity in vitro for these compounds is 
likely to differ from the in vivo mechanism of action. 
As discussed in sections 3.2 and 6.1, the compounds used in these experiments are likely to be 
converted from their original conformation in vivo. Previous testing of 3-formyl fluoroquinolone 
analogues in mice has revealed improved pharmacokinetic properties compared to the equivalent 
fluoroquinolone parent compound (Kondo et al., 1988). A similar experiment using the other novel 
fluoroquinolone analogues may also reveal an improvement in activity over existing, commercially 
available compounds, even when in vitro activity is not observed. As discussed in section 6.1, it would be 
preferable to carry out cytotoxicity testing on cultured human cells prior to carrying out animal work so 
as to avoid testing potentially dangerous compounds in vivo. The method employed for testing the 
toxicity of these compounds would be the same as the one described in that section. 
Any antibacterial activity displayed in animal experiments is more likely to occur via the same 
mechanism as would occur when treating infections in humans. It would also reveal the 
pharmacokinetic properties of these novel compounds which would allow a direct comparison to the 
parent compounds levofloxacin and pefloxacin. Should any of the compounds offer improved activity in 
vivo then the equivalent substitution of the carboxylic acid group in position 1 of any existing 
fluoroquinolone compound could potentially also offer an improved treatment. 
 
 
6.3 Alternative Biodegradable Materials for Shampoo Sachet Construction 
Despite the shortcomings of cellulose as a material for a biodegradable shampoo sachet, there are a 
number of other biodegradable polymers which may yet offer a solution to the issues outlined in section 
4.1. Like cellulose, starch is a polysaccharide made up of glucose monomers. It is made up of two 
different homopolymers of glucose: amylose contains glucose monomers exclusively linked by α-1,4-
glycosidic bonds in a linear manner and amylopectin which resembles the linear structure of amylose 
but also contains branched chains connected by α-1,6-glycosidic bonds. Starch is produced by plants as 
an energy store and is a common component of the human diet. 
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Figure 6.1. The structures of amylopectin and amylose, the two different homopolymer constituents of 
starch. 
 
 
Starch is readily broken down by a number of different amylase enzymes (Reis and Cunha, 2001). 
However, compared to other materials, biodegradable products based on starch have several 
drawbacks, such as water sensitivity, brittleness and poor mechanical properties (Lu et al., 2009) and is 
often used in blends with synthetic monomers such as vinyl alcohol. The MVTR of starch was measured, 
by Joshua Swann at the University of Sheffield, Department of Chemistry, as 140 g/ m2/ day. This is 
lower than the MVTR of the simple cellulose film but for a film nearly seven times thicker. This fact alone 
is sufficient to discount starch as a suitable packaging material for shampoo. 
Polylactic acid (PLA) is synthesised by condensation of lactic acid or by ring opening of lactide. The 
source of these starting materials is typically the fermentation of carbohydrates such as glucose. 
Degradation of PLA can occur either hydrolytically or enzymatically (Kikkawa et al., 2002). The enzymes 
responsible for degradation of PLA are proteases rather than specific PLA depolymerases (Williams, 
1981). Unfortunately, no commercially available PLAs are biodegradable and all rely on hydrolysis for 
degradation. This process is temperature dependent and will not occur without industrial composting 
maintaining a constant high temperature to initiate break down.  This is unsuitable as the poor waste 
processing facilities in developing countries are one of the main reasons behind the requirement for a 
fully biodegradable solution. 
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Figure 6.2.  Polymerisation of PLA via the ring opening hydrolysis of lactide. 
 
 
Polyhydroxyalkanoates (PHAs) are a type of linear polyesters which are synthesised by certain bacteria. 
The most common type of PHA is polyhydroxybutyrate (PHB) which is a polymer of butyric acid. PHAs 
are produced by bacteria in response to unbalanced growth conditions and serve as a stored carbon 
source until suitable growth conditions return. In order to utilise the stored carbon, PHA-producing 
bacteria produce PHA depolymerase enzymes. A wide range of different PHAs exist with several 
hundred different HA monomers known to be incorporated. PHAs are, therefore, a family of naturally 
occurring and fully biodegradable materials with a wide range of different properties. The suitability of 
PHAs as a packaging material for shampoo sachets is discussed in chapter 5. 
 
 
6.4 Use of PHAs in Shampoo Sachet Construction 
While the experiments carried out in chapter 5 demonstrate that the commercially available PHA tested 
is unsuitable as a material for the construction of a biodegradable shampoo sachet, there are a number 
of further experiments that could be carried out to better understand its breakdown. Initially, the 
negative control experiments discussed in section 5.2.1 should be carried out to determine whether the 
breakdown of the PHA film was due to the action of biological agents or simply the result of chemical or 
physical degradation. If biodegradation was taking place, an analysis of the bacteria and fungi present in 
each soil and water sample could be carried out to identify which species were causing the breakdown. 
This can be achieved by inoculating plates of minimal media containing PHA with a suspension of a soil 
or a sample of a water type. This should produce distinct strains of bacteria which can then be identified 
by sequencing their ribosomal RNA (Fierer et al., 2005). 
It would also be useful to carry out studies of the breakdown of PHAs in environmental conditions. This 
could be achieved by burying PHA samples directly in soil or submerging them in a fixed, porous 
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container in a lake, river or sea. The samples could then be retrieved after a fixed length of time and the 
extent of breakdown measured. This would confirm how good an estimation of the true rate of 
breakdown the experiments described in chapter 5 is.  
The work described in chapters 4 and 5 shows that it is not possible to produce a functional, 
biodegradable shampoo sachet using commercially available materials. However, while beyond the 
scope of this work, it may be possible to produce a novel material suitable for this purpose. PHAs may 
be an ideal candidate due to the potential for variation in their structures, as discussed in section 5.1.1. 
A range of different copolymers of 3HB and other PHA monomers could be produced and their rates of 
breakdown investigated. As discussed in section 5.2.4, varying the proportion of a particular monomer 
in a copolymer by as little as 5 % can have a significant impact on the rate of breakdown (Sudesh and 
Abe, 2010). 
If a PHA producing bacterium is grown in unbalanced growth conditions on a medium containing a 
carbon source that is structurally related to a particular HA monomer, it will produce crystals of the 
equivalent copolymer with 3HB. If these crystals are purified, they can be cast into films and their rates 
of breakdown in different environments measured. By varying the types and proportions of the carbon 
source during the initial bacterial growth, a range of different films could be investigated. If a polymer 
that broke down in an acceptable time-frame in a range of different conditions could be produced it 
may be a suitable candidate for use in shampoo sachets. 
It is unlikely that a film produced by this method would have an MVTR low enough to be the sole 
component of a viable sachet. A further area for investigation would be the inclusion of an additional 
layer to a PHA sachet, similar to the coated cellulose used in chapter 4, to reduce its MVTR. It is unlikely 
that a biodegradable material would be suitable for this task unless it was so thick as to increase the 
time taken for the sachet to breakdown to above an acceptable level. Non-biodegradable alternatives 
would have to have a minimal impact on the rate of breakdown of the PHA and also a minimal impact 
on the environment following that breakdown. 
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Chapter 7 
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7. Materials and Methods 
7.1 Materials and Equipment 
All chemicals used in the experiments described here were of molecular biology grade. dH2O was 
produced by a Millipore MilliQ system. ddH2O was produced by autoclaving MilliQ dH2O for a period of 
20 minutes at 121 °C in acid-cleaned glass containers. ddH2O was used in the preparation of all buffer 
solutions and in all experiments unless specified otherwise.  
 
 
Description Supplier Abbreviation 
3-Hydroxy-3-methylglutaryl-CoA 
Reductase Solution Human 
Sigma-Aldrich HMG-CoA Reductase 
Agar Bacteriological Oxoid - 
Albumin, from Bovine Serum Sigma-Aldrich BSA 
Cellobiase from Aspergillus 
niger, liquid 
Sigma-Aldrich - 
Cellulase from Aspergillus sp., 
aqueous solution 
Sigma-Aldrich - 
Cellulase from Trichoderma 
reesei ATCC 26921, aqueous 
solution 
Sigma-Aldrich - 
Cellulose, Microcrystalline 
Powder 
Sigma-Aldrich - 
D(+)-Glucose Monohydrate VWR BDH Prolabo Glucose 
Diaminoethanetetraacetic Acid 
Disodium Salt 
Fisher Scientific EDTA 
Dimethyl Sulfoxide Sigma-Aldrich DMSO 
Dimethyl Sulfoxide Sigma-Aldrich - 
Dipotassium Hydrogen 
Orthophosphate 
VWR BDH Prolabo K2HPO4 
DL-3-Hydroxy-3-methylglutaryl 
Coenzyme A Sodium Salt 
Hydrate 
Sigma-Aldrich HMG-CoA 
EM10020 50 micron A & O Film Pac - 
EM10020 60 micron A & O Film Pac - 
Filter Paper Grade 1 Whatman - 
Mowiol 10-98 Mowiol - 
Mowiol 20-98 Mowiol - 
Mowiol 28-99 Mowiol - 
Mowiol 40-88 Mowiol - 
Mowiol 4-98 Mowiol - 
Mowiol 6-98 Mowiol - 
Mowiol 8-88 Mowiol - 
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Mueller-Hinton Broth Oxoid - 
Natureflex 22DNE Innovia Films Coated Cellulose Film 
Natureflex NP21 Innovia Films Simple Cellulose Film 
Nutrient Broth Oxoid - 
Potassium Chloride Fisher Scientific KCl 
Potassium Dihydrogen 
Orthophosphate 
VWR BDH Prolabo KH2PO4 
Tryptone Soya Broth Oxoid - 
β-Nicotinamide Adenine 
Dinucleotide 2’-Phosphate 
Reduced Tetrasodium Salt 
Hydrate 
Sigma-Aldrich NADPH 
Table 7.1. Materials used during experimental work.  
Includes details of material supplier and, where applicable, the abbreviated description used in the text. 
 
 
All disposable plastic used in this work were obtained from Star Labs, Bibby Sterelin and Anachem. 
Other equipment used is listed in table 7.2. 
 
 
Equipment Supplier and Model 
Balances Mettler 0-60 g model AJ100 and Mettler 0-800 g 
model K7 
Microcentrifuge MSE Microcentaur 
Dry Heat Block Grant Instruments 
pH Meter Denver Instruments Basic with Tris electrode 
Pipettes Gilson Pipetman P10, P20, P100, P200, P1000, 
P5000 
Positive Displacement Pipette Gilson Microman M10 
UV/Vis Spectrophotometer Perkin Elmer Lambda 12 
Vortexer Labnet 
Microplate Reader Biorad  Model 550 
96 Well EIA/RIA Plate Costar 
Table 7.2. Equipment used during experimental work including supplier information. 
 
 
Staphylococcus aureus Newman, S. aureus SH1000, Pseudomonas aeruginosa and Enterococcus faecalis 
used in the testing of antibacterial compounds were provided by Professor Simon Foster. 
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7.2 In vitro Testing of HMG-CoA Reductase Inhibitors 
The reaction buffer contained 100 mM potassium phosphate buffer at pH 7.2, 1 mM EDTA, 500 mM KCl 
and 2 mg/ ml BSA. HMG-CoA reductase was diluted to working concentration in the reaction buffer. 
NADPH and HMG-CoA were also dissolved in the reaction buffer. Potential inhibitor compounds were 
dissolved in 99.5 % DMSO, all to the same stock concentration. The assay was carried out in flat-
bottomed 98-well microplates to a total volume of 200 μl. The final concentration of HMG-CoA 
reductase in each assay was 10 nM and the final concentrations of NADPH and HMG-CoA were both 
200 µM. The reaction was activated by the addition of HMG-CoA reductase. The plate was transferred to 
a UV spectrophotometer which was set to a temperature of 37 °C and recorded the absorption at 340 
nm every twenty seconds over a ten minute period. This cycle included 10 seconds of mixing prior to 
each of the first 10 absorption readings. All assays were carried out in triplicate as a minimum. All assays 
were carried out blind, i.e. the identity of each inhibitor was unknown when the experiments were 
carried out. 
Initial screening assays were carried out with 50 nM inhibitor which resulted in a final DMSO 
concentration of 0.5 %. The following controls were also carried out: 0 nM inhibitor, 50 nM atorvastatin, 
50 nM rosuvastatin and 0 nM inhibitor plus 0.5 % DMSO. 
In order to calculate IC50 values for compounds, the assay was repeated with all conditions remaining 
constant except for the inhibitor concentration. Inhibitor concentrations of 1 nM, 2 nM, 5 nM, 10 nM, 
20 nM, 30 nM and 40 nM were used for each compound along with the result of initial testing with 
50 nM inhibitor. This allowed a graph of initial rate of catalysis against time to be plotted for each 
compound. This data was then fitted to a Boltzmann function using a least-squares regression method, 
which produced an estimate of the IC50 value. 
 
 
7.3 In vitro Testing of Fluoroquinolone Compounds 
The parent compounds, levofloxacin and pefloxacin mesylate, were dissolved in 99.5 % DMSO and 
solutions of 1 µg / ml, 5 µg / ml, 10 µg / ml, 20 µg / ml, 50 µg / ml, 100 µg / ml and 200 µg / ml were 
produced. 6 mm disks of Whatman filter paper number one were produced and placed in an oven 
overnight for sterilisation. Antibacterial disks were produced by applying 5 µl of a prepared solution to a 
filter paper disk and allowing the disk to dry. Mueller-Hinton agar plates were produced using 21 g l-1 
Mueller-Hinton broth and 1.5 % (w/v) agar No 1. P. aeruginosa was grown in nutrient broth and S. 
aureus and E. faecalis were grown in tryptone soya broth all at 37 °C with shaking. All bacterial strains 
were grown to an optical density of between 0.07 and 0.1 at 625 nm. 100 µl of the bacterial culture was 
then mixed with 2 ml of Mueller-Hinton broth (21 g l-1) containing 0.7 % (w/v) agar No 1. The mixture 
was then spread evenly onto a Mueller-Hinton agar plate and allowed to set. 
Each bacterial strain was tested against both of the parent compounds. A single compound was tested 
on each agar plate. Disks containing different concentrations of an antibacterial compound were placed 
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onto the surface of the agar, each separated by a distance of at least 24 mm. The plates were incubated 
for 18 hours at 37 °C. Following incubation, the zone of inhibition for each disk was measured. Each 
concentration of each compound was tested three times. 
Six novel compounds were tested using the method above but the solutions applied to the filter paper 
discs were 2 μg / ml, 20 μg / ml, 200 μg / ml and 2000 μg / ml. Each plate also contained a positive 
control of a disc with 5 μl of a 20 μg / ml solution of levofloxacin applied. 
 
 
7.4 Degradation of Cellulose by Cellulolytic Enzymes 
10 mg of cellulose substrate were added to 490 μl of ddH2O and 10 μl of cellulolytic enzymes which 
were mixed at 25 revolutions per minute on a rotator at 37 °C for 20 hours. The reaction was stopped by 
placing the mixture on ice. The mixture was centrifuged at 14800 rpm for 5 minutes. 8.33 μl of the 
supernatant was added to 250 μl of glucose determination reagent containing 0.16 mM ATP, 0.09 mM 
NADP, 3.0 units of hexokinase and 2.4 units of glucose-6-phosphate dehydrogenase in 0.1 M Tris-HCl 
pH 7.2. The absorbance at 340 nm was measured every 30 seconds for one hour by UV spectroscopy 
and the final absorbance recorded. 
A glucose standard curve was constructed using the same glucose determination reagent and 8.33 μl of 
solutions of glucose in ddH2O. Thirteen different solutions were used with concentrations between 
0 mM and 15 mM. The standard curve was then used to convert the final absorbances at 340 nm to the 
equivalent mass of glucose produced during the cellulose digestion. 
10 mg of each different substrate was as follows: 10 mg of microcrystalline cellulose, two 6 mm 
diameter discs of Whatman Number 1 filter paper or 3 cm2 of simple cellulose film and coated cellulose 
film. When measuring the breakdown of bilayer films, 3 cm2 was also used. This represents a total mass 
of greater than 10 mg but a mass of cellulose of 10 mg. In addition to monitoring the breakdown of 
coated cellulose film over 20 hours, the assay was repeated with identical reagents but with increased 
incubation times of 44 hours, 68 hours and 116 hours. 
Two negative controls were carried out for each assay. Firstly, the protocol outlined above with no 
enzyme present and, secondly, the protocol outlined above with no substrate. For experiments involving 
bilayer films, a cellulose-PVOH bilayer was used as one control and a PVOH film containing cellulolytic 
enzyme was used as a second control. All assays and controls were repeated a minimum of three times. 
 
 
7.5 Degradation of Coated Cellulose by Different Enzyme Concentrations 
A further experiment monitored the breakdown of coated cellulose film with varying concentrations of 
cellulolytic enzymes in solution. The concentrations used in addition to the 0.7 units of cellulolytic 
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enzyme per mg of cellulose used in other assays were: 0.63 units per mg, 0.525 units per mg, 0.42 units 
per mg, 0.315 units per mg, 0.21 units per mg and 0.07 units per mg. Multiple cellulolytic digestions 
were set up at each concentration and incubated at 37 °C with mixing at 25 revolutions per minute on a 
rotator. After 24 hours, three tubes of each concentration were removed from the incubator and the 
reaction stopped with ice. The tubes were centrifuged at 14800 rpm for 5 minutes. 8.33 μl of the 
supernatant from each tube was added to 250 μl of glucose determination reagent containing 0.16 mM 
ATP, 0.09 mM NADP, 3.0 units of hexokinase and 2.4 units of glucose-6-phosphate dehydrogenase in 
0.1 M Tris-HCl pH 7.2. The absorbance at 340 nm was measured every 30 seconds for one hour by UV 
spectroscopy and the final absorbance recorded.  
A further three tubes of each concentration were analysed in the same manner every 24 hours. The 
experiment was stopped after no change in final absorbance had been observed for three consecutive 
24 hour periods. This was taken as an indication that complete digestion had taken place. 
 
 
7.6 Breakdown of Polyhydroxyalkanoate Films in Soil 
Samples of four different soils were collected as outlined in the table below. All soils were collected 
during December. 
 
 
Soil Type  Location 
Fertile Agricultural Soil Lincolnshire (current crop: beans) 
Sandy Soil Gibraltar Point, Skegness, 
Lincolnshire 
Sand Skegness, Lincolnshire 
Saline Soil Gibraltar Point, Skegness, 
Lincolnshire 
Table 7.3. Soil types used in breakdown experiments, the locations from which they were collected and 
a description of the soil. 
 
 
Soils were air-dried to constant mass. Samples of approximately 300 g of each dried soil were placed 
into polythene bags before dH2O was added to achieve the desired soil moisture content. A 3 cm x 3 cm 
piece of 50 micron EM10020 PHA film, of known mass, was then buried in each soil and the bags sealed, 
with straws inserted in order to provide ventilation. The bags were then incubated at 25 °C. At weekly 
intervals, the PHA samples were removed from the soil, washed with deionised water and dried in an 
incubator before being weighed. The samples were then returned to the bags and deionised water 
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added to maintain the soil moisture content before being returned to the 25 °C incubator. Degradation 
in each soil type was carried out in triplicate. The experiment was carried out for soil moisture contents 
of 9 %, 17 % and 20 %. 
 
 
7.7 Breakdown of Polyhydroxyalkanoate Films in Water 
Four different water samples were collected as outlined in the table below. All samples were collected 
during December, except for ‘lake water B’ which was collected during January. 
 
 
Water Type Location 
River Water River Don, Oughtibridge, South 
Yorkshire 
Lake Water A Lady Bower Reservoir, Derbyshire 
Lake Water B Doncaster, South Yorkshire 
Sea Water North Sea 
Table 7.4.  Water types used in breakdown experiments and the locations from which they were 
collected. 
 
 
500 ml samples of each water type were placed into 1 litre glass sample jars. A 3 cm x 3 cm piece of 
50 micron EM10020 PHA film, of known mass, was added to each jar. Holes were drilled into the lid of 
each sample jar to provide ventilation. The jars were incubated at 25 °C. At weekly intervals, the PHA 
samples were removed from the jars, washed with deionised water and dried in an incubator before 
being weighed. The samples were then returned to the jars and the jars returned to the 25 °C incubator. 
Experiments were carried out in triplicate for each water type. 
 
 
7.8 Breakdown of Polyhydroxyalkanoate Films for Mechanical Testing 
Soil was collected from a field planted with a grass ley, during March, and air-dried to constant mass. 
Ten polythene bags were each filled with approximately 750 g of the dry soil. dH2O was added to each 
bag to give a soil moisture content of 20 %. 25 strips of 60 micron EM10020 PHA film, approximately 
2 cm x 10 cm were buried in the soil with two or three strips in each bag. The bags were sealed, with a 
straw placed in each bag in order to provide ventilation. The bags were then incubated at 30 °C. dH2O 
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was added to each bag weekly, in order to maintain constant soil moisture content. Every two weeks 
five PHA strips were removed, each one coming from a different bag. These strips were then washed 
and dried in an incubator before being weighed. 
Five one-litre sample jars were each filled with 600 ml of ‘Lake Water B’ (see table 2) which was 
collected during March. Five 2 cm x 10 cm PHA strips were placed in each jar. Holes were drilled in the 
lid of each jar to provide ventilation. The jars were then incubated at 30 °C. Every two weeks one strip 
was removed from each jar. These strips were then washed and dried in an incubator before being 
weighed. This experiment was completed in duplicate using ‘Lake Water B’ which had been boiled for at 
least 30 minutes.
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A. Raw Data and Plots for IC50 Calculations 
 Initial Rate of Reaction / p.d.u.  
[Inhibitor] 
/ nM 
Assay 
1 
Assay 
2 
Assay 
3 
Assay 
4 
Assay 
5 
Assay 
6 
Assay 
7 
Assay 
8 
Mean Error 
0 0.047 0.046 0.041 0.043 0.043 0.042 0.042 0.045 0.044 0.001 
1 0.044 0.042 0.035 0.033 0.044 0.044 0.034 0.040 0.039 0.002 
2 0.032 0.030 0.036  0.038   0.036 0.034 0.001 
5 0.030 0.029 0.029  0.028  0.030  0.029 0.000 
10 0.018  0.022 0.023 0.017 0.016 0.023 0.020 0.020 0.001 
15  0.026 0.015 0.002 0.021    0.016 0.005 
20 0.020 0.011 0.025 0.011 0.008 0.004 0.013 0.019 0.014 0.002 
30 0.010 0.008 0.017 0.012 0.013 0.021 0.016 0.009 0.013 0.002 
40 0.007 0.009 0.015 0.015 0.012 0.012 0.012 0.009 0.012 0.001 
50 0.015 0.019 0.013 0.011 0.014 0.015 0.008 0.007 0.013 0.001 
Table A.1. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of Atorvastatin. 
Substrates HMG-CoA and NADPH both have a final concentration in the reaction of 200 µM and the 
HMG-CoA reductase concentration was 10 nM in all assays. All assays were biological repeats and errors 
are standard error of the mean. Initial rate of reaction is shown in procedure defined units as it is 
calculated from absorption measurements which have no units. 
 
 
 
 
 
 
 
 
Figure A.1. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of Atorvastatin. 
Data plotted are those shown in table A.1. The curve fitted is a Boltzmann function with the parameters 
shown, where A1 is the initial rate of reaction at minimal inhibition, A2 is the initial rate of reaction at 
maximal inhibition, x0 is the IC50 and dx is the concentration range over which inhibition changes from 
minimal to maximal. 
 
A1 / p.d.u. 0.044 
A2 / p.d.u. 0.011 
x0 / nM 6.516 
dx / nM 3.593 
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Assay 
1 
Assay 
2 
Assay 3 Assay 
4 
Assay 
5 
Assay 
6 
Assay 
7 
Assay 
8 
Mean Error 
0 0.047 0.046 0.041 0.043 0.043 0.042 0.042 0.045 0.044 0.001 
1 0.021 0.051 0.054 0.042 0.032    0.040 0.006 
2 0.041 0.024 0.032      0.032 0.005 
5 0.021 0.021 0.034  0.019    0.024 0.003 
10 0.016 0.011  0.011     0.013 0.002 
15 0.000 0.016 0.010      0.009 0.005 
20 0.005 0.007 0.008      0.007 0.001 
30 0.000 0.016 0.009      0.008 0.005 
40 0.004 0.007 0.009      0.007 0.001 
50 0.009 0.004 0.008      0.007 0.002 
Table A.2. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of Rosuvastatin. 
Substrates HMG-CoA and NADPH both have a final concentration in the reaction of 200 µM and the 
HMG-CoA reductase concentration was 10 nM in all assays. All assays were biological repeats and errors 
are standard error of the mean. Initial rate of reaction is shown in procedure defined units as it is 
calculated from absorption measurements which have no units. 
 
 
 
 
 
 
 
 
 
Figure A.2. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of Rosuvastatin. 
Data plotted are those shown in table A.2. The curve fitted is a Boltzmann function with the parameters 
shown, where A1 is the initial rate of reaction at minimal inhibition, A2 is the initial rate of reaction at 
maximal inhibition, x0 is the IC50 and dx is the concentration range over which inhibition changes from 
minimal to maximal. 
A1 / p.d.u. 0.044 
A2 / p.d.u. 0.010 
x0 / nM 3.880 
dx / nM 3.023 
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Assay 
1 
Assay 
2 
Assay 3 Assay 
4 
Assay 
5 
Assay 
6 
Assay 
7 
Assay 
8 
Mean Error 
0 0.047 0.046 0.041 0.043 0.043 0.042 0.042 0.045 0.044 0.001 
1 0.049 0.040 0.047      0.045 0.003 
2 0.045 0.042 0.039      0.042 0.002 
5 0.017 0.037 0.026      0.026 0.006 
10 0.020 0.005 0.007      0.011 0.005 
20 0.013 0.003 0.023      0.013 0.006 
30 0.010 0.014 0.013      0.012 0.001 
40 0.022 0.005 0.011      0.012 0.005 
50 0.010 0.004 0.001      0.011 0.004 
Table A.3. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of atorvastatin lactone. 
Substrates HMG-CoA and NADPH both have a final concentration in the reaction of 200 µM and the 
HMG-CoA reductase concentration was 10 nM in all assays. All assays were biological repeats and errors 
are standard error of the mean. Initial rate of reaction is shown in procedure defined units as it is 
calculated from absorption measurements which have no units. 
 
 
 
 
 
 
 
 
 
 
Figure A.3. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of atorvastatin lactone. 
Data plotted are those shown in table A.3. The curve fitted is a Boltzmann function with the parameters 
shown, where A1 is the initial rate of reaction at minimal inhibition, A2 is the initial rate of reaction at 
maximal inhibition, x0 is the IC50 and dx is the concentration range over which inhibition changes from 
minimal to maximal. 
A1 / p.d.u. 0.044 
A2 / p.d.u. 0.011 
x0 / nM 4.307 
dx / nM 1.703 
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Assay 
1 
Assay 
2 
Assay 3 Assay 
4 
Assay 
5 
Assay 
6 
Assay 
7 
Assay 
8 
Mean Error 
0 0.047 0.046 0.041 0.043 0.043 0.042 0.042 0.045 0.044 0.001 
1 0.025 0.037 0.038      0.033 0.004 
2 0.032 0.032 0.025      0.029 0.002 
5 0.025 0.014 0.021      0.020 0.003 
10 0.023 0.016 0.020      0.019 0.002 
20 0.011 0.008 0.014      0.011 0.002 
30 0.004 0.012 0.006      0.007 0.002 
40 0.005 0.008 0.014      0.009 0.003 
50 0.008 0.008 0.005      0.007 0.001 
Table A.4. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/13/1. 
Substrates HMG-CoA and NADPH both have a final concentration in the reaction of 200 µM and the 
HMG-CoA reductase concentration was 10 nM in all assays. All assays were biological repeats and errors 
are standard error of the mean. Initial rate of reaction is shown in procedure defined units as it is 
calculated from absorption measurements which have no units. 
 
 
 
 
 
 
 
 
 
Figure A.4. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/13/1. 
Data plotted are those shown in table A.4. The curve fitted is a Boltzmann function with the parameters 
shown, where A1 is the initial rate of reaction at minimal inhibition, A2 is the initial rate of reaction at 
maximal inhibition, x0 is the IC50 and dx is the concentration range over which inhibition changes from 
minimal to maximal. 
 
A1 / p.d.u. 0.044 
A2 / p.d.u. 0.007 
x0 / nM 5.024 
dx / nM 4.081 
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Assay 
1 
Assay 
2 
Assay 3 Assay 
4 
Assay 
5 
Assay 
6 
Assay 
7 
Assay 
8 
Mean Error 
0 0.047 0.046 0.041 0.043 0.043 0.042 0.042 0.045 0.044 0.001 
1 0.038 0.031 0.032 0.023 0.018 0.029 0.021 0.034 0.028 0.002 
2 0.017 0.017 0.023 0.025 0.024 0.023 0.024 0.022 0.022 0.001 
5 0.013   0.017 0.017 0.013 0.022 0.024 0.017 0.002 
10 0.011 0.010 0.014 0.010 0.011 0.015 0.018 0.013 0.013 0.001 
20 0.025 0.007 0.006 0.019 0.007 0.015 0.010 0.009 0.012 0.002 
30 0.012 0.010 0.004 0.008 0.013 0.011 0.010 0.006 0.009 0.001 
40 0.022 0.000 0.008 0.012 0.011 0.013 0.008 0.008 0.010 0.002 
50 0.008 0.003 0.013 0.008 0.008 0.006 0.008 0.005 0.011 0.003 
Table A.5. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/19/1. 
Substrates HMG-CoA and NADPH both have a final concentration in the reaction of 200 µM and the 
HMG-CoA reductase concentration was 10 nM in all assays. All assays were biological repeats and errors 
are standard error of the mean. Initial rate of reaction is shown in procedure defined units as it is 
calculated from absorption measurements which have no units. 
 
 
 
 
 
 
 
 
 
Figure A.5. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/19/1. 
Data plotted are those shown in table A.5. The curve fitted is a Boltzmann function with the parameters 
shown, where A1 is the initial rate of reaction at minimal inhibition, A2 is the initial rate of reaction at 
maximal inhibition, x0 is the IC50 and dx is the concentration range over which inhibition changes from 
minimal to maximal. 
 
A1 / p.d.u. 0.044 
A2 / p.d.u. 0.010 
x0 / nM 1.413 
dx / nM 0.761 
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Assay 
1 
Assay 
2 
Assay 3 Assay 
4 
Assay 
5 
Assay 
6 
Assay 
7 
Assay 
8 
Mean Error 
0 0.047 0.046 0.041 0.043 0.043 0.042 0.042 0.045 0.044 0.001 
1 0.051 0.040 0.029      0.040 0.006 
2 0.043 0.009 0.029      0.027 0.010 
5 0.019 0.009 0.029      0.019 0.006 
10 0.018 0.010 0.026      0.018 0.005 
20 0.009 0.015 0.007      0.010 0.003 
30 0.005 0.006 0.002      0.004 0.001 
40 0.013 0.005 0.021      0.013 0.005 
50 0.012 0.005 0.019      0.012 0.004 
Table A.6. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/20/1. 
Substrates HMG-CoA and NADPH both have a final concentration in the reaction of 200 µM and the 
HMG-CoA reductase concentration was 10 nM in all assays. All assays were biological repeats and errors 
are standard error of the mean. Initial rate of reaction is shown in procedure defined units as it is 
calculated from absorption measurements which have no units. 
 
 
 
 
 
 
 
 
 
Figure A.6. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/20/1. 
Data plotted are those shown in table A.6. The curve fitted is a Boltzmann function with the parameters 
shown, where A1 is the initial rate of reaction at minimal inhibition, A2 is the initial rate of reaction at 
maximal inhibition, x0 is the IC50 and dx is the concentration range over which inhibition changes from 
minimal to maximal. 
 
A1 / p.d.u. 0.044 
A2 / p.d.u. 0.010 
x0 / nM 2.562 
dx / nM 1.955 
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Assay 
1 
Assay 
2 
Assay 3 Assay 
4 
Assay 
5 
Assay 
6 
Assay 
7 
Assay 
8 
Mean Error 
0 0.047 0.046 0.041 0.043 0.043 0.042 0.042 0.045 0.044 0.001 
1 0.041 0.029 0.030 0.035 0.036 0.024 0.028 0.030 0.031 0.002 
2 0.023 0.029 0.028 0.023 0.027 0.024 0.025 0.025 0.025 0.001 
5 0.017 0.012 0.024 0.026 0.017 0.016 0.020 0.023 0.019 0.002 
10 0.011 0.013 0.015 0.015 0.021  0.016 0.021 0.016 0.001 
20 0.015 0.012 0.013 0.014 0.013 0.013 0.019 0.008 0.013 0.001 
30 0.010 0.010 0.014 0.015 0.016 0.011 0.010 0.012 0.012 0.001 
40 0.013 0.013 0.012 0.014 0.010 0.010 0.011 0.013 0.012 0.001 
50 0.010 0.008 0.005 0.009 0.010 0.008 0.012 0.011 0.010 0.002 
Table A.7. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/21/1. 
Substrates HMG-CoA and NADPH both have a final concentration in the reaction of 200 µM and the 
HMG-CoA reductase concentration was 10 nM in all assays. All assays were biological repeats and errors 
are standard error of the mean. Initial rate of reaction is shown in procedure defined units as it is 
calculated from absorption measurements which have no units. 
 
 
 
 
 
 
 
 
 
Figure A.7. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/21/1. 
Data plotted are those shown in table A.7. The curve fitted is a Boltzmann function with the parameters 
shown, where A1 is the initial rate of reaction at minimal inhibition, A2 is the initial rate of reaction at 
maximal inhibition, x0 is the IC50 and dx is the concentration range over which inhibition changes from 
minimal to maximal. 
 
A1 / p.d.u. 0.044 
A2 / p.d.u. 0.012 
x0 / nM 2.078 
dx / nM 1.433 
162 
 
0 
0.005 
0.01 
0.015 
0.02 
0.025 
0.03 
0.035 
0.04 
0.045 
0.05 
0 10 20 30 40 50 
In
it
ia
l r
at
e
 o
f 
re
ac
ti
o
n
 /
 p
.d
.u
. 
[Inhibitor] / nM 
 Initial Rate of Reaction / p.d.u.  
[Inhibitor] 
/ nM 
Assay 
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Assay 
2 
Assay 3 Assay 
4 
Assay 
5 
Assay 
6 
Assay 
7 
Assay 
8 
Mean Error 
0 0.047 0.046 0.041 0.043 0.043 0.042 0.042 0.045 0.044 0.001 
1 0.054 0.040 0.033      0.042 0.006 
2 0.025 0.031 0.037      0.031 0.003 
5 0.042 0.028 0.015      0.028 0.008 
10 0.024 0.026 0.015      0.021 0.003 
20 0.010 0.016 0.016      0.014 0.002 
30 0.020 0.014 0.022      0.019 0.002 
40 0.032 0.003 0.017      0.017 0.008 
50 0.028 0.010 0.006      0.014 0.007 
Table A.8. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/26/1. 
Substrates HMG-CoA and NADPH both have a final concentration in the reaction of 200 µM and the 
HMG-CoA reductase concentration was 10 nM in all assays. All assays were biological repeats and errors 
are standard error of the mean. Initial rate of reaction is shown in procedure defined units as it is 
calculated from absorption measurements which have no units. 
 
 
 
 
 
 
 
 
 
Figure A.8. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/26/1. 
Data plotted are those shown in table A.8. The curve fitted is a Boltzmann function with the parameters 
shown, where A1 is the initial rate of reaction at minimal inhibition, A2 is the initial rate of reaction at 
maximal inhibition, x0 is the IC50 and dx is the concentration range over which inhibition changes from 
minimal to maximal. 
 
A1 / p.d.u. 0.044 
A2 / p.d.u. 0.015 
x0 / nM 3.728 
dx / nM 3.172 
163 
 
0 
0.005 
0.01 
0.015 
0.02 
0.025 
0.03 
0.035 
0.04 
0.045 
0.05 
0 10 20 30 40 50 
In
it
ia
l r
at
e
 o
f 
re
ac
ti
o
n
 /
 p
.d
.u
. 
[Inhibitor] / nM 
 Initial Rate of Reaction / p.d.u.  
[Inhibitor] 
/ nM 
Assay 
1 
Assay 
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Assay 3 Assay 
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Assay 
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Assay 
7 
Assay 
8 
Mean Error 
0 0.047 0.046 0.041 0.043 0.043 0.042 0.042 0.045 0.044 0.001 
1    0.035 0.032 0.025 0.023  0.029 0.003 
2 0.017 0.013 0.018 0.016 0.018 0.025 0.020 0.017 0.018 0.001 
5 0.012    0.018 0.018 0.014 0.011 0.015 0.001 
10 0.011  0.019 0.016  0.012  0.016 0.015 0.002 
20 0.013 0.014 0.019 0.011 0.011 0.008 0.012 0.012 0.012 0.001 
30 0.014 0.020 0.013 0.008 0.010 0.020 0.014 0.012 0.014 0.001 
40 0.009 0.010 0.017 0.008 0.012 0.012 0.016 0.013 0.012 0.001 
50 0.012 0.009 0.014 0.007 0.006 0.020 0.010 0.011 0.011 0.002 
Table A.9. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/28/1. 
Substrates HMG-CoA and NADPH both have a final concentration in the reaction of 200 µM and the 
HMG-CoA reductase concentration was 10 nM in all assays. All assays were biological repeats and errors 
are standard error of the mean. Initial rate of reaction is shown in procedure defined units as it is 
calculated from absorption measurements which have no units. 
 
 
 
 
 
 
 
 
 
Figure A.9. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/28/1. 
Data plotted are those shown in table A.9. The curve fitted is a Boltzmann function with the parameters 
shown, where A1 is the initial rate of reaction at minimal inhibition, A2 is the initial rate of reaction at 
maximal inhibition, x0 is the IC50 and dx is the concentration range over which inhibition changes from 
minimal to maximal. 
 
A1 / p.d.u. 0.044 
A2 / p.d.u. 0.012 
x0 / nM 1.125 
dx / nM 0.478 
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Assay 3 Assay 
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Assay 
5 
Assay 
6 
Assay 
7 
Assay 
8 
Mean Error 
0 0.047 0.046 0.041 0.043 0.043 0.042 0.042 0.045 0.044 0.001 
1 0.037 0.044 0.037 0.036 0.042 0.046 0.042 0.036 0.040 0.001 
2 0.030 0.038 0.030 0.028 0.034 0.041 0.028 0.035 0.033 0.002 
5 0.025 0.022 0.026 0.021 0.030 0.022 0.029 0.028 0.025 0.001 
10 0.015 0.010 0.017 0.014 0.019 0.018 0.017 0.017 0.016 0.001 
20 0.010 0.012 0.011 0.013 0.011 0.010 0.012 0.010 0.011 0.000 
30 0.016 0.008 0.001 0.010 0.010 0.004  0.016 0.009 0.002 
40 0.007 0.007 0.007 0.010 0.010 0.011 0.012 0.008 0.009 0.001 
50 0.015 0.016 0.015 0.010 0.015 0.007 0.014 0.009 0.013 0.001 
Table A.10. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/29/1. 
Substrates HMG-CoA and NADPH both have a final concentration in the reaction of 200 µM and the 
HMG-CoA reductase concentration was 10 nM in all assays. All assays were biological repeats and errors 
are standard error of the mean. Initial rate of reaction is shown in procedure defined units as it is 
calculated from absorption measurements which have no units. 
 
 
 
 
 
 
 
 
 
Figure A.10. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/29/1. 
Data plotted are those shown in table A.10. The curve fitted is a Boltzmann function with the parameters 
shown, where A1 is the initial rate of reaction at minimal inhibition, A2 is the initial rate of reaction at 
maximal inhibition, x0 is the IC50 and dx is the concentration range over which inhibition changes from 
minimal to maximal. 
 
A1 / p.d.u. 0.044 
A2 / p.d.u. 0.011 
x0 / nM 4.515 
dx / nM 2.195 
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Mean Error 
0 0.047 0.046 0.041 0.043 0.043 0.042 0.042 0.045 0.044 0.001 
1 0.046 0.039 0.040      0.042 0.002 
2 0.033 0.039 0.027      0.033 0.003 
5 0.036 0.025 0.014      0.025 0.006 
10 0.019 0.007 0.018      0.015 0.004 
20 0.021 0.006 0.006      0.011 0.005 
30 0.007 0.011 0.006      0.008 0.002 
40 0.003 0.013 0.007      0.008 0.003 
50 0.010 0.003 0.001      0.008 0.002 
Table A.11. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/32/1. 
Substrates HMG-CoA and NADPH both have a final concentration in the reaction of 200 µM and the 
HMG-CoA reductase concentration was 10 nM in all assays. All assays were biological repeats and errors 
are standard error of the mean. Initial rate of reaction is shown in procedure defined units as it is 
calculated from absorption measurements which have no units. 
 
 
 
 
 
 
 
 
 
Figure A.11. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/32/1. 
Data plotted are those shown in table A.11. The curve fitted is a Boltzmann function with the parameters 
shown, where A1 is the initial rate of reaction at minimal inhibition, A2 is the initial rate of reaction at 
maximal inhibition, x0 is the IC50 and dx is the concentration range over which inhibition changes from 
minimal to maximal. 
 
A1 / p.d.u. 0.044 
A2 / p.d.u. 0.007 
x0 / nM 5.779 
dx / nM 2.447 
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Mean Error 
0 0.047 0.046 0.041 0.043 0.043 0.042 0.042 0.045 0.044 0.001 
1 0.040 0.039 0.031 0.028 0.041 0.043 0.028 0.035 0.036 0.002 
2 0.032 0.031 0.032 0.030 0.031 0.037 0.024 0.033 0.031 0.001 
5 0.021 0.012 0.017 0.027 0.030 0.029 0.016 0.027 0.022 0.002 
10 0.016 0.018 0.013 0.024 0.023 0.011 0.015 0.013 0.017 0.002 
20 0.016 0.011 0.014 0.018 0.010 0.017 0.015 0.015 0.014 0.001 
30 0.011  0.018 0.014 0.007 0.018 0.020  0.014 0.002 
40 0.008 0.014 0.011 0.012 0.012 0.011 0.014 0.014 0.012 0.001 
50   0.012  0.012 0.011 0.011 0.011 0.011 0.000 
Table A.12. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/56/1. 
Substrates HMG-CoA and NADPH both have a final concentration in the reaction of 200 µM and the 
HMG-CoA reductase concentration was 10 nM in all assays. All assays were biological repeats and errors 
are standard error of the mean. Initial rate of reaction is shown in procedure defined units as it is 
calculated from absorption measurements which have no units. 
 
 
 
 
 
 
 
 
 
Figure A.12. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/56/1. 
Data plotted are those shown in table A.12. The curve fitted is a Boltzmann function with the parameters 
shown, where A1 is the initial rate of reaction at minimal inhibition, A2 is the initial rate of reaction at 
maximal inhibition, x0 is the IC50 and dx is the concentration range over which inhibition changes from 
minimal to maximal. 
 
A1 / p.d.u. 0.044 
A2 / p.d.u. 0.012 
x0 / nM 3.536 
dx / nM 2.097 
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Mean Error 
0 0.047 0.046 0.041 0.043 0.043 0.042 0.042 0.045 0.044 0.001 
1 0.002 0.003 0.004      0.003 0.001 
2 0.006 0.011 0.008      0.008 0.001 
5 0.010 0.007 0.005      0.007 0.001 
10 0.006 0.001 0.015      0.007 0.004 
20 0.002 0.009 0.007      0.006 0.002 
30 0.004 0.005 0.002      0.004 0.001 
40 0.005 0.007 0.002      0.005 0.002 
50 0.005 0.005 0.007      0.005 0.001 
Table A.13. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/57/1. 
Substrates HMG-CoA and NADPH both have a final concentration in the reaction of 200 µM and the 
HMG-CoA reductase concentration was 10 nM in all assays. All assays were biological repeats and errors 
are standard error of the mean. Initial rate of reaction is shown in procedure defined units as it is 
calculated from absorption measurements which have no units. 
 
 
 
 
 
 
 
 
 
Figure A.13. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/57/1. 
Data plotted are those shown in table A.13. The curve fitted is a Boltzmann function with the parameters 
shown, where A1 is the initial rate of reaction at minimal inhibition, A2 is the initial rate of reaction at 
maximal inhibition, x0 is the IC50 and dx is the concentration range over which inhibition changes from 
minimal to maximal. 
 
A1 / p.d.u. 0.044 
A2 / p.d.u. 0.005 
x0 / nM 0.126 
dx / nM 0.018 
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Mean Error 
0 0.047 0.046 0.041 0.043 0.043 0.042 0.042 0.045 0.044 0.001 
1 0.019 0.026 0.031 0.021  0.016 0.038 0.019 0.024 0.003 
2 0.025 0.014 0.021 0.013 0.032 0.018 0.018 0.012 0.019 0.002 
5  0.017 0.011  0.015 0.012 0.016 0.015 0.014 0.001 
10 0.012 0.020  0.017 0.014 0.018 0.010 0.018 0.016 0.001 
20 0.010 0.008 0.010 0.008 0.012 0.008 0.009 0.013 0.010 0.001 
30 0.014 0.005 0.010 0.013 0.012 0.008 0.014 0.010 0.011 0.001 
40 0.011 0.012 0.007 0.014 0.008 0.015 0.009 0.011 0.011 0.001 
50 0.007 0.009 0.006 0.010 0.011 0.016 0.014 0.003 0.009 0.002 
Table A.14. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/60/1. 
Substrates HMG-CoA and NADPH both have a final concentration in the reaction of 200 µM and the 
HMG-CoA reductase concentration was 10 nM in all assays. All assays were biological repeats and errors 
are standard error of the mean. Initial rate of reaction is shown in procedure defined units as it is 
calculated from absorption measurements which have no units. 
 
 
 
 
 
 
 
 
 
Figure A.14. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/60/1. 
Data plotted are those shown in table A.14. The curve fitted is a Boltzmann function with the parameters 
shown, where A1 is the initial rate of reaction at minimal inhibition, A2 is the initial rate of reaction at 
maximal inhibition, x0 is the IC50 and dx is the concentration range over which inhibition changes from 
minimal to maximal. 
 
A1 / p.d.u. 0.044 
A2 / p.d.u. 0.010 
x0 / nM 1.071 
dx / nM 0.581 
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Mean Error 
0 0.047 0.046 0.041 0.043 0.043 0.042 0.042 0.045 0.044 0.001 
1 0.033 0.025 0.048      0.035 0.007 
2 0.021 0.022 0.030      0.024 0.003 
5 0.012 0.008 0.011      0.010 0.001 
10 0.009 0.013 0.005      0.009 0.002 
20 0.005 0.008 0.010      0.008 0.001 
30 0.007 0.005 0.008      0.006 0.001 
40 0.002 0.010 0.010      0.008 0.003 
50 0.007 0.009 0.005      0.007 0.001 
Table A.15. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/61/1. 
Substrates HMG-CoA and NADPH both have a final concentration in the reaction of 200 µM and the 
HMG-CoA reductase concentration was 10 nM in all assays. All assays were biological repeats and errors 
are standard error of the mean. Initial rate of reaction is shown in procedure defined units as it is 
calculated from absorption measurements which have no units. 
 
 
 
 
 
 
 
 
 
Figure A.15. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/61/1. 
Data plotted are those shown in table A.15. The curve fitted is a Boltzmann function with the parameters 
shown, where A1 is the initial rate of reaction at minimal inhibition, A2 is the initial rate of reaction at 
maximal inhibition, x0 is the IC50 and dx is the concentration range over which inhibition changes from 
minimal to maximal. 
 
A1 / p.d.u. 0.044 
A2 / p.d.u. 0.006 
x0 / nM 2.004 
dx / nM 0.777 
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Mean Error 
0 0.047 0.046 0.041 0.043 0.043 0.042 0.042 0.045 0.044 0.001 
1 0.051 0.028 0.027      0.035 0.008 
2 0.045 0.037 0.046      0.043 0.003 
5 0.037 0.032 0.037      0.035 0.002 
10 0.022 0.009 0.003      0.011 0.006 
20 0.028 0.012 0.008      0.016 0.006 
30 0.038 0.010 0.014      0.021 0.009 
40 0.023 0.008 0.019      0.017 0.004 
50 0.051 0.000 0.003      0.014 0.002 
Table A.16. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/62/1. 
Substrates HMG-CoA and NADPH both have a final concentration in the reaction of 200 µM and the 
HMG-CoA reductase concentration was 10 nM in all assays. All assays were biological repeats and errors 
are standard error of the mean. Initial rate of reaction is shown in procedure defined units as it is 
calculated from absorption measurements which have no units. 
 
 
 
 
 
 
 
 
 
Figure A.16. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/62/1. 
Data plotted are those shown in table A.16. The curve fitted is a Boltzmann function with the parameters 
shown, where A1 is the initial rate of reaction at minimal inhibition, A2 is the initial rate of reaction at 
maximal inhibition, x0 is the IC50 and dx is the concentration range over which inhibition changes from 
minimal to maximal. 
 
A1 / p.d.u. 0.044 
A2 / p.d.u. 0.013 
x0 / nM 5.144 
dx / nM 0.162 
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Mean Error 
0 0.047 0.046 0.041 0.043 0.043 0.042 0.042 0.045 0.044 0.001 
1 0.035 0.068 0.040      0.047 0.010 
2 0.028 0.062 0.043      0.045 0.010 
5 0.064 0.029 0.032      0.042 0.011 
10 0.058 0.038 0.028      0.042 0.009 
20 0.020 0.009 0.024      0.018 0.004 
30 0.028 0.009 0.023      0.020 0.006 
40 0.032 0.003 0.023      0.019 0.009 
50 0.030 0.018 0.007      0.018 0.007 
Table A.17. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/66/1. 
Substrates HMG-CoA and NADPH both have a final concentration in the reaction of 200 µM and the 
HMG-CoA reductase concentration was 10 nM in all assays. All assays were biological repeats and errors 
are standard error of the mean. Initial rate of reaction is shown in procedure defined units as it is 
calculated from absorption measurements which have no units. 
 
 
 
 
 
 
 
 
 
Figure A.17. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/66/1. 
Data plotted are those shown in table A.17. The curve fitted is a Boltzmann function with the parameters 
shown, where A1 is the initial rate of reaction at minimal inhibition, A2 is the initial rate of reaction at 
maximal inhibition, x0 is the IC50 and dx is the concentration range over which inhibition changes from 
minimal to maximal. 
 
A1 / p.d.u. 0.044 
A2 / p.d.u. 0.015 
x0 / nM 15.151 
dx / nM 2.273 
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Mean Error 
0 0.047 0.046 0.041 0.043 0.043 0.042 0.042 0.045 0.044 0.001 
1 0.046 0.054 0.032      0.044 0.006 
2 0.064 0.045 0.033      0.047 0.009 
5 0.023 0.009 0.010      0.014 0.005 
10 0.004 0.013 0.004      0.007 0.003 
20 0.001 0.015 0.019      0.012 0.005 
30 0.020 0.006 0.006      0.010 0.005 
40 0.007 0.014 0.006      0.009 0.003 
50 0.016 0.012 0.011      0.006 0.003 
Table A.18. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/67/1. 
Substrates HMG-CoA and NADPH both have a final concentration in the reaction of 200 µM and the 
HMG-CoA reductase concentration was 10 nM in all assays. All assays were biological repeats and errors 
are standard error of the mean. Initial rate of reaction is shown in procedure defined units as it is 
calculated from absorption measurements which have no units. 
 
 
 
 
 
 
 
 
 
Figure A.18. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/67/1. 
Data plotted are those shown in table A.18. The curve fitted is a Boltzmann function with the parameters 
shown, where A1 is the initial rate of reaction at minimal inhibition, A2 is the initial rate of reaction at 
maximal inhibition, x0 is the IC50 and dx is the concentration range over which inhibition changes from 
minimal to maximal. 
 
A1 / p.d.u. 0.044 
A2 / p.d.u. 0.008 
x0 / nM 4.662 
dx / nM 0.211 
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Mean Error 
0 0.047 0.046 0.041 0.043 0.043 0.042 0.042 0.045 0.044 0.001 
1 0.039 0.043 0.044      0.042 0.002 
2 0.037 0.021 0.056 0.038     0.038 0.007 
5 0.016 0.029 0.020 0.033     0.024 0.004 
10 0.018 0.015 0.016      0.016 0.001 
20 0.019 0.010 0.026      0.018 0.005 
30 0.022 0.018 0.007      0.015 0.005 
40 0.008 0.014 0.022      0.015 0.004 
50 0.024 0.027 0.025      0.025 0.001 
Table A.19. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/83/1/4. 
Substrates HMG-CoA and NADPH both have a final concentration in the reaction of 200 µM and the 
HMG-CoA reductase concentration was 10 nM in all assays. All assays were biological repeats and errors 
are standard error of the mean. Initial rate of reaction is shown in procedure defined units as it is 
calculated from absorption measurements which have no units. 
 
 
 
 
 
 
 
 
 
Figure A.19. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/83/1/4. 
Data plotted are those shown in table A.19. The curve fitted is a Boltzmann function with the parameters 
shown, where A1 is the initial rate of reaction at minimal inhibition, A2 is the initial rate of reaction at 
maximal inhibition, x0 is the IC50 and dx is the concentration range over which inhibition changes from 
minimal to maximal. 
 
A1 / p.d.u. 0.044 
A2 / p.d.u. 0.014 
x0 / nM 4.132 
dx / nM 1.350 
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Mean Error 
0 0.047 0.046 0.041 0.043 0.043 0.042 0.042 0.045 0.044 0.001 
1 0.032 0.040 0.037      0.036 0.002 
2 0.029 0.035 0.024      0.030 0.003 
5 0.020 0.023 0.026      0.023 0.002 
10 0.002 0.015 0.013      0.010 0.004 
20 0.004 0.008 0.018      0.010 0.004 
30 0.016 0.002 0.009      0.009 0.004 
40 0.020 0.029 0.018      0.022 0.003 
50 0.003 0.021 0.015      0.013 0.005 
Table A.20. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/87/1/2. 
Substrates HMG-CoA and NADPH both have a final concentration in the reaction of 200 µM and the 
HMG-CoA reductase concentration was 10 nM in all assays. All assays were biological repeats and errors 
are standard error of the mean. Initial rate of reaction is shown in procedure defined units as it is 
calculated from absorption measurements which have no units. 
 
 
 
 
 
 
 
 
 
Figure A.20. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/87/1/2. 
Data plotted are those shown in table A.20. The curve fitted is a Boltzmann function with the parameters 
shown, where A1 is the initial rate of reaction at minimal inhibition, A2 is the initial rate of reaction at 
maximal inhibition, x0 is the IC50 and dx is the concentration range over which inhibition changes from 
minimal to maximal. 
 
A1 / p.d.u. 0.044 
A2 / p.d.u. 0.008 
x0 / nM 4.198 
dx / nM 2.026 
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Mean Error 
0 0.047 0.046 0.041 0.043 0.043 0.042 0.042 0.045 0.044 0.001 
1 0.032 0.043 0.040      0.038 0.003 
2 0.017 0.045 0.012 0.050     0.031 0.010 
5 0.019 0.027 0.018 0.012     0.019 0.003 
10 0.011 0.014 0.016      0.014 0.001 
15 0.006 0.016 0.023      0.015 0.005 
20 0.012 0.009 0.011      0.011 0.001 
30 0.006 0.016 0.023      0.015 0.005 
40 0.010 0.013 0.009      0.011 0.001 
50 0.023 0.002 0.012      0.012 0.006 
Table A.21. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/87/1/3. 
Substrates HMG-CoA and NADPH both have a final concentration in the reaction of 200 µM and the 
HMG-CoA reductase concentration was 10 nM in all assays. All assays were biological repeats and errors 
are standard error of the mean. Initial rate of reaction is shown in procedure defined units as it is 
calculated from absorption measurements which have no units. 
 
 
 
 
 
 
 
 
 
Figure A.21. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/87/1/3. 
Data plotted are those shown in table A.21. The curve fitted is a Boltzmann function with the parameters 
shown, where A1 is the initial rate of reaction at minimal inhibition, A2 is the initial rate of reaction at 
maximal inhibition, x0 is the IC50 and dx is the concentration range over which inhibition changes from 
minimal to maximal. 
A1 / p.d.u. 0.044 
A2 / p.d.u. 0.011 
x0 / nM 3.078 
dx / nM 1.430 
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Mean Error 
0 0.047 0.046 0.041 0.043 0.043 0.042 0.042 0.045 0.044 0.001 
1 0.042 0.046 0.038      0.042 0.002 
2 0.038 0.039 0.044      0.040 0.002 
5 0.033 0.034 0.041      0.036 0.003 
10 0.031 0.031 0.034      0.032 0.001 
15 0.021 0.025 0.026      0.024 0.002 
20 0.038 0.030 0.031      0.033 0.003 
30 0.022 0.023 0.027      0.024 0.002 
40 0.010 0.036 0.030      0.025 0.008 
50 0.021 0.025 0.024      0.023 0.001 
Table A.22. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/89/1T. 
Substrates HMG-CoA and NADPH both have a final concentration in the reaction of 200 µM and the 
HMG-CoA reductase concentration was 10 nM in all assays. All assays were biological repeats and errors 
are standard error of the mean. Initial rate of reaction is shown in procedure defined units as it is 
calculated from absorption measurements which have no units. 
 
 
 
 
 
 
 
 
 
Figure A.22. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of IB/89/1T. 
Data plotted are those shown in table A.22. The curve fitted is a Boltzmann function with the parameters 
shown, where A1 is the initial rate of reaction at minimal inhibition, A2 is the initial rate of reaction at 
maximal inhibition, x0 is the IC50 and dx is the concentration range over which inhibition changes from 
minimal to maximal. 
A1 / p.d.u. 0.044 
A2 / p.d.u. 0.023 
x0 / nM 9.596 
dx / nM 5.634 
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Assay 
2 
Assay 3 Assay 
4 
Assay 
5 
Assay 
6 
Assay 
7 
Assay 
8 
Mean Error 
0 0.047 0.046 0.041 0.043 0.043 0.042 0.042 0.045 0.044 0.001 
1 0.042 0.047 0.046      0.045 0.002 
2 0.023 0.037 0.057      0.039 0.010 
5 0.035 0.043 0.037 0.027 0.032 0.040   0.036 0.002 
10 0.024 0.023 0.024      0.023 0.000 
15 0.013 0.032 0.023      0.023 0.005 
20 0.021 0.013 0.020      0.018 0.002 
30 0.005 0.013 0.010      0.009 0.003 
40 0.022 0.017 0.015      0.018 0.002 
50 0.005 0.009 0.010      0.008 0.002 
Table A.23. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of ED/05/01B. 
Substrates HMG-CoA and NADPH both have a final concentration in the reaction of 200 µM and the 
HMG-CoA reductase concentration was 10 nM in all assays. All assays were biological repeats and errors 
are standard error of the mean. Initial rate of reaction is shown in procedure defined units as it is 
calculated from absorption measurements which have no units. 
 
 
 
 
 
 
 
 
 
Figure A.23. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of ED/05/01B. 
Data plotted are those shown in table A.23. The curve fitted is a Boltzmann function with the parameters 
shown, where A1 is the initial rate of reaction at minimal inhibition, A2 is the initial rate of reaction at 
maximal inhibition, x0 is the IC50 and dx is the concentration range over which inhibition changes from 
minimal to maximal. 
A1 / p.d.u. 0.044 
A2 / p.d.u. 0.008 
x0 / nM 12.222 
dx / nM 5.627 
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Assay 
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Assay 3 Assay 
4 
Assay 
5 
Assay 
6 
Assay 
7 
Assay 
8 
Mean Error 
0 0.047 0.046 0.041 0.043 0.043 0.042 0.042 0.045 0.044 0.001 
1 0.053 0.037 0.027      0.039 0.008 
2 0.045 0.049 0.025 0.022 0.025    0.033 0.006 
5 0.016 0.012 0.016 0.019 0.028    0.018 0.003 
10 0.021 0.006 0.003      0.010 0.005 
15 0.018 0.013 0.013      0.015 0.002 
20 0.008 0.014 0.009      0.010 0.002 
30 0.016 0.012 0.016      0.015 0.001 
40 0.018 0.008 0.014      0.013 0.003 
50 0.017 0.000 0.017      0.012 0.006 
Table A.24. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of ED/05/01T. 
Substrates HMG-CoA and NADPH both have a final concentration in the reaction of 200 µM and the 
HMG-CoA reductase concentration was 10 nM in all assays. All assays were biological repeats and errors 
are standard error of the mean. Initial rate of reaction is shown in procedure defined units as it is 
calculated from absorption measurements which have no units. 
 
 
 
 
 
 
 
 
 
Figure A.24. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of ED/05/01T. 
Data plotted are those shown in table A.24. The curve fitted is a Boltzmann function with the parameters 
shown, where A1 is the initial rate of reaction at minimal inhibition, A2 is the initial rate of reaction at 
maximal inhibition, x0 is the IC50 and dx is the concentration range over which inhibition changes from 
minimal to maximal. 
A1 / p.d.u. 0.044 
A2 / p.d.u. 0.012 
x0 / nM 3.010 
dx / nM 1.218 
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Assay 
1 
Assay 
2 
Assay 3 Assay 
4 
Assay 
5 
Assay 
6 
Assay 
7 
Assay 
8 
Mean Error 
0 0.047 0.046 0.041 0.043 0.043 0.042 0.042 0.045 0.044 0.001 
1 0.041 0.044 0.048 0.034 0.037 0.043 0.037 0.035 0.040 0.002 
2 0.026 0.024 0.025 0.025 0.026 0.023 0.030 0.029 0.026 0.001 
5 0.019 0.021 0.025 0.013 0.025 0.025 0.021 0.021 0.021 0.001 
10 0.016 0.020 0.014 0.016 0.021 0.018 0.016 0.020 0.018 0.001 
15 0.021 0.014 0.013      0.016 0.003 
20 0.014 0.005 0.015 0.005 0.015 0.012 0.014 0.010 0.011 0.002 
30 0.014 0.010 0.005 0.007 0.007 0.013 0.009 0.011 0.010 0.001 
40 0.010 0.010 0.008 0.006 0.012 0.010 0.013 0.011 0.010 0.001 
50 0.003 0.020 0.027 0.026 0.004 0.002 0.003 0.006 0.011 0.004 
Table A.25. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of ED/05/02T. 
Substrates HMG-CoA and NADPH both have a final concentration in the reaction of 200 µM and the 
HMG-CoA reductase concentration was 10 nM in all assays. All assays were biological repeats and errors 
are standard error of the mean. Initial rate of reaction is shown in procedure defined units as it is 
calculated from absorption measurements which have no units. 
 
 
 
 
 
 
 
 
 
Figure A.25. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of ED/05/02T. 
Data plotted are those shown in table A.25. The curve fitted is a Boltzmann function with the parameters 
shown, where A1 is the initial rate of reaction at minimal inhibition, A2 is the initial rate of reaction at 
maximal inhibition, x0 is the IC50 and dx is the concentration range over which inhibition changes from 
minimal to maximal. 
A1 / p.d.u. 0.044 
A2 / p.d.u. 0.009 
x0 / nM 3.820 
dx / nM 1.622 
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Assay 
1 
Assay 
2 
Assay 3 Assay 
4 
Assay 
5 
Assay 
6 
Assay 
7 
Assay 
8 
Mean Error 
0 0.047 0.046 0.041 0.043 0.043 0.042 0.042 0.045 0.044 0.001 
1 0.046 0.045 0.031 0.043 0.037 0.044 0.042 0.042 0.041 0.002 
2 0.037 0.033 0.034 0.022 0.038 0.034 0.022 0.047 0.033 0.003 
5 0.022  0.030 0.022  0.028 0.030 0.020 0.025 0.002 
10 0.015 0.030 0.033 0.015 0.011 0.017 0.014 0.021 0.020 0.003 
15 0.020 0.012 0.014      0.015 0.002 
20 0.015 0.016 0.017 0.009 0.017 0.011 0.009 0.025 0.015 0.002 
30 0.012 0.013 0.016 0.006 0.010 0.016 0.010 0.016 0.012 0.001 
40 0.009 0.012 0.016 0.014 0.007 0.003 0.012 0.009 0.010 0.001 
50 0.009 0.012 0.008 0.007 0.014 0.015 0.007 0.013 0.011 0.001 
Table A.26. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of ED/06/02. 
Substrates HMG-CoA and NADPH both have a final concentration in the reaction of 200 µM and the 
HMG-CoA reductase concentration was 10 nM in all assays. All assays were biological repeats and errors 
are standard error of the mean. Initial rate of reaction is shown in procedure defined units as it is 
calculated from absorption measurements which have no units. 
 
 
 
 
 
 
 
 
 
Figure A.26. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of ED/06/02. 
Data plotted are those shown in table A.26. The curve fitted is a Boltzmann function with the parameters 
shown, where A1 is the initial rate of reaction at minimal inhibition, A2 is the initial rate of reaction at 
maximal inhibition, x0 is the IC50 and dx is the concentration range over which inhibition changes from 
minimal to maximal. 
A1 / p.d.u. 0.044 
A2 / p.d.u. 0.010 
x0 / nM 6.280 
dx / nM 3.645 
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Assay 
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Assay 
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Assay 3 Assay 
4 
Assay 
5 
Assay 
6 
Assay 
7 
Assay 
8 
Mean Error 
0 0.047 0.046 0.041 0.043 0.043 0.042 0.042 0.045 0.044 0.001 
1 0.051 0.034 0.057      0.047 0.007 
2 0.042 0.030 0.039      0.037 0.004 
5 0.029 0.016 0.040 0.029 0.038 0.013   0.028 0.004 
10 0.029 0.019 0.025      0.024 0.003 
15 0.020 0.035 0.035      0.030 0.005 
20 0.020 0.031 0.030      0.027 0.003 
30 0.025 0.025 0.040      0.030 0.005 
40 0.022 0.028 0.031      0.027 0.002 
50 0.016 0.023 0.024      0.021 0.003 
Table A.27. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of ED/07/02. 
Substrates HMG-CoA and NADPH both have a final concentration in the reaction of 200 µM and the 
HMG-CoA reductase concentration was 10 nM in all assays. All assays were biological repeats and errors 
are standard error of the mean. Initial rate of reaction is shown in procedure defined units as it is 
calculated from absorption measurements which have no units. 
 
 
 
 
 
 
 
 
 
Figure A.27. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of ED/07/02. 
Data plotted are those shown in table A.27. The curve fitted is a Boltzmann function with the parameters 
shown, where A1 is the initial rate of reaction at minimal inhibition, A2 is the initial rate of reaction at 
maximal inhibition, x0 is the IC50 and dx is the concentration range over which inhibition changes from 
minimal to maximal. 
A1 / p.d.u. 0.044 
A2 / p.d.u. 0.024 
x0 / nM 3.209 
dx / nM 0.929 
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Assay 
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Assay 
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Assay 3 Assay 
4 
Assay 
5 
Assay 
6 
Assay 
7 
Assay 
8 
Mean Error 
0 0.047 0.046 0.041 0.043 0.043 0.042 0.042 0.045 0.044 0.001 
1 0.044 0.043 0.041      0.043 0.001 
2 0.029 0.036 0.032      0.032 0.002 
5 0.024 0.035 0.031      0.030 0.003 
10 0.028 0.028 0.032      0.029 0.001 
20 0.027 0.016 0.027      0.023 0.004 
30 0.020 0.016 0.021      0.019 0.002 
40 0.015 0.012 0.018      0.015 0.002 
50 0.015 0.011 0.012      0.013 0.001 
Table A.28. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of ED/09/02. 
Substrates HMG-CoA and NADPH both have a final concentration in the reaction of 200 µM and the 
HMG-CoA reductase concentration was 10 nM in all assays. All assays were biological repeats and errors 
are standard error of the mean. Initial rate of reaction is shown in procedure defined units as it is 
calculated from absorption measurements which have no units. 
 
 
 
 
 
 
 
 
 
Figure A.28. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of ED/09/02. 
Data plotted are those shown in table A.28. The curve fitted is a Boltzmann function with the parameters 
shown, where A1 is the initial rate of reaction at minimal inhibition, A2 is the initial rate of reaction at 
maximal inhibition, x0 is the IC50 and dx is the concentration range over which inhibition changes from 
minimal to maximal. 
 
A1 / p.d.u. 0.044 
A2 / p.d.u. 0.011 
x0 / nM 13.986 
dx / nM 10.782 
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Assay 3 Assay 
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Assay 
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Assay 
6 
Assay 
7 
Assay 
8 
Mean Error 
0 0.047 0.046 0.041 0.043 0.043 0.042 0.042 0.045 0.044 0.001 
1 0.023 0.022 0.027      0.024 0.002 
2 0.019 0.022 0.024      0.022 0.001 
5 0.027 0.022 0.022      0.024 0.002 
10 0.021 0.023 0.022      0.022 0.001 
20 0.022 0.022 0.017      0.020 0.002 
30 0.016 0.027 0.020      0.021 0.003 
40 0.014 0.012 0.013      0.013 0.000 
50 0.018 0.016 0.026      0.020 0.003 
Table A.29. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of ED/11/02. 
Substrates HMG-CoA and NADPH both have a final concentration in the reaction of 200 µM and the 
HMG-CoA reductase concentration was 10 nM in all assays. All assays were biological repeats and errors 
are standard error of the mean. Initial rate of reaction is shown in procedure defined units as it is 
calculated from absorption measurements which have no units. 
 
 
 
 
 
 
 
 
 
Figure A.29. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of ED/11/02. 
Data plotted are those shown in table A.29. The curve fitted is a Boltzmann function with the parameters 
shown, where A1 is the initial rate of reaction at minimal inhibition, A2 is the initial rate of reaction at 
maximal inhibition, x0 is the IC50 and dx is the concentration range over which inhibition changes from 
minimal to maximal. 
 
A1 / p.d.u. 0.044 
A2 / p.d.u. 0.018 
x0 / nM 0.742 
dx / nM 0.219 
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7 
Assay 
8 
Mean Error 
0 0.047 0.046 0.041 0.043 0.043 0.042 0.042 0.045 0.044 0.001 
1 0.033 0.034 0.033      0.033 0.000 
2 0.027 0.021 0.041      0.030 0.006 
5 0.023 0.038 0.038      0.033 0.005 
10 0.026 0.035 0.033      0.031 0.003 
20 0.026 0.029 0.025      0.027 0.001 
30 0.025 0.025 0.034      0.028 0.003 
40 0.013 0.016 0.015      0.015 0.001 
50 0.025 0.025 0.025      0.025 0.000 
Table A.30. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of SH-II-87A. 
Substrates HMG-CoA and NADPH both have a final concentration in the reaction of 200 µM and the 
HMG-CoA reductase concentration was 10 nM in all assays. All assays were biological repeats and errors 
are standard error of the mean. Initial rate of reaction is shown in procedure defined units as it is 
calculated from absorption measurements which have no units. 
 
 
 
 
 
 
 
 
 
Figure A.30. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of SH-II-87A. 
Data plotted are those shown in table A.30. The curve fitted is a Boltzmann function with the parameters 
shown, where A1 is the initial rate of reaction at minimal inhibition, A2 is the initial rate of reaction at 
maximal inhibition, x0 is the IC50 and dx is the concentration range over which inhibition changes from 
minimal to maximal. 
 
A1 / p.d.u. 0.044 
A2 / p.d.u. 0.024 
x0 / nM 3.631 
dx / nM 7.354 
185 
 
0 
0.005 
0.01 
0.015 
0.02 
0.025 
0.03 
0.035 
0.04 
0.045 
0.05 
0 10 20 30 40 50 
In
it
ia
l r
at
e
 o
f 
re
ac
ti
o
n
 /
 p
.d
.u
. 
[Inhibitor] / nM 
 Initial Rate of Reaction / p.d.u.  
[Inhibitor] 
/ nM 
Assay 
1 
Assay 
2 
Assay 3 Assay 
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Assay 
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Assay 
7 
Assay 
8 
Mean Error 
0 0.047 0.046 0.041 0.043 0.043 0.042 0.042 0.045 0.044 0.001 
1 0.031 0.027 0.030      0.029 0.001 
2 0.022 0.032 0.022      0.025 0.003 
5 0.025 0.029 0.031      0.028 0.002 
10 0.021 0.019 0.021      0.020 0.001 
20 0.026 0.023 0.024      0.024 0.001 
30 0.017 0.024 0.027      0.022 0.003 
40 0.015 0.016 0.026      0.019 0.003 
50 0.021 0.023 0.018      0.021 0.002 
Table A.31. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of TD-I-31A. 
Substrates HMG-CoA and NADPH both have a final concentration in the reaction of 200 µM and the 
HMG-CoA reductase concentration was 10 nM in all assays. All assays were biological repeats and errors 
are standard error of the mean. Initial rate of reaction is shown in procedure defined units as it is 
calculated from absorption measurements which have no units. 
 
 
 
 
 
 
 
 
 
Figure A.31. The initial rate of conversion of HMG-CoA to mevalonate by HMG-CoA reductase in the 
presence of different concentrations of TD-I-31A. 
Data plotted are those shown in table A.31. The curve fitted is a Boltzmann function with the parameters 
shown, where A1 is the initial rate of reaction at minimal inhibition, A2 is the initial rate of reaction at 
maximal inhibition, x0 is the IC50 and dx is the concentration range over which inhibition changes from 
minimal to maximal. 
A1 / p.d.u. 0.044 
A2 / p.d.u. 0.019 
x0 / nM 1.051 
dx / nM 0.582 
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B. Antibacterial Plates 
 
 
Figure B.1. Activity of levofloxacin against A) P. aeruginosa B) E. faecalis C) S. aureus SH1000 
D) S. aureus Newman 
Discs of filter paper soaked with different masses of levofloxacin dissolved in 5 μl of DMSO are placed 
onto Mueller-Hinton agar (21 g l-1 Mueller-Hinton broth, 1.5 % (w/v) agar) plates inoculated with 
Mueller-Hinton top agar (21 g l-1 Mueller-Hinton broth, 0.7 % (w/v) agar) different strains of bacteria 
which are incubated at 37 °C for 18 hours. The control used is 100 ng of levofloxacin. 
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Figure B.2. Activity of pefloxacin mesylate against A) P. aeruginosa B) E. faecalis C) S. aureus SH1000 
D) S. aureus Newman 
Discs of filter paper soaked with different masses of pefloxacin mesylate dissolved in 5 μl of DMSO are 
placed onto Mueller-Hinton agar (21 g l-1 Mueller-Hinton broth, 1.5 % (w/v) agar) plates inoculated with 
Mueller-Hinton top agar (21 g l-1 Mueller-Hinton broth, 0.7 % (w/v) agar) different strains of bacteria 
which are incubated at 37 °C for 18 hours. The control used is 100 ng of levofloxacin. 
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Figure B.3. Activity of a 3-formyl levofloxacin derivative against A) P. aeruginosa B) E. faecalis C) S. 
aureus SH1000 D) S. aureus Newman 
Discs of filter paper soaked with different masses of a 3-formyl levofloxacin derivative dissolved in 5 μl of 
DMSO are placed onto Mueller-Hinton agar (21 g l-1 Mueller-Hinton broth, 1.5 % (w/v) agar) plates 
inoculated with Mueller-Hinton top agar (21 g l-1 Mueller-Hinton broth, 0.7 % (w/v) agar) different 
strains of bacteria which are incubated at 37 °C for 18 hours. The control used is 100 ng of levofloxacin. 
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Figure B.4. Activity of fluoroquinolone derivative number one against A) P. aeruginosa B) E. faecalis C) 
S. aureus SH1000 D) S. aureus Newman 
Discs of filter paper soaked with different masses of fluoroquinolone derivative number one dissolved in 5 
μl of DMSO are placed onto Mueller-Hinton agar (21 g l-1 Mueller-Hinton broth, 1.5 % (w/v) agar) plates 
inoculated with Mueller-Hinton top agar (21 g l-1 Mueller-Hinton broth, 0.7 % (w/v) agar) different 
strains of bacteria which are incubated at 37 °C for 18 hours. The control used is 100 ng of levofloxacin. 
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Figure B.5. Activity of fluoroquinolone derivative number two against A) P. aeruginosa B) E. faecalis C) 
S. aureus SH1000 D) S. aureus Newman 
Discs of filter paper soaked with different masses of fluoroquinolone derivative number two dissolved in 
5 μl of DMSO are placed onto Mueller-Hinton agar (21 g l-1 Mueller-Hinton broth, 1.5 % (w/v) agar) 
plates inoculated with Mueller-Hinton top agar (21 g l-1 Mueller-Hinton broth, 0.7 % (w/v) agar) different 
strains of bacteria which are incubated at 37 °C for 18 hours. The control used is 100 ng of levofloxacin. 
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Figure B.6. Activity of fluoroquinolone derivative number three against A) P. aeruginosa B) E. faecalis 
C) S. aureus SH1000 D) S. aureus Newman 
Discs of filter paper soaked with different masses of fluoroquinolone derivative number three dissolved in 
5 μl of DMSO are placed onto Mueller-Hinton agar (21 g l-1 Mueller-Hinton broth, 1.5 % (w/v) agar) 
plates inoculated with Mueller-Hinton top agar (21 g l-1 Mueller-Hinton broth, 0.7 % (w/v) agar) different 
strains of bacteria which are incubated at 37 °C for 18 hours. The control used is 100 ng of levofloxacin. 
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Figure B.7. Activity of fluoroquinolone derivative number four against A) P. aeruginosa B) E. faecalis C) 
S. aureus SH1000 D) S. aureus Newman 
Discs of filter paper soaked with different masses of fluoroquinolone derivative number four dissolved in 
5 μl of DMSO are placed onto Mueller-Hinton agar (21 g l-1 Mueller-Hinton broth, 1.5 % (w/v) agar) 
plates inoculated with Mueller-Hinton top agar (21 g l-1 Mueller-Hinton broth, 0.7 % (w/v) agar) different 
strains of bacteria which are incubated at 37 °C for 18 hours. The control used is 100 ng of levofloxacin. 
 
 
 
 
194 
 
 
Figure B.8. Activity of fluoroquinolone derivative number five against A) P. aeruginosa B) E. faecalis C) 
S. aureus SH1000 D) S. aureus Newman 
Discs of filter paper soaked with different masses of fluoroquinolone derivative number five dissolved in 5 
μl of DMSO are placed onto Mueller-Hinton agar (21 g l-1 Mueller-Hinton broth, 1.5 % (w/v) agar) plates 
inoculated with Mueller-Hinton top agar (21 g l-1 Mueller-Hinton broth, 0.7 % (w/v) agar) different 
strains of bacteria which are incubated at 37 °C for 18 hours. The control used is 100 ng of levofloxacin. 
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C. Raw Data For Cellulose Breakdown Assays 
C.1 Determination of Optimum Cellulolytic Enzymes 
 Δ Absorbance / no units 
 Assay 1 Assay 2 Assay 3 Assay 4 Assay 5 Mean Error 
Reaction  0.066 0.064 0.062 0.069 0.066 0.001 
Control 1 0.026 0.017 0.021 0.034 0.036 0.027 0.004 
Control 2 0.002 0.000 0.006  0.001 0.003 0.001 
Table C.1. Initial absorbance data for enzyme mixture A. 
Composition of enzyme mixture is described in table 4.1. Control 1 contains no cellulose substrate, 
control 2 contains no enzyme. Reactions were diluted 40-fold to ensure absorbance is within a suitable 
range to calculate the mass of glucose produced. Substrate was digested by cellulolytic enzymes for 20-
hours before being placed on ice to terminate the reaction. The change in absorption of the supernatant 
in a hexokinase/glucose-6-phosphate dehydrogenase assay was monitored by UV-spectrophotometry. 
 
 
 Δ Absorbance / no units 
 Assay 1 Assay 2 Assay 3 Assay 4 Assay 5 Mean Error 
Reaction 0.003  0.001  0.004 0.003 0.001 
Control 1 -0.006 -0.003 -0.005 0.004 0.004 -0.001 0.002 
Control 2 0.002 0.000 0.006  0.001 0.003 0.001 
Table C.2. Initial absorbance data for enzyme mixture B. 
Composition of enzyme mixture is described in table 4.1. Control 1 contains no cellulose substrate, 
control 2 contains no enzyme. Reactions were diluted 40-fold to ensure absorbance is within a suitable 
range to calculate the mass of glucose produced. Substrate was digested by cellulolytic enzymes for 20-
hours before being placed on ice to terminate the reaction. The change in absorption of the supernatant 
in a hexokinase/glucose-6-phosphate dehydrogenase assay was monitored by UV-spectrophotometry. 
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 Δ Absorbance / no units 
 Assay 1 Assay 2 Assay 3 Assay 4 Assay 5 Mean Error 
Reaction 0.019 0.015 0.018  0.010 0.016 0.002 
Control 1 0.113 0.125 0.120   0.120 0.003 
Control 2 0.002 0.000 0.006  0.001 0.003 0.001 
Table C.3. Initial absorbance data for enzyme mixture C. 
Composition of enzyme mixture is described in table 4.1.Control 1 contains no cellulose substrate, control 
2 contains no enzyme. Reactions were diluted 10-fold to ensure absorbance is within a suitable range to 
calculate the mass of glucose produced. Substrate was digested by cellulolytic enzymes for 20-hours 
before being placed on ice to terminate the reaction. The change in absorption of the supernatant in a 
hexokinase/glucose-6-phosphate dehydrogenase assay was monitored by UV-spectrophotometry. 
 
 
 Δ Absorbance / no units 
 Assay 1 Assay 2 Assay 3 Assay 4 Assay 5 Mean Error 
Reaction 0.035  0.042 0.033 0.038 0.025 0.002 
Control 1 0.012 0.008 0.011 0.014 0.008 0.011 0.001 
Control 2 0.002 0.000 0.006  0.001 0.003 0.001 
Table C.4. Initial absorbance data for enzyme mixture D. 
Composition of enzyme mixture is described in table 4.1. Control 1 contains no cellulose substrate, 
control 2 contains no enzyme. Reactions were diluted 60-fold to ensure absorbance is within a suitable 
range to calculate the mass of glucose produced. Substrate was digested by cellulolytic enzymes for 20-
hours before being placed on ice to terminate the reaction. The change in absorption of the supernatant 
in a hexokinase/glucose-6-phosphate dehydrogenase assay was monitored by UV-spectrophotometry. 
 
 
 Δ Absorbance / no units 
 Assay 1 Assay 2 Assay 3 Assay 4 Assay 5 Mean Error 
Reaction 0.230   0.219 0.237 0.229 0.005 
Control 1 0.056 0.067 0.068 0.057 0.059 0.062 0.003 
Control 2 0.002 0.000 0.006  0.001 0.003 0.001 
Table C.5. Initial absorbance data for enzyme mixture E. 
Composition of enzyme mixture is described in table 4.1. Control 1 contains no cellulose substrate, 
control 2 contains no enzyme. Reactions were diluted 40-fold to ensure absorbance is within a suitable 
range to calculate the mass of glucose produced. Substrate was digested by cellulolytic enzymes for 20-
hours before being placed on ice to terminate the reaction. The change in absorption of the supernatant 
in a hexokinase/glucose-6-phosphate dehydrogenase assay was monitored by UV-spectrophotometry. 
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 Δ Absorbance / no units 
 Assay 1 Assay 2 Assay 3 Assay 4 Assay 5 Mean Error 
Reaction 0.008 0.003   0.004 0.005 0.002 
Control 1 0.006 0.005 0.011 0.001 0.000 0.005 0.002 
Control 2 0.002 0.000 0.006  0.001 0.003 0.001 
Table C.6. Initial absorbance data for enzyme mixture F. 
Composition of enzyme mixture is described in table 4.1. Control 1 contains no cellulose substrate, 
control 2 contains no enzyme. Reactions were diluted 40-fold to ensure absorbance is within a suitable 
range to calculate the mass of glucose produced. Substrate was digested by cellulolytic enzymes for 20-
hours before being placed on ice to terminate the reaction. The change in absorption of the supernatant 
in a hexokinase/glucose-6-phosphate dehydrogenase assay was monitored by UV-spectrophotometry. 
 
 
 Δ Absorbance / no units 
 Assay 1 Assay 2 Assay 3 Assay 4 Assay 5 Mean Error 
Reaction 0.157 0.139 0.134 0.132  0.141 0.006 
Control 1 0.038 0.026 0.033 0.040 0.036 0.035 0.002 
Control 2 0.002 0.000 0.006  0.001 0.003 0.001 
Table C.7. Initial absorbance data for enzyme mixture G. 
Composition of enzyme mixture is described in table 4.1. Control 1 contains no cellulose substrate, 
control 2 contains no enzyme. Reactions were diluted 40-fold to ensure absorbance is within a suitable 
range to calculate the mass of glucose produced. Substrate was digested by cellulolytic enzymes for 20-
hours before being placed on ice to terminate the reaction. The change in absorption of the supernatant 
in a hexokinase/glucose-6-phosphate dehydrogenase assay was monitored by UV-spectrophotometry. 
 
 
 Δ Absorbance / no units 
 Assay 1 Assay 2 Assay 3 Assay 4 Assay 5 Mean Error 
Reaction 0.159  0.142 0.159 0.155 0.154 0.004 
Control 1 0.036 0.037 0.034 0.036 0.041 0.037 0.001 
Control 2 0.002 0.000 0.006  0.001 0.003 0.001 
Table C.8. Initial absorbance data for enzyme mixture H. 
Composition of enzyme mixture is described in table 4.1. Control 1 contains no cellulose substrate, 
control 2 contains no enzyme. Reactions were diluted 40-fold to ensure absorbance is within a suitable 
range to calculate the mass of glucose produced. Substrate was digested by cellulolytic enzymes for 20-
hours before being placed on ice to terminate the reaction. The change in absorption of the supernatant 
in a hexokinase/glucose-6-phosphate dehydrogenase assay was monitored by UV-spectrophotometry. 
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 Δ Absorbance / no units 
 Assay 1 Assay 2 Assay 3 Assay 4 Assay 5 Mean Error 
Reaction 0.086 0.088 0.090 0.086 0.102 0.091 0.003 
Control 1 0.007 0.010 0.014  0.012 0.011 0.001 
Control 2 0.002 0.000 0.006  0.001 0.003 0.001 
Table C.9. Initial absorbance data for enzyme mixture I. 
Composition of enzyme mixture is described in table 4.1. Control 1 contains no cellulose substrate, 
control 2 contains no enzyme. Reactions were diluted 10-fold to ensure absorbance is within a suitable 
range to calculate the mass of glucose produced. Substrate was digested by cellulolytic enzymes for 20-
hours before being placed on ice to terminate the reaction. The change in absorption of the supernatant 
in a hexokinase/glucose-6-phosphate dehydrogenase assay was monitored by UV-spectrophotometry. 
 
 
 Δ Absorbance / no units 
 Assay 1 Assay 2 Assay 3 Assay 4 Assay 5 Mean Error 
Reaction 0.001   0.004 0.002 0.003 0.001 
Control 1 0.000 0.007 0.009 -0.005 -0.005 0.001 0.003 
Control 2 0.002 0.000 0.006  0.001 0.003 0.001 
Table C.10. Initial absorbance data for enzyme mixture J. 
Composition of enzyme mixture is described in table 4.1. Control 1 contains no cellulose substrate, 
control 2 contains no enzyme. Reactions were diluted 40-fold to ensure absorbance is within a suitable 
range to calculate the mass of glucose produced. Substrate was digested by cellulolytic enzymes for 20-
hours before being placed on ice to terminate the reaction. The change in absorption of the supernatant 
in a hexokinase/glucose-6-phosphate dehydrogenase assay was monitored by UV-spectrophotometry. 
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C.2 Breakdown of Different Substrates 
 Δ Absorbance / no units 
 Assay 1 Assay 2 Assay 3 Assay 4 Assay 5 Mean Error 
Reaction 0.346  0.310 0.298 0.341 0.216 0.012 
Control 1 0.061 0.072 0.073 0.062 0.064 0.066 0.003 
Control 2 0.000 0.002 0.002   0.002 0.001 
Table C.11. Initial absorbance data for the breakdown of simple cellulose film. 
The enzyme mixture used is mixture E described in table 4.1. Control 1 contains no cellulose substrate, 
control 2 contains no enzyme. Reactions were diluted 60-fold to ensure absorbance is within a suitable 
range to calculate the mass of glucose produced. Substrate was digested by cellulolytic enzymes for 20-
hours before being placed on ice to terminate the reaction. The change in absorption of the supernatant 
in a hexokinase/glucose-6-phosphate dehydrogenase assay was monitored by UV-spectrophotometry. 
 
 
 Δ Absorbance / no units 
 Assay 1 Assay 2 Assay 3 Assay 4 Assay 5 Mean Error 
Reaction 0.243 0.244 0.232   0.240 0.004 
Control 1 0.061 0.072 0.073 0.062 0.064 0.066 0.003 
Control 2 -0.004 0.010 -0.001 -0.001 0.000 0.001 0.002 
Table C.12. Initial absorbance data for the breakdown of coated cellulose film. 
The enzyme mixture used is mixture E described in table 4.1. Control 1 contains no cellulose substrate, 
control 2 contains no enzyme. Reactions were diluted 40-fold to ensure absorbance is within a suitable 
range to calculate the mass of glucose produced. Substrate was digested by cellulolytic enzymes for 20-
hours before being placed on ice to terminate the reaction. The change in absorption of the supernatant 
in a hexokinase/glucose-6-phosphate dehydrogenase assay was monitored by UV-spectrophotometry. 
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 Δ Absorbance / no units 
 Assay 1 Assay 2 Assay 3 Assay 4 Assay 5 Mean Error 
Reaction 0.196 0.207 0.208 0.215 0.240 0.214 0.007 
Control 1 0.061 0.072 0.073 0.062 0.064 0.066 0.003 
Control 2 0.008 -0.008 0.009 -0.002 -0.002 0.001 0.003 
Table C.13. Initial absorbance data for the breakdown of microcrystalline cellulose. 
The enzyme mixture used is mixture E described in table 4.1. Control 1 contains no cellulose substrate, 
control 2 contains no enzyme. Reactions were diluted 40-fold to ensure absorbance is within a suitable 
range to calculate the mass of glucose produced. Substrate was digested by cellulolytic enzymes for 20-
hours before being placed on ice to terminate the reaction. The change in absorption of the supernatant 
in a hexokinase/glucose-6-phosphate dehydrogenase assay was monitored by UV-spectrophotometry. 
 
 
  Δ Absorbance / no units 
 Assay 1 Assay 2 Assay 3 Assay 4 Assay 5 Mean Error 
Reaction 0.230   0.219 0.237 0.229 0.005 
Control 1 0.056 0.067 0.068 0.057 0.059 0.062 0.003 
Control 2 0.002 0.000 0.006  0.001 0.003 0.001 
Table C.14. Initial absorbance data for the breakdown of Whatman filter paper. 
The enzyme mixture used is mixture E described in table 4.1. Control 1 contains no cellulose substrate, 
control 2 contains no enzyme. Reactions were diluted 40-fold to ensure absorbance is within a suitable 
range to calculate the mass of glucose produced. Substrate was digested by cellulolytic enzymes for 20-
hours before being placed on ice to terminate the reaction. The change in absorption of the supernatant 
in a hexokinase/glucose-6-phosphate dehydrogenase assay was monitored by UV-spectrophotometry. 
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C.3 Breakdown of Composite Films 
  Δ Absorbance / no units 
 Assay 1 Assay 2 Assay 3 Assay 4 Assay 5 Mean Error 
Reaction 0.218 0.258 0.197 0.220 0.221 0.223 0.010 
Control 1 0.030 0.034 0.034 0.033 0.032 0.033 0.001 
Control 2 0.001  0.004 0.004 0.005 0.003 0.001 
Table C.15. Initial absorbance data for the breakdown of a composite film containing PVOH type 4-88. 
The enzyme mixture used is mixture E described in table 4.1 with a load of 0.7 units per mg of cellulose 
film. Control 1 contains a PVOH film with cellulolytic enzymes incorporated, control 2 contains no 
enzyme. Reactions were diluted 40-fold to ensure absorbance is within a suitable range to calculate the 
mass of glucose produced. Substrate was digested by cellulolytic enzymes for 20-hours before being 
placed on ice to terminate the reaction. The change in absorption of the supernatant in a 
hexokinase/glucose-6-phosphate dehydrogenase assay was monitored by UV-spectrophotometry. 
 
 
  Δ Absorbance / no units 
 Assay 1 Assay 2 Assay 3 Assay 4 Assay 5 Mean Error 
Reaction 0.219 0.231 0.249 0.239 0.228 0.234 0.005 
Control 1 0.045 0.046 0.051 0.053 0.055 0.050 0.002 
Control 2 0.001  0.004 0.004 0.005 0.003 0.001 
Table C.16. Initial absorbance data for the breakdown of a composite film containing PVOH type 8-88. 
The enzyme mixture used is mixture E described in table 4.1 with a load of 0.7 units per mg of cellulose 
film. Control 1 contains a PVOH film with cellulolytic enzymes incorporated, control 2 contains no 
enzyme. Reactions were diluted 40-fold to ensure absorbance is within a suitable range to calculate the 
mass of glucose produced. Substrate was digested by cellulolytic enzymes for 20-hours before being 
placed on ice to terminate the reaction. The change in absorption of the supernatant in a 
hexokinase/glucose-6-phosphate dehydrogenase assay was monitored by UV-spectrophotometry. 
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  Δ Absorbance / no units 
 Assay 1 Assay 2 Assay 3 Assay 4 Assay 5 Mean Error 
Reaction 0.209 0.247  0.190 0.198 0.211 0.013 
Control 1 0.034 0.041 0.035 0.051 0.048 0.042 0.003 
Control 2 0.001  0.004 0.004 0.005 0.003 0.001 
Table C.17. Initial absorbance data for the breakdown of a composite film containing PVOH type 40-
88. 
The enzyme mixture used is mixture E described in table 4.1 with a load of 0.7 units per mg of cellulose 
film. Control 1 contains a PVOH film with cellulolytic enzymes incorporated, control 2 contains no 
enzyme. Reactions were diluted 40-fold to ensure absorbance is within a suitable range to calculate the 
mass of glucose produced. Substrate was digested by cellulolytic enzymes for 20-hours before being 
placed on ice to terminate the reaction. The change in absorption of the supernatant in a 
hexokinase/glucose-6-phosphate dehydrogenase assay was monitored by UV-spectrophotometry. 
 
 
  Δ Absorbance / no units 
 Assay 1 Assay 2 Assay 3 Assay 4 Assay 5 Mean Error 
Reaction 0.240 0.207 0.211 0.244 0.228 0.226 0.007 
Control 1 0.087 0.053 0.063 0.057 0.055 0.063 0.006 
Control 2 0.001  0.004 0.004 0.005 0.003 0.001 
Table C.18. Initial absorbance data for the breakdown of a composite film containing PVOH type 4-98. 
The enzyme mixture used is mixture E described in table 4.1 with a load of 0.7 units per mg of cellulose 
film. Control 1 contains a PVOH film with cellulolytic enzymes incorporated, control 2 contains no 
enzyme. Reactions were diluted 40-fold to ensure absorbance is within a suitable range to calculate the 
mass of glucose produced. Substrate was digested by cellulolytic enzymes for 20-hours before being 
placed on ice to terminate the reaction. The change in absorption of the supernatant in a 
hexokinase/glucose-6-phosphate dehydrogenase assay was monitored by UV-spectrophotometry. 
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  Δ Absorbance / no units 
 Assay 1 Assay 2 Assay 3 Assay 4 Assay 5 Mean Error 
Reaction 0.242 0.217 0.263 0.211  0.234 0.012 
Control 1 0.051 0.074 0.079 0.078 0.083 0.073 0.006 
Control 2 0.001  0.004 0.004 0.005 0.003 0.001 
Table C.19. Initial absorbance data for the breakdown of a composite film containing a mixture of 
PVOH types 6-98 and 40-88. 
The enzyme mixture used is mixture E described in table 4.1 with a load of 0.7 units per mg of cellulose 
film. Control 1 contains a PVOH film with cellulolytic enzymes incorporated, control 2 contains no 
enzyme. Reactions were diluted 40-fold to ensure absorbance is within a suitable range to calculate the 
mass of glucose produced. Substrate was digested by cellulolytic enzymes for 20-hours before being 
placed on ice to terminate the reaction. The change in absorption of the supernatant in a 
hexokinase/glucose-6-phosphate dehydrogenase assay was monitored by UV-spectrophotometry. 
 
 
  Δ Absorbance / no units 
 Assay 1 Assay 2 Assay 3 Assay 4 Assay 5 Mean Error 
Reaction 0.249 0.209 0.224 0.223 0.226 0.227 0.006 
Control 1 0.068 0.070 0.074 0.056 0.063 0.067 0.003 
Control 2 0.001  0.004 0.004 0.005 0.003 0.001 
Table C.20. Initial absorbance data for the breakdown of a composite film containing PVOH type 6-98. 
The enzyme mixture used is mixture E described in table 4.1 with a load of 0.7 units per mg of cellulose 
film. Control 1 contains a PVOH film with cellulolytic enzymes incorporated, control 2 contains no 
enzyme. Reactions were diluted 40-fold to ensure absorbance is within a suitable range to calculate the 
mass of glucose produced. Substrate was digested by cellulolytic enzymes for 20-hours before being 
placed on ice to terminate the reaction. The change in absorption of the supernatant in a 
hexokinase/glucose-6-phosphate dehydrogenase assay was monitored by UV-spectrophotometry. 
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  Δ Absorbance / no units 
 Assay 1 Assay 2 Assay 3 Assay 4 Assay 5 Mean Error 
Reaction   0.254 0.250 0.268 0.172 0.005 
Control 1 0.078 0.069 0.070 0.075 0.073 0.073 0.002 
Control 2 0.001  0.004 0.004 0.005 0.003 0.001 
Table C.21. Initial absorbance data for the breakdown of a composite film containing a mixture of 
PVOH types 10-98 and 4-88. 
The enzyme mixture used is mixture E described in table 4.1 with a load of 0.7 units per mg of cellulose 
film. Control 1 contains a PVOH film with cellulolytic enzymes incorporated, control 2 contains no 
enzyme. Reactions were diluted 60-fold to ensure absorbance is within a suitable range to calculate the 
mass of glucose produced. Substrate was digested by cellulolytic enzymes for 20-hours before being 
placed on ice to terminate the reaction. The change in absorption of the supernatant in a 
hexokinase/glucose-6-phosphate dehydrogenase assay was monitored by UV-spectrophotometry. 
 
 
  Δ Absorbance / no units 
 Assay 1 Assay 2 Assay 3 Assay 4 Assay 5 Mean Error 
Reaction 0.225 0.226   0.235 0.229 0.003 
Control 1 0.054 0.066 0.060 0.059 0.054 0.059 0.002 
Control 2 0.001  0.004 0.004 0.005 0.003 0.001 
Table C.22. Initial absorbance data for the breakdown of a composite film containing PVOH type 10-
98. 
The enzyme mixture used is mixture E described in table 4.1 with a load of 0.7 units per mg of cellulose 
film. Control 1 contains a PVOH film with cellulolytic enzymes incorporated, control 2 contains no 
enzyme. Reactions were diluted 40-fold to ensure absorbance is within a suitable range to calculate the 
mass of glucose produced. Substrate was digested by cellulolytic enzymes for 20-hours before being 
placed on ice to terminate the reaction. The change in absorption of the supernatant in a 
hexokinase/glucose-6-phosphate dehydrogenase assay was monitored by UV-spectrophotometry. 
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  Δ Absorbance / no units 
 Assay 1 Assay 2 Assay 3 Assay 4 Assay 5 Mean Error 
Reaction 0.262 0.268 0.249  0.241 0.170 0.006 
Control 1 0.073 0.044 0.073 0.050 0.090 0.066 0.008 
Control 2 0.001  0.004 0.004 0.005 0.003 0.001 
Table C.23. Initial absorbance data for the breakdown of a composite film containing a mixture of 
PVOH types 20-98 and 8-88. 
The enzyme mixture used is mixture E described in table 4.1 with a load of 0.7 units per mg of cellulose 
film. Control 1 contains a PVOH film with cellulolytic enzymes incorporated, control 2 contains no 
enzyme. Reactions were diluted 60-fold to ensure absorbance is within a suitable range to calculate the 
mass of glucose produced. Substrate was digested by cellulolytic enzymes for 20-hours before being 
placed on ice to terminate the reaction. The change in absorption of the supernatant in a 
hexokinase/glucose-6-phosphate dehydrogenase assay was monitored by UV-spectrophotometry. 
 
 
  Δ Absorbance / no units 
 Assay 1 Assay 2 Assay 3 Assay 4 Assay 5 Mean Error 
Reaction 0.272 0.228 0.194 0.211 0.245 0.230 0.014 
Control 1 0.076 0.061 0.009 0.081 0.079 0.062 0.014 
Control 2 0.001  0.004 0.004 0.005 0.003 0.001 
Table C.24. Initial absorbance data for the breakdown of a composite film containing PVOH type 20-
98. 
The enzyme mixture used is mixture E described in table 4.1 with a load of 0.7 units per mg of cellulose 
film. Control 1 contains a PVOH film with cellulolytic enzymes incorporated, control 2 contains no 
enzyme. Reactions were diluted 40-fold to ensure absorbance is within a suitable range to calculate the 
mass of glucose produced. Substrate was digested by cellulolytic enzymes for 20-hours before being 
placed on ice to terminate the reaction. The change in absorption of the supernatant in a 
hexokinase/glucose-6-phosphate dehydrogenase assay was monitored by UV-spectrophotometry. 
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  Δ Absorbance / no units 
 Assay 1 Assay 2 Assay 3 Assay 4 Assay 5 Mean Error 
Reaction   0.241 0.289 0.211 0.247 0.023 
Control 1 0.063 0.059 0.064 0.063 0.061 0.062 0.001 
Control 2 0.001  0.004 0.004 0.005 0.003 0.001 
Table C.25. Initial absorbance data for the breakdown of a composite film containing PVOH type 28-
99. 
The enzyme mixture used is mixture E described in table 4.1 with a load of 0.7 units per mg of cellulose 
film. Control 1 contains a PVOH film with cellulolytic enzymes incorporated, control 2 contains no 
enzyme. Reactions were diluted 40-fold to ensure absorbance is within a suitable range to calculate the 
mass of glucose produced. Substrate was digested by cellulolytic enzymes for 20-hours before being 
placed on ice to terminate the reaction. The change in absorption of the supernatant in a 
hexokinase/glucose-6-phosphate dehydrogenase assay was monitored by UV-spectrophotometry. 
 
 
  Δ Absorbance / no units 
 Assay 1 Assay 2 Assay 3 Assay 4 Assay 5 Mean Error 
Reaction 0.013  0.013  0.011 0.013 0.001 
Control 1 0.006 0.014 0.010 0.016 0.017 0.013 0.002 
Control 2 0.001  0.004 0.004 0.005 0.003 0.001 
Table C.26. Initial absorbance data for the breakdown of a composite film containing PVOH type 28-99 
with a low enzyme loading. 
The enzyme mixture used is mixture E described in table 4.1 with a load of 0.04 units per mg of cellulose 
film. Control 1 contains a PVOH film with cellulolytic enzymes incorporated, control 2 contains no 
enzyme. Reactions were diluted 40-fold to ensure absorbance is within a suitable range to calculate the 
mass of glucose produced. Substrate was digested by cellulolytic enzymes for 20-hours before being 
placed on ice to terminate the reaction. The change in absorption of the supernatant in a 
hexokinase/glucose-6-phosphate dehydrogenase assay was monitored by UV-spectrophotometry. 
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C.4 Glucose Standard Curve 
 
 
C.1. Glucose standard curve for hexokinase/glucose-6-phosphate dehydrogenase assay. 
The change in absorbance at 340 nm of solutions of different concentrations of glucose was measured. 
Each measurement was repeated at least three times. The error bars shown are standard error. The 
equation of the linear part of the curve was calculated by a least-squares regression method and is show. 
y = 0.0009277864x + 0.0019695230 
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